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ABSTRACT 
Objectives This project aimed to investigate the abnormal neutrophil functions in 
terms of cell survival, phagocytosis, ROS production and chemotaxis in JSLE 
patients. Furthermore, factors that could affect normal neutrophil functions (such as 
patient sera, recombinant human cytokines and commonly-used medications) were 
investigated. 
Methods Neutrophils and sera were isolated from whole blood of JSLE patients, 
healthy juvenile controls and healthy adult controls. Neutrophils from healthy adult 
controls were incubated with 10% serum from either JSLE patients or juvenile 
controls. Different recombinant cytokines or hydroxychloroquine were added in 
10% human AB serum to neutrophils from healthy adult controls. Neutrophil 
apoptosis was measured using flow cytometry using annexin V-FITC and 
propidium iodide. The expression of proteins (Mcl-1, caspases 3,7,8 and 9) was 
measured by Western blotting. Phagocytosis and ROS production from neutrophils 
incubated with S. aureus opsonised with JSLE serum were quantified. Levels of 
cytokines in JSLE serum were measured using a Luminex assay and effects of GM-
CSF and TNF-! on neutrophil apoptosis induced by JSLE serum were measured. 
JSLE neutrophil apoptosis was measured and Mcl-1 mRNA expression from JSLE 
neutrophils was quantified using real-time PCR. Phagocytosis, ROS production and 
neutrophil chemotaxis by JSLE neutrophils were investigated. Lastly, the effects of 
hydroxychloroquine on neutrophil functions were explored. 
Results The results showed that neutrophils incubated with inactive and active 
JSLE sera had significantly increased apoptosis at 6 h compared to control sera. 
Cleaved (active) forms of caspases 3,7,8 were identified in neutrophils incubated 
with inactive and active JSLE sera (that showed high rates of apoptosis) compared 
to control sera. Decreased bacterial opsonisation leading to defective phagocytosis 
and ROS production was observed in neutrophils incubated with S. aureus 
opsonised with JSLE serum. Serum analysis showed IL-8 levels in active JSLE 
patients were significantly increased. GM-CSF was the most potent cytokine in 
delaying apoptosis and significantly saved neutrophil apoptosis induced by JSLE 
serum. Low concentrations of TNF-! significantly protected neutrophils against 
apoptosis by down-regulating several genes and proteins involved in death receptor 
signaling pathway (e.g. TNFR, FADD, TRADD, caspases 8 and 10). No significant 
differences were detected in apoptosis, phagocytosis, ROS production and 
chemotaxis of neutrophils isolated from JSLE patients compared to healthy juvenile 
controls, and healthy adult neutrophils treated with hydroxychloroquine compared 
to untreated cells. 
Conclusions This study demonstrated that JSLE serum played an important role in 
regulating the functions of JSLE neutrophils. Factor(s) in JSLE serum induced 
neutrophil apoptosis and caused decreased bacterial opsonisation, leading to 
defective neutrophil phagocytosis and ROS production. Increased IL-8 levels could 
be used as an indicator of disease activity. GM-CSF was the most protective 
cytokine and overcame the pro-apoptotic effects of JSLE serum; thus, GM-CSF 
could potentially be used as an alternative treatment in JSLE patients. Effects of 
TNF-! are probably tissue-specific and the clinical application of TNF blockers in 
JSLE patients needs to be carefully considered. The functions of JSLE neutrophils 
were unimpaired and hydroxychloroquine showed no effects on neutrophil 
functions. 
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Chapter 1: Introduction 
1.1 Neutrophils 
 Neutrophilic polymorphonuclear leukocytes (neutrophils) are the 
most abundant white blood cells in the circulation of human blood. They 
play a major role during acute inflammation, as they are the first white 
blood cells to migrate through the vasculature to the inflammatory site 
and are able to recognize and eliminate pathogens (1, 2). Neutrophils 
normally constitute about 40-65% of all human white blood cells and are 
found at concentrations around 3-5 x 106 cells/mL blood. Their shape in 
the circulation is approximately spherical, and they have a diameter of 7-
10 µm. Their cytoplasm has many granules that contain essential 
enzymes, and they possess a multi-lobed nucleus. Neutrophils have a 
short life span in the circulation (estimated at 8-20 h), but infections may 
be prolong their life span up to several days, especially when the 
neutrophils migrate from the blood circulation into infected tissues (3).  
1.1.1 Neutrophil production and maturation 
 Hematopoietic stem cells in the bone marrow continuously-
generate white blood cells (leukocytes), including neutrophils, and 
release them into the blood circulation. The rate of neutrophil production 
is approximately 1-2 x 1011 cells per day in a normal adult human and 
this process is essentially regulated by G-CSF in response to IL-17A 
! ""!
synthesized by T cells. IL-17A production is itself regulated by IL-23 that 
is released from macrophages and dendritic cells (2). During 
inflammation, the number of neutrophils in the circulation is increased, 
but over time, the cells become apoptotic, and are removed by 
macrophages and dendritic cells, or other phagocytic cells. This safe 
removal process down-regulates IL-23 synthesis, and then decreases G-
CSF production. For this reason, neutrophil production is generally 
controlled by the removal of apoptotic neutrophils in tissues (4). 
 Neutrophil maturation (terminal granulocytopoiesis) is regulated 
by the expression of transcription factors, especially PU.1 and 
CCAAT/enhancer-binding protein (C/EBP) !-% (4). The balance between 
PU.1 and C/EBP! activity determines the direction of differentiation 
towards either the granulocytic or monocytic lineages. For example, high 
expression of PU.1 results in monocytic differentiation, whilst the 
expression of C/EBP! is required for granulocytopoiesis. Other C/EBP 
transcription factors are also involved during neutrophil maturation e.g. 
C/EBP" is essential for the production of mature neutrophils in response 
to fungal infections (4).  
 The formation of granules occurs during the process of neutrophil 
maturation. There are three different major types of granules, based on 
their protein content and the control of their mobilization. Primary 
(azurophilic or peroxidase-positive) granules contain myeloperoxidase 
! "#!
(MPO), defensins and azurocidin. Secondary (specific or peroxidase-
negative) granules contain lactoferrin, ficolin 1, cysteine-rich secretory 
protein 3 (CRISP3) and gelatinase. Tertiary (gelatinase) granules contain 
matrix metalloproteinase 9 (MMP9) or gelatinase B. These granules, 
containing various proteins and enzymes, have different functions. For 
example, primary granules mainly store proteins and peptides for killing 
and digestion of ingested microorganism, whereas secondary granules 
enrich membranes for proteins, such as receptors and oxidase 
components while tertiary granules deliver proteases for digesting 
basement membranes, hence allowing neutrophil transmigration (5). 
In addition, neutrophils also possess secretory vesicles, containing 
a number of proteins and receptors involved in neutrophil adhesion, 
migration and chemotaxis. These vesicles can be transported to the cell 
surface and they either release their proteins into phagosomes or 
incorporate their membranes into the surface membrane and so their 
proteins become expressed on the surface membrane, for example, in 
response to cell rolling and adhesion (e.g. "2-integrins) (4, 6). However, 
the full characterization of the protein content of secretory vesicles is still 
unknown.  
 After the processes of neutrophil production and maturation, 
neutrophils are released into the circulation, but mature cells can also be 
found in the bone marrow, lung, spleen and liver where they may exist as 
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reservoirs of mature cells (7). It is believed that these reservoirs (marginal 
pool) can rapidly deploy mature neutrophils to the site of infection or 
inflammation. 
1.1.2 Neutrophil response to infections or inflammation 
 Neutrophils are recruited to sites of bacterial, viral and fungal 
infections to rapidly attack and remove these pathogens. Their numbers 
can dramatically increase in cases of infection, and they may move 
effectively into tissues in order to respond to cytokines and chemo- 
attractive factors generated during infections or inflammation (8). The 
role of neutrophils during infection or inflammation is regulated at 
several steps (4). First, many chemotactic factors are produced at the site 
of infection, including those released by bacteria, injured host cells, 
microbes engulfed by macrophages or complement activation. These 
chemoattractants (e.g. TNF-!, GM-CSF, IL-8 and IFN-#) can prime 
neutrophils (neutrophil priming) to express increased number and/or 
affinity of membrane receptors, to release cytokines, and trigger the 
release of secretory granules containing pre-formed receptors to the 
surface membrane, thereby preparing the cell for the process of cell 
migration (8). They also affect the endothelial cells lining the blood 
vessels, which themselves generate cytokines, such as TNF-!, IL-1". 
These cytokines are recognized by membrane receptors on the surface of 
circulating neutrophils and promote neutrophils to roll onto and attach to 
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the endothelial cells (neutrophil rolling and adhesion). These processes 
are regulated by interactions between receptors and ligands on the 
surfaces of neutrophils and endothelial cells. For example, activated 
endothelial cells express P-selectin and E-selectin which bind to the 
Selectin ligands on circulating neutrophils, such as PSGL-1, L-selectin, 
ESL-1 or CD44 (9). These neutrophils then roll slowly until they stop and 
attach to the activated endothelial cells. The inflammed tissue produces 
and transports chemoattractant cytokines or chemokines, such as IL-8, to 
the luminal surface of endothelial cells. The rolling neutrophils express 
chemokine receptors that bind with these chemokines and the expression 
of leukocyte adhesion molecules ("2-integrins, LFA-1 and Mac-1) is 
increased. These adhesion molecules interact with ICAM-1 and ICAM-2 
on endothelial cells and mediate strong adhesion of neutrophils to 
endothelial cells (10). The endothelial tight junctions are opened by 
molecules expressed by neutrophils, such as PECAM-1, "2-integrins 
LFA-1 and Mac-1 (4). Neutrophils then transmigrate through the gaps by 
diapedesis (neutrophil transmigration), a process that changes neutrophil 
morphology during movement into the inflamed tissues by the process of 
chemotaxis. There are two possible methods of neutrophil transmigration: 
paracellular (between endothelial cells) and transcellular (through an 
endothelial cell). Neutrophils usually migrate paracellularly because this 
way is more efficient and less time-consuming (Figure 1.1).  
! "&!
 
Figure 1.1 The sequential steps of neutrophil responses to infection or 
inflammation. After neutrophils are primed by chemoattractants, they 
start rolling on and then adhering to endothelial cells by the interaction 
between membrane receptors and corresponding ligands. Neutrophils 
then transmigrate through endothelial cells either paracellularly or 
transcellularly. These process result in changes to neutrophil morphology 
and mobilize neutrophils toward the site of infection or inflammation. 
The neutrophils phagocytose microorganisms and then undergo either 
apoptosis or NET formation (see sections 1.1.3 and 1.1.4). 
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By the time the neutrophils reach the site of infection, the 
microbes may be opsonised by complement fragments, immunoglobulins 
or acute-phase reactant proteins in serum. Neutrophils can detect the 
opsonised microbes and ingest them by opsono-phagocytosis (4).  
1.1.3 Neutrophil phagocytosis and respiratory burst 
 Phagocytosis is an important process for neutrophils to eliminate 
invasive pathogens and also to activate other innate immune responses. 
Numerous molecules and cell surface receptors have been identified that 
are required for the process of phagocytosis and activation of 
microbicidal mechanisms e.g. CD16 (Fc#RIII), CD32 (Fc#RII), CD64 
(Fc#RI), ICAM-1, integrins, CD11b, CD62-L and complement receptors 
(11). Activation of these molecules and receptors can stimulate the 
neutrophil cell membrane to extend pseudopodia and engulf 
microorganisms. For example, opsonins, activated complement proteins 
(C3) and IgG antibodies in serum bind to invasive pathogens such as 
Staphylococcus aureus, Escherichia coli. The opsonised pathogens can 
then bind to neutrophil opsonic receptors (the number and affinity of 
these receptors on the neutrophil surface can be increased) and these 
membrane-bound glycoprotein complexes trigger neutrophil 
phagocytosis (12, 13). 
 One of the most important neutrophil receptors recognizing 
bacterial peptides is the N-formyl-methionyl-leucyl-phenylalanine 
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(fMLP) receptor. fMLP is a very potent bacterial-derived peptide and it 
binds to FRP receptors. Up-regulation of complement receptors CR1 and 
CR3 (CD11b/CD18 or Mac-1) additionally occurs during neutrophil 
priming and these complement receptors bind with the complement 
factors (C3bi-opsonised pathogens, C3a and C5a) to initiate neutrophil 
adhesion, chemotaxis and phagocytosis (14, 15). Furthermore, bacteria 
may be opsonised by immunoglobulins such that the exposed Fc domains 
are recognized by immunoglobulin receptors on neutrophils, namely Fc# 
receptors. Neutrophils express several types of Fc# receptors on their 
surface such as Fc#RII (CD32) and Fc#RIII (CD16) on both peripheral 
blood and inflammatory neutrophils, whilst Fc#RI (CD64) is only 
expressed on neutrophils primed by cytokines such as GM-CSF and 
interferon-# (IFN-#) (16). Fc#RI and Fc#RII binds to monomeric IgG, 
Fc#RI has a high affinity whereas Fc#RII has a low affinity but its 
affinity is greater when IgG dimerization or aggregation occurs (17). 
There are 2 forms of Fc#RIII (Fc#RIII -a and -b), which bind to IgG with 
low affinity and merely Fc#RIIIb is expressed on neutrophils (18). 
Fc#RIIIb is expressed abundantly with 100,000-200,000 receptors per 
cell and it is shed rapidly by cytokine stimulation such as GM-CSF, and 
the internal stores of this receptor will maintain cell surface expression 
(19). These receptors facilitate phagocytosis (20). 
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During the process of phagocytosis, the neutrophil plasma 
membrane first flows around and engulfs the bacteria to form a 
phagosome. The neutrophil morphology usually changes from spherical 
to amoeboid shape following the formation of pseudopodia, in order to 
engulf those organisms. Next, neutrophil granules are released into the 
phagocytic vacuoles to form a phagolysosome. These granules contain 
anti-microbial peptides, proteins and enzymes such as myeloperoxidase, 
hydrolases, elastase and proteinases to kill and digest the invasive 
pathogens (4, 21). In addition, neutrophils can also produce cytotoxic 
molecules, such as reactive oxygen metabolites and can also release from 
their granules a range of proteins with cytotoxic properties. They may 
also generate neutrophil extracellular traps (NETs) which entrap and kill 
extracellular pathogens that cannot be phagocytosed (2). 
Reactive oxygen species are generated by the membrane-bound 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
(22). Once the oxidase is activated, it accepts electrons from NADPH to 
reduce O2 and generate the superoxide anion (O2-) as a primary oxidant, 
during a process known as the respiratory burst. NADPH is generated 
from NADP+ via the hexose monophosphate (HMP) shunt. O2- is 
relatively unstable and rapidly dismutates into secondary oxidants; 
hydrogen peroxide (H2O2) and hypochlorous acid (HOCl). 
Myeloperoxidase utilizes H2O2 to generate HOCl, which is highly 
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bacteriocidal (Figure 1.2). Degranulation of cytotoxic enzymes and 
activation of the NADPH oxidase enzyme occur concurrently and these 
combine to kill and digest the microbes. Finally, when the infection is 
cleared, neutrophils will enter apoptosis (programmed cell death), which 
eventually leads to their clearance by phagocytosis via tissue 
macrophages. 
NETs (neutrophil extracellular traps) are web-like structures, that 
have recently been shown to trap invasive pathogens such as bacteria, 
viruses, fungi and protozoa to aid the killing and clearance of 
extracellular microorganisms (2, 4, 11). NET structures are composed of 
nuclear components (e.g. large strands of de-condensed DNA, nuclear 
histones), proteins from neutrophil granules and several anti-microbial 
enzymes (23). The efficiency of NETs as a killing mechanism has not 
been clearly documented and their role in vivo is still controversial (24). 
1.1.4 Neutrophil apoptosis (programmed cell death) 
 Human neutrophils can release a range of toxic molecules to kill 
invading microorganisms, but many of these molecules can also 
indiscriminately attack host tissues. Therefore, there must be a safe 
mechanism to remove neutrophils when they have completed their role in 
infections. When neutrophils complete their lifespan or their role in 
infection, they become apoptotic. This allows for the safe removal of 
cells and limits the release of destructive neutrophil products into  
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Figure 1.2 Reactive oxygen species production in neutrophils: the 
NADPH oxidase receives electrons from NADPH to reduce O2 to the 
superoxide anion (O2-), which then dismutates into hydrogen peroxide 
(H2O2): .OH formation may also occur. Myeloperoxidase reacts with 
H2O2 and Cl- to produce hypochlorous acid (HOCl). The combination of 
HOCl, .OH and granule enzymes provides an environment within the 
phagosome that is able to destroy the invasive pathogens (e.g. bacteria). 
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surrounding tissues that would occur via if neutrophils died by the 
process of necrosis (25). Apoptotic cells undergo characteristic 
morphological changes: they round up, start blebbing, their mitochondrial 
membrane potential is dissipated, expression of many cell surface 
markers is altered (e.g. phosphatidylserine residues are expressed on the 
cell surface) (Figure 1.3) (26), the nucleus breaks down and, if not 
phagocytosed by macrophages, the cell will undergo secondary necrosis.
 Two major pathways control neutrophil apoptosis (26–28). The 
extrinsic pathway is initiated by extracellular proteins, which bind to 
membrane receptors, such as death receptors, to activate proteins and 
proteolytic cascades inside the cell. The intrinsic pathway is controlled 
by the mitochondria and the Bcl-2 family members (Figure 1.4) (29, 30). 
1.1.5 The extrinsic pathway and death receptors 
The extrinsic apoptotic pathway occurs after engagement of cell 
membrane receptors or death receptors. This activates the caspase 
cascade but can be linked to the intrinsic apoptotic pathway that is 
regulated by pro-apoptotic Bcl-2 family members, via Bid, suggesting a 
level of crosstalk between these two pathways. There are two main 
factors regulating apoptosis: pro-apoptotic factors that induce cell death 
(e.g. FasL, TRAIL and high dose TNF-!) and anti-apoptotic factors that 
prevent cell death (e.g. interferons, G-CSF, GM-CSF and low dose TNF-
!) (31). 
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Figure 1.3 Morphological differences between healthy neutrophils and 
apoptotic neutrophils. Healthy neutrophils possess a multi-lobed nucleus 
and granular cytoplasm, whilst apoptotic neutrophils (arrowed) have a 
condensed nucleus and cytoplasm, and are smaller and rounder. 
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Figure 1.4 Summary of the pathways that control neutrophil apoptosis: 
The extrinsic pathway involves receptors e.g. death receptors (such as 
Fas, TRAIL) and is activated via caspase-8. The extrinsic pathway 
usually may be linked to the intrinsic pathway via Bid. The intrinsic 
pathway involves mitochondria, Bcl-2 family proteins and Mcl-1. When 
this pathway is activated, cytochrome c is released which then combines 
with Apaf-1, ATP and pro-caspase-9 to form an apoptosome, and 
activates caspase-9. Both pathways finally activate caspases -3, -7 and 
induce neutrophil apoptosis (26). 
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The two most characterized neutrophil death receptors are TNFR1 
and Fas (32). TNFR1 binds TNF-!, whilst Fas receptor binds Fas ligand 
(FasL), and both receptors sequentially activate the caspase cascade. A 
group of adaptor proteins are recruited during the engagement of death 
receptors, such as TNF-associated death domain-containing proteins 
(TRADD) and Fas-associated death domain-containing protein (FADD). 
These adaptor proteins facilitate interaction with other proteins, including 
pro-apoptotic proteins. For example, the clustering of Fas, FADD and 
pro-caspase-8 (the death-inducing signaling complex; DISC) can cleave 
and activate pro-caspase-8, and initiate the caspase cascade (33). The 
clustering of TRADD with TNFR1 usually includes FADD, pro-caspase-
8 and several adaptor proteins to induce and trigger apoptosis (34). 
1.1.6 The intrinsic pathway, mitochondria and Bcl-2 family members 
The intrinsic apoptotic pathway is initiated by mitochondria and 
regulated by Bcl-2 family members. The proteins of the Bcl-2 family 
comprise both pro-apoptotic (e.g. Bid, Bax, Bim, Bak, Bik) and anti-
apoptotic proteins (e.g. Mcl-1, XIAP, Bcl-XL) (35). They are classified 
into 3 groups; the anti-apoptotic (prosurvival), pro-apoptotic and the 
BH3-only proteins (36). The anti-apoptotic Bcl-2 family members are 
crucial regulators of mitochondrial membrane integrity (mainly of the 
intrinsic apoptotic pathway) and include Bcl-2, Bcl-XL, Bcl-w, A1, Mcl-
1, Boo/DIVA/Bcl2-L-10 and Bcl-B. The proteins contain three or four 
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regions of Bcl-2 homology (BH regions) (Figure 1.5). Their function is 
mainly to protect against the release of cytochrome c from mitochondria 
into the cytoplasm, and to keep the mitochondrial membranes intact. 
Another group of proteins is the pro-apoptotic proteins, such as Bax and 
Bak, which have three BH domains (BH1, 2 and 3). These proteins move 
to the outer mitochondrial membrane and promote the release of 
cytochrome c from mitochondria, which then induces caspase activation 
via the apoptosome. The last group in the family is the BH3-only 
proteins, which are essential initiators of the mitochondrial apoptotic 
pathway and are able to bind to Bcl-2-like prosurvival proteins and 
initiate cell apoptosis. There are at least 10 BH3-only proteins in most 
cells, such as Bid, Bim, Bmf, Puma, etc. which are required for 
programmed cell death. 
One of the most important Bcl-2 family members regulating 
intrinsic neutrophil apoptosis is Myeloid Cell Leukemia-1 (Mcl-1). Mcl-1 
is an anti-apoptotic that was first described as an early induction gene 
expressed during the differentiation of the ML-1 myeloid cell line along 
the monocytic lineage (37). Up-regulation of expression of this protein 
prevents intrinsic neutrophil apoptosis (38). It can be expressed as short 
and long forms after the processes of transcription and alternative 
splicing, and it shares some homology with other members of the Bcl-2 
family (Figure 1.5). Differences to the other family members (Bcl-2, Bcl- 
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Figure 1.5 Bcl-2 family proteins. Most proteins have a transmembrane 
domain (TM) helping them to bind to intracellular membranes. BH=Bcl-2 
homology domains (1-4), PEST=Proline/Glutamic acid/Serine/Threonine 
residues (39). 
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X), include: (a) it is a larger protein (42 kDa compared 26 kDa to for Bcl-
2); (b) its N-terminal region contains PEST sequences that are targets for 
phosphorylation and ubiquitination; (c) Mcl-1 does not contain a BH4 
domain, which suggests that it interacts with different proteins compared 
with Bcl-2 and Bcl-X, which both have this domain (39).  
 Neutrophils express the anti-apoptotic protein Mcl-1 and the level 
of expression of this protein correlates with neutrophil survival (38). Mcl-
1 has a very short half-life of approximately 2 h in neutrophils because of 
the PEST domains (proline, glutamic acid, serine and threonine residues) 
that target it for rapid turnover by the proteasome, which is a very large 
protein complex that degrades unnecessary or damaged proteins by 
proteolysis (39). This is in contrast to the function of pro-apoptotic Bcl-2 
homologues such as Bax, Bid and Bim that induce neutrophil apoptosis 
(35), which are more stable. Therefore, a balance between anti- and pro-
apoptotic proteins controls neutrophil fate. If there is an excess level of 
pro-apoptotic proteins or an attenuation of anti-apoptotic expression, 
including Mcl-1 protein, neutrophils lose their outer mitochondrial 
membrane protection and become apoptotic (40). 
 Mcl-1 expression can be enhanced by some factors (e.g. GM-
CSF, IL-1", sodium butyrate and lipopolysaccharide), that induce 
neutrophil survival (41). For example, GM-CSF is a cytokine that 
functions as a growth factor for white blood cells, especially granulocytes 
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and monocytes. GM-CSF enhances neutrophil survival by changing Mcl-
1 turnover rate, enhancing Mcl-1 stability and also up-regulating mRNA 
levels of Mcl-1.  
1.1.7 Caspase cascade 
 Caspases are an important family of intracellular enzymes 
involved in the regulation of programmed cell death (apoptosis). Their 
name comes from their description: cysteine-dependent aspartate-specific 
protease. The pro-forms of caspases are single-chain proteins and 
comprise an N-terminal pro-domain preceding the conserved catalytic 
domains, which are then cleaved into large and small portions during 
activation to form active dimeric molecules (Figure 1.6) (42).  
The classification of human caspases is based on their function 
and location within signaling pathways, and they are categorized into two 
groups; apoptotic and pro-inflammatory. This classification is useful, 
although there are some overlaps between the groups. The apoptotic 
subgroup contains two subtypes of caspases that are (a) the initiator 
(apical) and (b) the executioner (effector, downstream) caspases. The 
initiators (caspase -8, -9 and -10) activate the executioners (caspase -3, -6 
and -7) to induce the apoptotic cascade. The initiator caspases are 
activated by homodimerization, which is facilitated by adaptor proteins, 
and are divided into 2 sub-types: caspases involved in the extrinsic 
(caspase -8, -10) or intrinsic (caspase -9) apoptotic pathways (Figure 1.4).  
! $+!
A. 
 
B. 
 
 
Figure 1.6 (A) The N-terminal pro-domain precedes the catalytic 
domain, while the large and small portions are covalently-linked 
subunits. (B) Caspase activation occurs by dimerization or cleavage of 
inter-subunit and pro-domain linkers of pro-caspases, followed by 
maturation as an active caspase tetramer with constituted active sites. !
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Caspase activation occurs by proteolytic maturation or auto-proteolytic 
cleavage. This activation mechanism is associated with trimming/removal 
of the pro-domain and the linkers of caspases, and the formation of 
dimers (particularly in initiator caspases), which stabilizes the caspase 
catalytic domain and activates downstream signaling (43). 
 There are three feedback strategies to prevent caspase over-
activity; caspase inhibition, caspase degradation and decoy inhibitors. 
Caspase inhibitors in human cells, such as XIAP (X-linked inhibitor of 
apoptotic protein) can effectively and selectively inhibit caspases-9, -3 
and -7. Many viruses encode proteins that circumvent the host apoptotic 
response, and so viruses can survive and proliferate in the host, by 
generating proteins that are caspase inhibitors; for example, CrmA 
(cytokine response modifier A) in cowpox virus or p35/p49 proteins in 
baculovirus (44, 45). 
1.1.8 Neutrophils and diseases 
The primary role of neutrophils is in the control of infections or 
inflammation. They are major players in the elimination of invasive 
pathogens, especially intracellular and extracellular bacteria (e.g. 
Staphylococcus spp., group A Streptococcus and Mycobacterium 
tuberculosis) and can use several mechanisms to achieve this. Neutrophil 
phagocytosis, release of granule enzymes containing anti-microbial 
peptides, reactive oxygen species production and NETs formation 
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essentially occur during the process of bacterial elimination, as 
mentioned previously (2, 4). It has been reported that impairment of these 
functions and/or a decreased number of neutrophils can cause severe 
immunodeficiency in humans (46). Thus, neutrophil recruitment and 
appropriate activation of their killing mechanisms at the site of infection 
are crucial.  
However, neutrophils also play damaging roles in the 
pathophysiology of many types of human disease, including chronic 
inflammation and autoimmune diseases (11). Examples of the role of 
neutrophils contributing to the exacerbation of chronic inflammation are 
rheumatoid arthritis (RA), chronic obstructive pulmonary disease 
(COPD) and Behçet’s Disease. Neutrophils are inappropriately activated 
in these conditions to release cytotoxic granules, cytokines and 
chemokines, leading to persistent inflammation in the joints in RA, the 
lungs in COPD, and many organ systems in Behçet’s disease (8, 47, 48). 
In autoimmune diseases, one example of neutrophil contribution to 
disease pathology is systemic lupus erythematosus (SLE). Abnormalities 
in neutrophil functions have been reported in SLE patients, such as 
increased neutrophil aggregation and apoptosis, ineffective neutrophil 
phagocytosis, a decreased cytokine and chemokine response and the 
presence of neutrophil autoantibodies (49). Interestingly, one subgroup of 
SLE, patients of which often present with severe clinical manifestations, 
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is juvenile SLE (JSLE). JSLE patients usually have multi-organ 
involvement at presentation, especially renal, hematological and 
neurological manifestations, and these clinical features usually indicate 
the worst prognosis. There are increasing number of reports of a 
correlation between abnormal neutrophil function and disease 
pathogenesis, including disease activity and severity in JSLE patients 
(50–52). 
 
1.2 Juvenile Systemic Lupus Erythematosus (JSLE) 
Systemic Lupus Erythematosus (SLE) is one of the most 
important autoimmune diseases and it has a varied clinical spectrum and 
abnormal immune regulation (53). Although there are numerous groups 
working on SLE and JSLE worldwide, the etiology remains unknown. 
Some of the current studies are associated with the search for particular 
genetic backgrounds, but environmental factors also appear to contribute 
to immune-pathogenesis. These genetic and environmental factors may 
lead to altered innate and adaptive immune responses in patients (54). 
1.2.1 Epidemiology 
Most SLE patients are adults, with a prevalence 40 to 50 per 
100,000 people globally, particularly in childbearing aged females (16-55 
years old); however, 15-20% of patients present in childhood (55). The 
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incidence of childhood SLE or JSLE across the world varies between 0.3-
0.9 per 100,000 cases per year, and its prevalence rate is approximately 
4-250 per 100,000. Asian, Hispanic and African-American children have 
a higher incidence of disease (56, 57). JSLE is commonly-diagnosed up 
to 16 years of age (age range from 14 to 20 years in different studies). 
The female to male ratio changes from 4:3 during the first decade of life 
to 4:1 during the second decade (58). 
1.2.2 Diagnosis 
Patients diagnosed with JSLE have a broad range of organ system 
involvement and the clinical symptoms, including immunological 
findings, are similar in both adults and children. The diagnosis of JSLE is 
based upon any 4 out of 11 criteria from The American College of 
Rheumatology (1997 revision) and the criteria are used for both adults 
and children (Table 1.1) (59).  
1.2.3 Clinical Manifestations 
The clinical signs and symptoms of JSLE range from mild, 
chronic and slowly progressive disease with exacerbations and 
remissions, to a severe, acute and rapidly-aggressive disease (60). Most 
JSLE patients initially present with symptoms such as low-grade fever, 
malaise, poor appetite and weight loss (55). Notably, JSLE is clinically 
more severe than adult SLE and most patients often present with major  
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Table 1.1 Classification criteria for JSLE or SLE from the American 
College of Rheumatology                                            
Malar (butterfly) rash 
Discoid rash 
Photosensitivity 
Oral or nasal mucocutaneous ulceration 
Nonerosive arthritis 
Nephritis 
      Proteinuria >0.5 g/day 
      Cellular casts 
Encephalopathy 
      Seizures 
      Psychosis 
Pleuritis or pericarditis 
Cytopenia 
Positive immunoserology 
      Antibodies to dsDNA 
      Antibodies to Sm nuclear antigen 
      Positive finding of antiphospholipid antibodies based on: 
      (a) IgG or IgM anticardiolipin antibodies, or 
      (b) Lupus anti-coagulant, or 
      (c) False-positive serologic test for syphilis for at least 6 months,    
      confirmed by Treponema pallidum immobilization or fluorescent  
      treponemal antibody absorption test 
Positive antinuclear antibody test 
                                                                  (Hochberg M. Arthritis Rheum 1997; 40:1725) 
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organ or systemic involvement, particularly renal, neuropsychiatric and 
hematological symptoms (61). Table 1.2 demonstrates differences in the 
frequency of clinical manifestations in JSLE and adult SLE. 
 
Table 1.2 Differences in the frequency of clinical characteristics in JSLE 
and adult SLE according to the ACR classification criteria (55, 61–64). 
Clinical features JSLE Adult SLE 
Malar rash 
Discoid rash 
Photosensitivity 
Oral ulcers 
Non-erosive arthritis 
Renal disease 
CNS involvement 
Pulmonary involvement 
Cardiac involvement 
Hematological involvement 
44-85 % 
< 10% 
35-50% 
20-30% 
60-70% 
75-80% 
20-45% 
15-40% 
10-15% 
50-100% 
40-52% 
20% 
35-63% 
20-30% 
80-100% 
35-67% 
10-25% 
20-40% 
25-30% 
42-72% 
 
Renal disease is more common in JSLE compared to adult SLE 
(55, 61). It has been estimated that approximately 75-80% JSLE patients 
exhibit nephritis either at presentation, or some time over the course of 
the follow-up period. Nephritis in JSLE is usually more severe than in 
adults, and it represents the most dominant feature of prognosis and 
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mortality in children (65). The most common manifestations of renal 
disease in JSLE are microscopic hematuria (79%), proteinuria (60-70%) 
and hypertension (25-40%) (66). Many reports have shown that most 
JSLE patients with severe and aggressive renal disease required higher 
doses of corticosteroids or immunosuppressive drugs, compared with 
adult SLE. Moreover, studies also reported that these JSLE patients 
showed a higher risk of acute renal failure and a requirement for renal 
dialysis (67). 
Neuropsychiatric involvement is not uncommon in JSLE, with 
approximately 20-45% incidence, and up to 65% of patients has been 
reported in some case series (68, 69). These clinical manifestations vary 
from mild cognitive dysfunction, such as memory or attention deficit, to 
severe neurological and psychiatric symptoms, including seizures and 
psychosis. Neuropsychiatric disorder usually occurs within the first year 
after disease onset, and psychosis with visual hallucination is a hallmark 
of this disorder in JSLE patients. Severe neuropsychiatric disorder is a 
high risk factor of poor outcome in JSLE and the patients usually require 
the most aggressive therapies and immunosuppressive drugs in order to 
suppress symptoms (63).  
Hematologic features are more common in JSLE compared with 
adult SLE (50-100% VS 42-72%). More than 50% of JSLE patients 
present with cytopenia, particularly leukopenia as the most common 
hematological involvement (60). Anemia is also common and can be 
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presented as Coombs-positive hemolytic anemia, anemia of chronic 
disease or iron-deficiency anemia (61). Thrombocytopenia caused by 
autoimmune-mediated mechanisms is also observed in JSLE. The 
symptoms range from minor bleeding to life-threatening blood loss (60). 
Hematological involvement in JSLE usually predicts a high mortality rate 
and strongly correlates to disease activity and severity. 
Other clinical signs and symptoms, which are non-specific for 
JSLE and do not form part of the ACR classification criteria, can 
sometimes be detected at presentation (55, 60, 61), and these are 
summarised in Table 1.3. 
1.2.4 Pathophysiology 
In spite of the fact that there have been many studies designed to 
understand the pathogenesis of SLE, the actual cause of the disease is still 
unknown. The pathophysiology of SLE is characterized by the presence 
of autoantibodies directed against nuclear antigens and abnormal immune 
regulation, and these clinical markers are similar in both adult SLE and 
JSLE (70). Autoantigen and autoantibody complexes are capable of 
damaging human tissues and organs via immune cell activation.! It has 
been proposed that the triggers for the formation of these immune 
complexes are multifactorial, including genetic, environmental and 
immunological factors (54). 
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Table 1.3 Other clinical findings in JSLE 
Constitutional 
Cutaneous 
 
 
Musculoskeletal 
Cardiopulmonary 
 
 
 
Gastrointestinal 
 
Neuropsychiatric 
 
Renal 
Low grade fever, poor appetite, weight loss 
Non-scaring alopecia, maculopapular lupus rash, 
cutaneous vasculitis, Raynaud phenomenon, livedo 
reticularis 
Arthralgia, myalgia, myositis, osteopenia 
Myocarditis, non-infective (Libmann-Sack) 
endocarditis, accelerated atherosclerosis, interstitial 
pneumonitis, pulmonary hemorrhage, pulmonary 
hypertension 
Abdominal vessel vasculitis, pancreatitis, 
hepatomegaly, splenomegaly 
Headache, cognitive dysfunction, depression, 
anxiety, movement disorder (chorea), neuropathy 
Nephrotic syndrome, tubulointerstitial nephritis, 
hypertension 
 
A genetic predisposition associated with the development of SLE 
has been shown a number of ways. The combination effects of numerous 
genes belonging to different pathways that may contribute to 
autoimmunity include IRF5, STAT4, IRAK1 and TLR8 (54). 
Interestingly, a recent large-scale replication study has found that single-
nucleotide polymorphisms (SNPs) of some candidate genes e.g. TNIP1, 
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PRDM1, JAZF1, UHRF1BP1 and IL10, significantly increase the risk of 
SLE (71). However, the identified loci are found only 15% of SLE 
patients and their relatives, and the importance of each gene in the 
development of the disease and their contribution to phenotype and 
disease severity, is unclear. Therefore, the relationship between candidate 
genes and the pathophysiology needs to be further explored in future 
studies.  
Abnormal immune regulation has been widely described in many 
studies and T and B cell lymphocytes play important roles in the 
abnormal immune response in patient with SLE (54), although most 
patients present with lymphopenia. It has been demonstrated that T cells 
from SLE patients activate B cells to produce autoantibodies directed 
against a variety of autoantigens (72).  
Enhanced activation of T cell signaling pathways occurs when T 
cell receptors (TCRs) are engaged by factors in SLE sera, such as 
cytokines, autoantibodies and immune complexes (54, 72). Consequently, 
activation of transcription factors and gene expression is dysregulated, 
particularly in CD4 T cells; this results in up-regulation of nuclear factor 
of activated T cells (NFAT) and CRE-modulator (CREM), and down-
regulation of CRE-binding (CREB) and activator protein 1 (AP-1). 
Dysregulation of the function of these genes results in an increased 
number of SLE CD4 T cells and increased levels of pro-inflammatory 
cytokines, such as IL-17 (73–75). The abnormally high levels of IL-17 
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have been reported to contribute to T cell recruitment to damaged organs, 
and B cell activation and proliferation (76). Moreover, regulatory T cells, 
which maintain tolerance to self-antigens and suppress the activation of 
abnormal responses such as self-reactivity, are low and functionally 
abnormal in SLE patients (77). Therefore, these lupus T cells are capable 
of activating B cells to become hyperactive. 
Hyperactivity of B cells is a prominent finding in SLE patients as 
they produce an array of autoantibodies against autoantigens, such as 
antinuclear antibodies (ANA) (54, 70). Analysis of the B cell 
subpopulation demonstrated an increased number of CD27high plasma 
cells that was significantly correlated with levels of serum autoantibodies, 
autoantibody production and disease activity in lupus patients (78). 
Furthermore, it has been reported that the expression of genes involved in 
inhibitory intracellular signaling of B cells such as Lyn, complement 
receptor 2 (CR2), surface receptor CD22 and Fc#RIIB, is decreased, 
suggesting defects in inhibitory processes, leading to lupus B cell 
hyperactivity (79–81). 
Apart from T and B lymphocyte over-activity, over-stimulation 
and abnormal functions of dendritic cells have been reported in lupus 
patients (82). Dendritic cell over-stimulation can be induced by 
autoantigens released from deregulated apoptotic cells that may 
accumulate either via defective clearance by macrophages or other 
phagocytic cells, or by increases in the rate of cell apoptosis. Following 
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autoantigen engulfment and processing, these dendritic cells activate T 
and B cells to produce a range of autoantibodies and form immune 
complexes. Moreover, dendritic cells also secrete large amounts of type I 
interferon particularly IFN-!, which has a major role in the pathogenesis 
of SLE, increasing the expression of autoantigens (e.g. SSA/Ro) and 
promoting dendritic cell maturation (83). Figure 1.7 summaries one 
hypothesis for the pathogenesis of SLE based on abnormal phagocytosis. 
 Environmental factors have been reported as another contributing 
factor in the pathogenesis of SLE. Exposure to UV and smoking are 
thought to be triggering factors in lupus patients, and they are associated 
with disease activity. Viral infections, such as parvovirus B19, 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are also common 
in lupus patients, and it has been found that some viral infections, 
particularly EBV, may precede the development of autoantibody 
production (e.g. anti-SSA/Ro) via cross-reactivity of self-antigens and 
EBV protein (EBNA-1) (84, 85). Other environmental factors may 
include sex hormones (e.g. estrogen and prolactin), and drug-induced 
lupus has been reported (e.g. hydralazine and procainamide) (86, 87). 
1.2.5 Laboratory findings 
Routine laboratory tests during active disease episodes often show 
anemia, leukopenia (lymphopenia and thrombocytopenia), and elevated 
inflammatory markers, such as erythrocyte sedimentation rate (ESR) and  
! %#!
 
Figure 1.7 A hypothesis to explain the pathogenesis of SLE. Increased 
and deregulated apoptotic cells may arise from defective clearance by 
macrophages, leading to the release of autoantigens. These autoantigens 
are phagocytosed and processed by dendritic cells (DC), and then 
presented to T and B cells, which then induces autoantibody production. 
Consequently, immune complexes are formed and the complexes 
eventually bind to basement membrane to initiate abnormal autoimmune 
responses leading to tissue and organ damage (72). 
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C-reactive protein (CRP). Urinary analysis also reveals hematuria and 
proteinuria with cellular casts. These laboratory results together with the 
clinical signs and symptoms, are usually sufficient to make a diagnosis of 
SLE (55, 60). However, other laboratory tests are usually required to 
confirm the diagnosis, particularly autoantibody profiles which are a 
hallmark of SLE; for example, ANA, anti-dsDNA and anti-Sm 
autoantibodies. 
Antinuclear antibody (ANA) is present in more than 95% of JSLE 
patients (55, 60, 88). The serum titer of this autoantibody is often higher 
than 1:80 in children, but there is no difference in ANA levels between 
JSLE and adult SLE patients (89). A positive ANA titer may also be 
present in other non-specific conditions, such as infections, following 
certain medications, or other autoimmune diseases (e.g. Juvenile 
Rheumatoid Arthritis) (55). Thus, the presence of ANA alone is not 
appropriate to make a diagnosis and other specific autoantibodies, such as 
anti-dsDNA and anti-Sm autoantibodies, must be tested for to confirm a 
diagnosis. 
Anti-double stranded DNA (dsDNA) and anti-smooth muscle 
(Sm) autoantibodies are usually measured alongside the ANA profile, as 
they have high specificity for JSLE. They are found in approximately 61-
93% and 50% of children, respectively. Both autoantibodies are 
correlated with renal involvement and disease severity (60). Other 
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autoantibodies observed in JSLE include anti SSA/Ro, anti-SSB/La, anti-
ribonuclear protein (anti-RNP), anti-histone and Rheumatoid Factor (55). 
Another prominent laboratory finding is low levels of serum 
complement proteins, particularly C3 and C4. They are very helpful for 
disease monitoring and present in up to 90% of JSLE patients. Low 
serum complement levels, cytopenias (anemia, leukopenia, lymphopenia 
or thrombocytopenia) and elevated ESR or CRP can be indicators that the 
disease has become active (89). 
1.2.6 Treatment 
As the clinical signs and symptoms, such as lupus nephritis, 
seizure, psychosis, autoimmune hemolytic anemia, leukopenia and 
thrombocytopenia can lead to long-term morbidity and mortality, 
appropriate and early treatment should be started as soon as possible. 
However, current treatments can only suppress the disease activity and 
prevent organ or system damage, rather than eliminate the disease. 
Commonly-used treatments include corticosteroids, anti-malarial drugs, 
immunosuppressive drugs and new biologics. All medications have side 
effects, and so the relative risk and benefit needs to be considered. 
Corticosteroids is the mainstay of treatment as they are the most 
effective and rapidly-acting drugs for JSLE patients (55, 60). The dose 
and duration of corticosteroid therapy depends on clinical presentation, 
types of involved organs or systems, and disease activity and severity. It 
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has been observed that more than 90% of children diagnosed with JSLE 
will receive corticosteroids at some point during the course of treatment 
and follow up. However, these benefits must be counter-balanced by 
serious side effects, such as growth retardation, delayed puberty, 
osteoporosis and osteonecrosis, opportunistic infections and Cushing 
syndrome. 
Anti-malarial drugs (hydroxychloroquine) have become an 
important component for the treatment in JSLE, especially in children 
presenting with cutaneous lesions and non-erosive arthritis (90). These 
drugs have shown many beneficial effects in lupus patients and long-term 
use is now recommended. Hydroxychloroquine can prevent disease flares 
and protect against irreversible organ damage. Furthermore, they can 
lower serum cholesterol levels and prevent against premature 
atherosclerosis in JSLE patients (64). The most serious side effect is an 
irreversible ocular toxicity (retinopathy), which is very rare and it can be 
prevented by annual eye examinations (91). 
Immunosuppressive drugs are given to patients who are resistant 
to corticosteroids and hydroxychloroquine or who require steroid sparing: 
alternatively, they may be given to patients with persistent 
glomerulonephritis or protracted neuropsychiatric disorders (55, 60). For 
example, Methotrexate is the first line immunosuppressive therapy for 
children with persistent arthritis who are first treated with corticosteroids 
or hydroxychloroquine, but who show no improvement. 
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Cyclophosphamide is given for severe and life-threatening conditions, 
such as proliferative lupus nephritis and acute psychosis. Azathioprine is 
effective for non-erosive arthritis, lupus nephritis, severe cytopenias and 
serositis. Mycophenolate mofetil is commonly-used in children with 
lupus nephritis for either induction of remission and maintenance therapy. 
New therapies are currently under investigation and show 
beneficial effects in lupus patients (55, 60). Rituximab, a monoclonal 
antibody against CD20 on B cells, has been reported to be effective in 
patients with cytopenia, refractory nephritis and pulmonary hemorrhage 
(92, 93). Belimumab is a B lymphocyte stimulator (BLyS) antibody, 
which has been recently received FDA approval for use in combination 
with other therapies, and is used for the treatment of active adult SLE 
(55). However, studies examining the effectiveness of Belimumab in 
JSLE are still ongoing. 
1.2.7 Prognosis 
 As previously mentioned, JSLE patients have more severe clinical 
manifestations and higher morbidity and mortality rates than adult SLE. 
Nevertheless, the prognosis of JSLE has improved dramatically over the 
past ten years because of effective treatments and new therapies. 5-year 
survival rates of 90-95%, and 10-year survival rates of > 90% have been 
reported after short and long-term treatment (63). 
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 In spite of these improvements in therapy, lupus nephritis, 
neuropsychiatric disorders and hematological involvement are still 
significant causes of morbidity and mortality. The major causes of death 
in JSLE include severe disease flares, severe lupus nephritis, and 
particularly infections, often due to the side effects of medication and 
immune-suppression (55, 60, 63).  
 
1.3 Neutrophils and Juvenile Systemic Lupus Erythematosus 
Many studies have been reported the involvement of neutrophils 
in the pathogenesis of SLE. An increase of neutrophil apoptosis and 
enhancement of neutrophil extracellular traps (NETs) has been observed 
in neutrophils from lupus patients, which probably are a key role in the 
induction of autoimmune response and the development of organ and 
system damage (49). Moreover, SLE-derived low-density granulocytes 
(LDGs), an abnormal subset of neutrophils isolated from lupus patients, 
are able to induce vascular damage and increase levels of type I 
interferon; an important cytokine involved in the pathogenesis of the 
disease (94).  
Neutrophil functional defects have been described in patients with 
SLE. They are not only associated with the pathogenesis of SLE, but are 
also involved in the etiology of several types of infection in patients. One 
of the most common infections results from pathogenic bacteria (e.g. S. 
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aureus and E. coli) and they are responsible for more than half of all 
infected cases (95). Noticeably, these microorganisms are usually 
effectively engulfed and destroyed by neutrophils and many studies have 
reported defective neutrophil function in these patients, including 
impaired phagocytosis, ROS production and chemotaxis (96–98). 
1.3.1 Neutrophil apoptosis 
It is hypothesised that the pathogenesis of the disease is triggered 
by autoantigens that induce autoantibody production. It has been found 
that autoantigens may be clustered in blebs on the surface of apoptotic 
cells (99). It has also been found that there are increased numbers and 
impaired clearance of apoptotic white blood cells such as neutrophils, 
monocytes and lymphocytes, in patients with SLE (100). Moreover, a 
high rate of secondary necrosis in lupus neutrophils is observed in vitro. 
The increased levels of neutrophil apoptosis and defective clearance of 
apoptotic cells are associated with disease activity (101).  
During apoptosis, many kinase- and proteolytic-pathways are 
activated and these may lead to the production of autoreactive 
lymphocytes, and result in expression of autoantigens (99). For example, 
Ro, La, dsDNA or RNP are presented on the cell membrane of apoptotic 
cells, which are increased in SLE patients compared to healthy controls 
and are significantly correlated with disease activity. In particular, 
neutrophils, the most abundant white blood cells in human blood, show 
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increased apoptosis and may also contribute to the expression of 
autoantigens, and probably are involved in the pathogenesis of the 
disease.  
The actual causes of increased neutrophil apoptosis are not fully 
defined. Several studies have reported the development of apoptotic 
neutrophils in lupus patients is probably because of increased death 
receptor expression particularly Fas (100), an imbalance of neutrophil 
apoptosis regulatory cytokines (such as IL-1", GM-CSF, which delay 
apoptosis and TNF-!, which induces apoptosis) (101), and the 
autoantibody production against dsDNA and ribonucleoprotein La (102). 
These possibilities need to be further investigated. Notably, much of the 
data on neutrophil dysfunction comes from studies of adult SLE; there 
have been only a few studies in JSLE. Recently, it has been found that an 
imbalance in pro-apoptotic and anti-apoptotic factors in JSLE results in 
increased neutrophil apoptosis, and nuclear components from apoptotic 
neutrophils are expressed on the cell surface, presumably acting as a 
major source of autoantigens leading to autoantibody production (103, 
104). It has also been found that factors within JSLE serum induce 
neutrophil apoptosis via both the intrinsic and extrinsic pathways (105). 
1.3.2 NETosis 
NETosis is a process described as a specialized form of neutrophil 
death and results in the formation of neutrophil extracellular traps (NETs) 
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(49). It is induced by metabolites of reactive oxygen species, in addition 
to proteins from neutrophil granules, which generate chromatin 
decondensation and nuclear membrane breakdown. An accumulation of 
these nuclear components causes an expulsion of a mesh-like structure, 
namely a NET, into the extracellular compartment (106). As this web-like 
structure contains chromatin and DNA, therefore it can potentially be 
another source for extracellular DNA or autoantigen exposure, leading to 
the development of autoantibodies in lupus patients. 
A number of studies have shown an important role for NETosis 
and the formation of extracellular DNA in the pathogenesis of SLE. 
Increased NET formation and impairment of NET degradation have been 
demonstrated in patients with SLE (51, 107, 108). NETs are usually 
degraded by the action of deoxyribonuclease 1 (DNase 1), but it has been 
found that this enzyme is inhibited in patients with SLE, because of an 
increased production of anti-NET antibodies and DNase 1 inhibitors 
(107). Moreover, autoantibodies to neutrophil anti-microbial peptides 
LL-37 detected in patient serum, could attach to NETs and promote 
NETosis (108). The process of NETosis was also identified in the skin 
and kidney of lupus patients, and it correlated with increased levels of 
anti-dsDNA autoantibodies in serum (109). A study in JSLE patients 
recently reported that mature neutrophils exposed to serum-derived anti-
ribonucleoprotein antibodies from JSLE patients die by NETosis, and the 
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products from this form of cell death (NETs), are able to activate 
plasmacytoid dendritic cells to produce type I interferon (e.g. IFN-!) in a 
TLR9- and DNA- dependent manner (51). 
1.3.3 Low-density granulocytes 
 Several studies have demonstrated an abnormal subset of 
neutrophils in preparations of peripheral blood mononuclear cells 
(PBMCs) from both JSLE and adult SLE patients (94, 110, 111). These 
cells have been shown to express type I interferon (94). More 
importantly, high numbers of low-density granulocytes are associated 
with skin involvement and vasculitis in patients with SLE. 
 Low-density granulocytes have an immature morphology and 
present a pro-inflammatory phenotype (94). They secrete type I and type 
II interferon and TNF-! after stimulation, which promote organ and 
tissue damage. Furthermore, they have an increased ability to destroy 
cell-cell interactions on endothelial cells and exhibit high rates of NET 
formation (109). Nevertheless, the origin and the full function of low-
density granulocytes in patients with SLE need to be further investigated. 
1.3.4 Defective neutrophil function 
Defective phagocytic ability by neutrophils and decreased 
opsonisation of S. aureus by sera from adult SLE patients with active 
disease has been demonstrated (112). Interestingly, these conditions are 
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more common in patients who are not treated with corticosteroids or 
other immunosuppressive drugs (96, 112). It has been found that 
circulating autoantibodies in patient serum e.g. autoantibodies directed 
against CD11b/CD18 (Mac-1) block opsonin receptor binding on 
neutrophils, thereby decreasing their phagocytic ability (113). Moreover, 
factors in serum of SLE patients are able to induce neutrophil aggregation 
and interfere with granule enzyme release (114). Other studies have 
shown that neutrophils activated by serum from SLE patients 
overexpressed adhesion molecules on their cell surface, which promoted 
aggregation (115). These findings suggest that serum factors most likely 
cause defective neutrophil phagocytosis as they activate neutrophil 
aggregation, and also interrupt the process of opsonisation and neutrophil 
phagocytosis and killing.  
The release of granule enzymes and anti-microbial peptides by 
neutrophils during phagocytosis in SLE patients is controversial. One 
study has demonstrated that serum levels of lysosomal enzyme released 
from neutrophils were decreased in SLE patients, compared to controls, 
but the decrease was unrelated to disease activity (98). Another recent 
study showed that the expression level of lactoferrin, a secondary granule 
of neutrophils, was lower in SLE neutrophils compared to normal control 
neutrophils (116). In contrast, some evidence has described increased 
levels of anti-microbial peptides such as defensins and lactoferrin in 
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serum from SLE patients (117–119). These protein levels, released by 
neutrophils, also correlated with disease activity and severity. While the 
presence of these autoantibodies against these proteins in patient serum 
has been shown, the actual role of these released neutrophilic enzymes 
and anti-microbial peptides in the pathogenesis of the disease remains 
unclear. 
Some reports have shown that SLE neutrophils express high 
levels of Fc#RI (CD64) and complement receptor CR3 (CD11b/ITGAM), 
inflammatory receptors leading to downstream inflammatory process 
(115, 120, 121). Fc#RIIB (CD32), which is an inhibitory receptor in 
normal immune response, is expressed at lower levels on SLE 
neutrophils, compared with healthy controls (122). The decreased 
expression of Fc#RIIB, may therefore result in a decreased ability to 
down-regulate inflammation after cell stimulation in SLE patients. Such 
studies have demonstrated that the expression of cell surface receptors 
and adhesion molecules on neutrophils is dysregulated and this could be 
another contributing factor of the abnormal inflammatory process in SLE. 
Defective neutrophil chemotaxis has also been reported in patients 
with SLE (97, 123). The data demonstrated that serum chemotactic 
factors produced by SLE neutrophils after endotoxin exposure or 
activation by insoluble immune complexes was markedly decreased. 
Neutrophil chemotactic activity was significantly decreased and these 
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findings correlated with a high incidence of infection in SLE patients. In 
contrast, another study demonstrated that neutrophil chemotaxis was 
hyperactive (124). The expression of cell surface markers such as MCP-
1c, MIP-1!, CCL-5, CXCR4 and CXCL-12, which are involved in 
neutrophil chemotaxis, and their receptors, were increased in SLE 
patients both in vitro and ex vivo (125–127). Moreover, other studies 
have shown that BX471, a CCR1 antagonist and CXCR4 and CXCL12 
blockers were able to prevent the progression of lupus nephritis in mice 
(128, 129). These findings suggest that hyperactive neutrophil 
chemotaxis may be involved in inflammatory processes leading to tissue- 
or organ damage in SLE patients.  
Several studies have demonstrated that ROS production is 
decreased in JSLE patients (130, 131). The data showed that superoxide 
production after phorbol myristate acetate (PMA) stimulation was 
decreased in patients compared to healthy controls, regardless of the 
immunosuppressive treatments. However, there was no significant 
difference in neutrophil ROS production between inactive and active 
cases of lupus patients (131). In contrast, increased ROS production in 
SLE neutrophils has been reported in several studies (124). For example, 
after stimulation with bacterial peptide, (N-formyl-methionyl-leucyl-
phenylalanine; fMLP) or patient serum, lupus neutrophils showed 
increased superoxide production compared to normal control neutrophils 
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(132). The degree of oxidative metabolism from lupus neutrophils relates 
to the disease activity and tissue or organ damage observed in the patients 
(e.g. vascular damage, skin lesions and lupus nephritis) (49, 133). In 
addition, clinical administration of anti-oxidants, such as Vitamin E 
resulted in decreased autoantibody production in SLE patients (134). 
Taken together, these findings support the idea that an increase in ROS 
production is involved in the pathogenesis of SLE, particularly in terms 
of autoantigen and autoantibody production. Nevertheless, the regulation 
of ROS production in SLE is still unclear, and further investigations are 
required. 
1.3.5 Neutrophils and tissue or organ damage 
 Current evidence suggests that neutrophils are key players in the 
development of tissue or organ damage in patients with SLE, particularly 
in patients presenting with cutaneous lupus lesions, cardiovascular 
complications and renal disorders (135). Neutrophil infiltration has been 
demonstrated in various types of cutaneous lupus lesions (135). The most 
common skin lesions infiltrated by neutrophils include bullous lupus 
erythematosus, cutaneous vasculitis, and urticarial vasculitis (136–138). 
The prominent findings in skin histopathology often have abundant 
neutrophil infiltration and neutrophil debris at the dermo-epidermal 
junction, deep dermis and skin appendages, including blood vessels 
(139). It has been found that autoantigens, such as dsDNA, anti-microbial 
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peptides (including LL-37) and pro-inflammatory cytokines, such as IL-
17, are produced by neutrophils via the process of NETosis in the 
affected skin (109). Moreover, NETosis of affected skin lesions are 
associated with increased serum levels of autoantibodies in these patients. 
 JSLE patients have a higher risk of cardiovascular and 
cerebrovascular events, particularly premature atherosclerosis (64). The 
accelerated vascular damage in these patients results from an imbalance 
between endothelial damage and repair mechanisms. It has been 
demonstrated that type I interferon produced by low-density 
granulocytes, interferes endothelial progenitor cells and circulating 
myeloid angiogenic cell functions (140, 141). Dysfunction of these two 
types of cells leads to ineffective vascular repair. Moreover, low-density 
granulocytes are able to induce endothelial cytotoxicity (94). For this 
reason, this abnormal subset of neutrophils seems to be most involved in 
the induction of premature atherosclerosis in patients with JSLE. 
 Lupus nephritis is one of the worst prognostic factors in patients 
with JSLE and adult-onset SLE (55, 60, 61). Neutrophils are most likely 
to become involved in kidney inflammation during in disease flare. It has 
been demonstrated that neutrophils are mainly localized within the 
glomeruli in lupus nephritis and numerous enzymes produced by 
neutrophils, such as myeloperoxidase, elastase and cathepsin, are released 
into the affected area leading to glomerular inflammation and kidney 
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damage (142–144). This finding is supported by evidence of the presence 
of the neutrophilic enzyme, neutrophil gelatinase-associated lipocalin 
(NGAL), in urine and plasma of patients with JSLE (145). NGAL is 
released by neutrophils in certain circumstances, particularly in acute 
renal damage. It has been found that the levels of NGAL could predict 
the worsening of lupus nephritis and to correlate with disease activity. In 
addition, NET formation, associated with the development of 
glomerulonephritis in lupus patients, has been described (107, 109). 
Neutrophils producing NETs are identified in patient kidneys and 
correlated with the levels of autoantibodies in serum. 
 
1.4 Role of Cytokines in Juvenile Systemic Lupus Erythematosus 
A number of reports suggest that an imbalance of cytokine levels 
in serum is probably one of the major factors involved in the immune-
pathogenesis of JSLE and adult-onset SLE (146). The serum levels of IL-
2, IL-6, IL-10, IL-17, IL-18, IL-21, type I IFNs, TNF-! and B 
lymphocytes stimulators (BLys), are suggested as important factors to 
correlate with the degree of disease activity in SLE patients (146). It has 
been found that patients with active SLE have significantly increased 
serum IL-6, IL-17 and TNF-!, particularly IL-6 and TNF-!, which are 
also demonstrated in kidney biopsies of lupus nephritic patients (83). 
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1.4.1 Interleukin 6 (IL-6) 
 The association between IL-6 and the pathogenesis of SLE has 
been reported in many studies (83, 146–148). IL-6 is expressed by many 
cell types, such as monocytes, fibroblasts, endothelial cells and 
lymphocytes, including T- and B- cells, and it has a different biological 
effects on these target cells (149). One of its most important effects in the 
pathogenesis of SLE is to promote B cell differentiation into plasma cells 
and induce IgG production (150). IL-6 signaling requires a coupling of 
the heteromeric receptor complex, which is composed of IL-6 receptor 
(IL-6R) and a signal transducing chain (gp130). Binding of IL-6 to IL-6R 
induces gp130 dimerization followed by JAK1 activation and tyrosine 
phosphorylation of gp130. This signal subsequently triggers activation of 
the ERK/MAPK and p-STAT3 pathways and promotes differentiation 
and maturation of target cells (149). 
 The role of IL-6 in the development of SLE has been 
demonstrated in murine lupus mice (MRL/lpr) (151). Increased serum 
levels of IL-6 and IL-6R correlate with age in lupus mice (152). IL-6-
deficient mice showed a decreased infiltration of T-lymphocytes and 
macrophages, and lowered deposition of IgG and C3 in kidneys. These 
lupus mice had a delayed onset of lupus nephritis and increased survival. 
In addition, exogenous administration of recombinant human IL-6 in 
NZB/W F1 mice accelerated glomerulonephritis, whilst IL-6 receptor 
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blockage decreased renal proteinuria. The serum levels of IgG antibodies, 
particularly anti-dsDNA autoantibodies, were decreased and this therapy 
significantly increased the survival rate of these animals (153, 154).  
 In active lupus patients, increased serum levels of IL-6 correlate 
with B-cell hyperactivity, anti-DNA levels and disease activity (155–
157). Circulating IgG anti-DNA antibodies secreted by B-cells were 
decreased by IL-6 blockade and restored by exogenous IL-6 
administration. Several studies showed increased levels of urinary IL-6 
and high expression of IL-6 in the glomeruli and renal tubules of the 
kidneys from patients with lupus nephritis (158). Moreover, elevated IL-6 
levels were also observed in cerebrospinal fluid of patients with 
neuropsychiatric disorders (159). These studies proposed that IL-6 and 
IL-6R could serve as markers for monitoring disease activity and disease 
flare (160). IL-6 shows a correlation with lupus nephritis; therefore, its 
receptor antagonist may be potentially be used for treatment. 
 Tocilizumab is an IL-6 receptor antagonist (a humanized 
monoclonal antibody), that has been tested in an open label-phase I trial 
in patients with SLE (161). The preliminary results showed an 
improvement of disease activity score, decreased levels of anti-dsDNA 
and acute phase reactants. 
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1.4.2 Interleukin 17 (IL-17) 
 IL-17 is a potent pro-inflammatory cytokine primarily produced 
by activated T-lymphocytes, including CD4+ T cells, CD8+ T cells, CD4-
CD8- CD3+ T cells and #&-T cells, but it is also reported to be released by 
other cell types such as neutrophils, mast cells and natural killer (NK) 
cells (162). Several effects of IL-17 on different cell types via IL-17 
receptors (IL-17R) have been reported (163, 164). There are six IL-17 
family members (A to F) and five IL-17Rs (A to E). Signaling via these 
receptors induces inflammatory responses by increasing production of 
pro-inflammatory cytokines and chemokines, particularly IL-1", IL-6 and 
IL-8 in SLE (165). Moreover, IL-17 signaling promotes up-regulation of 
adhesion molecules (e.g. ICAM1), B cell differentiation into plasma cells 
and autoantibody production (76, 166, 167). 
One of the CD4+ T cell subsets that specifically produces IL-17, is 
the Th17 cell. Th17 lymphocytes originate from naïve T cells and they 
are initially activated by certain cytokines (e.g. TGF-", IL-1", IL-6, IL-21 
and IL-23) leading to an up-regulation of the retinoic acid 
receptor‐related orphan receptor‐#t (ROR#t), expression and then 
selectively produce IL-17 (165, 168). IL-23 is one of the most important 
factors for Th17 differentiation and the association between the IL-23/IL-
17 axis and the pathogenesis of SLE has been reported in both animal and 
human studies (147, 169). 
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In MRL/lpr mice, increased production of IL-17 by CD4- CD8- 
CD3+ T cells and up-regulation of IL-17R and IL23R expression on 
lymphocytes have been described, and is associated with disease 
progression (170). Lymphoid cells from these mice after IL-23 treatment 
in vitro and then transferred to other non-autoimmune mice and were able 
to induce lupus nephritis (171). In addition, IL-23R deficiency in lupus-
prone mice (C57BL/6-lpr/lpr) resulted in lowered numbers of CD4- CD8- 
CD3+ T cells and IL-17 producing cells in the lymph nodes. These mice 
had decreased levels of anti-DNA antibodies and were devoid of 
pathological and clinical features of lupus nephritis (170). 
 Increased serum levels of IL-17 and IL-23 were observed in SLE 
patients and these levels correlated with disease activity (172). IL-17 can 
promote B lymphocyte proliferation and differentiation, leading to 
autoantibody production in SLE patients (76). IL-17 producing cells were 
also identified in skin, lungs and kidneys in the patients and were more 
likely to be involved in the inflammatory process of tissue or organ 
damage (173–175).  
 Despite IL-17 being an important cytokine in the pathogenesis of 
SLE, the therapeutic targeting of IL-17 or IL-17 blockade is still 
inconclusive (147). A relationship between Th17 cells and other T cell 
subsets has been in several studies. For example, one study showed that 
Th17 cells down-regulated Th1 differentiation, and improved acute graft-
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versus-host-disease in recipient mice (176). Neutralizing IL-17 may 
induce exacerbation of the disease. Another study demonstrated that an 
increased number of Th17 cells were associated with a decrease in 
regulatory T (Treg) cells in active SLE patients (177). Notably, Treg cells 
and Th17 cells differentiate from the same precursor cell and they can 
inhibit each other’s function (178). Therefore, IL-17 blockade and the 
manipulation of the balance between Th17 cells and other T cell subsets 
should be considered for the treatment of SLE. 
1.4.3 Type I interferon (type I IFN) 
 All types of white blood cells, including plasmacytoid dendritic 
cells can synthesize type I IFN (179). Several mechanisms have been 
postulated to explain how type I IFN may play a role in the pathogenesis 
of SLE. One possibility is that autoantigen-autoantibody complexes 
activate plasmacytoid dendritic cells to secrete type I IFN and this 
cytokine then promotes dendritic cell maturation, and enhance 
autoantigen presentation (180, 181). Moreover, type I IFN promotes B 
cell hyperactivity and autoantibody production (182). 
 In lupus-prone mice (B6 lpr), a study has shown that a potent 
inducer of type I IFN, polyinosinic:polycytidylic acid, increased numbers 
of macrophages and activated lymphocytes (183). In this study, levels of 
autoantibody and immune complex deposition were measured, followed 
by progression of lupus nephritis. Another study demonstrated that mice 
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deficient in type I IFN receptors, had decreased titers of anti-DNA 
autoantibodies, and diminished kidney manifestations, including disease 
severity (184). Numbers of activated dendritic cells and lymphocytes 
were also decreased (185). These finding support the important role of 
type I IFN in the pathogenesis of SLE.  
The association of Toll-like receptors (TLRs) and type I IFN 
production has been well documented in the lupus mouse model. TLR-7 
and TLR-9 bind single-strand RNA and hypomethylated CpG-rich DNA, 
respectively (146). Signaling through these two receptors on B cells 
results in autoantibody production and lupus nephritis (186). It has been 
demonstrated that type I IFN signaling is essential for the process of up-
regulation TLRs and activation through TLR-7 and -9 on B cells resulting 
in autoantibody production (187). Moreover, dual inhibition of TLR-7 
and TLR-9 results in a significant improvement of lupus nephritis and 
decreased the level of autoantibodies in lupus-prone mice. 
 Increased levels of type I IFN were observed in patients with SLE 
(188). The association between the levels of type I IFN and the titers of 
autoantibodies, and disease activity have also been described. An 
accumulation of plasmacytoid dendritic cells, which are major sources of 
type I IFN production, has been reported in the epidermal layer of 
cutaneous lupus lesions and the glomeruli of lupus nephritis (189). In 
addition, the expression of IFN-inducible genes in PBMC isolated from 
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patients with SLE correlates with disease activity (190). There are several 
identified IFN-inducible genes associated with increased risk of SLE. For 
example, many functional variants of Interferon regulatory factor 5 
(IRF5), together with a number of SNPs have been identified (191). The 
resulting haplotypes derived from these variants correlate with high 
serum levels of IFN-! and autoantibodies, which are associated with 
heightened risk of SLE. One SNP in the third intron of signal transducer 
and activator of transcription 4 (STAT4), associates with a severe SLE 
phenotype, that is characterized by young age of onset with severe 
clinical manifestations and the presence of typical autoantibodies (192). 
This SNP correlates with IFN-! hypersensitivity and anti-dsDNA 
autoantibody production in SLE patients. Moreover, a combination of 
these variants from different genes (e.g. IRF5 and STAT4) results in an 
additive risk factor of the disease (193). 
 An anti-IFN-! monoclonal antibody, Sifalimumab, has been 
studied in a phase I clinical trail (194) for the treatment of active SLE. 
The results showed an improvement of the disease, in terms of disease 
activity, disease flare and immunosuppressive drug usage. 
1.4.4 Tumour necrosis factor-" (TNF-") 
TNF-! is another important cytokine involved in the pathogenesis 
of SLE, but its actual role is still unclear (195). Immune-regulatory and 
pro-inflammatory functions of TNF-! have been reported, including 
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different effects on a range of cells (e.g. B cells, T cells and dendritic 
cells) (196).  
It has been demonstrated that immune complexes can activate 
lupus macrophages to produce high levels of TNF-! (197). There are two 
forms of TNF-!; a membrane-bound form expressed as a trimer on the 
cell membrane and a soluble form which is secreted to the extracellular 
compartment (83). Both forms are involved in the generation of B cell 
follicles of the secondary lymphoid organ structures, such as lymph 
nodes and Peyer’s patches and they are growth factors for B cells, 
inducing IL-1 and IL-6 production (198–200). TNF-! is also involved in 
the proliferation of T cells responding to certain stimuli (e.g. IL-2) (201). 
However, the duration of T cells exposure to TNF-! is crucial: short-term 
stimulation leads to proliferation, further activation of T cells and 
induction of IFN-# production, whilst long-term stimulation promotes a 
loss of T cell receptors (TCRs) on the cell membrane and results in a 
decreased response of T cells (195, 201, 202). In addition, TNF-! is 
directly involved in both apoptotic and anti-apoptotic pathways 
depending on the TNF-! receptors engaged (TNFR) (34). TNFR1 
mediates both apoptotic and anti-apoptotic, and inflammatory responses 
while TNFR2 is involved only in the apoptotic pathway. Therefore, TNF-
! and their receptors determine may regulate cell survival, differentiation, 
inflammatory responses or cell apoptosis. 
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Decreased production of TNF-! has been reported to correlate 
with severe disease in lupus mice (NZB/W) (203). The mice with intact 
TNF-! had only mild disease activity, and these findings suggest that 
TNF-! deficiency may be a trigger factor in the development of SLE. In 
contrast, another study described increased serum levels of TNF-! in 
lupus mice (MRL/lpr) and the levels correlated with the severity of renal 
disease (204). High concentrations of TNF-! were also observed in renal 
tissue. Furthermore, treatment of lupus mice with anti-TNF-! resulted in 
an improvement of the disease, including decreased arthritis and 
pulmonary disease (205, 206). As a result, the role of TNF-! in the 
pathogenesis of murine SLE is still questionable in murine lupus mice. 
Many studies have demonstrated that serum levels of TNF-! are 
markedly high in patients with SLE, compared to healthy controls and 
higher in patients with active disease (207–210). Increased levels of 
TNF-! in renal tissue from patients with lupus nephritis, particularly in 
glomeruli, have also been observed (209), with levels correlated with 
urine TNF-! levels and renal disease activity. These findings suggest that 
TNF-! plays a pro-inflammatory role in the development of lupus 
nephritis.  
In addition, many studies have described TNF-! gene 
polymorphisms associated with susceptibility to SLE (195). Most of these 
studies have demonstrated microsatellites (single sequence repeat; SSRs) 
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and SNPs in the promoter regions of TNF-! gene, and showed a 
correlation with specific clinical features. For example, the 
microsatellites of TNF-!2, TNF-"3 and TNF-#2 alleles were associated 
with mucocutaneous manifestations (e.g. photosensitivity and Raynaud’s 
phenomenon) (211). The -308A/G polymorphism correlated with 
mucocutaneous manifestations (e.g. malar rash, oral ulcers and classic 
discoid LE) and hematological involvement (212). Furthermore, an 
abnormal TNF-! expression correlating with disease activity has been 
reported in PBMC and bone marrow cells from patients with SLE (213, 
214).  
Anti-TNF-! therapy has been used in clinical studies in patients 
with SLE, but shows contradicting results. Several lines of evidence have 
demonstrated that patients with other rheumatic diseases who received 
TNF-! blockers, have developed lupus-like symptoms, such as malar 
rash, oral ulcers and discoid rash, and a presence of autoantibodies (e.g. 
ANA and anti-dsDNA antibodies) (215). Therefore, the role of TNF-! 
and the application of TNF-! antagonists for patients with SLE are still 
unclear. 
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1.5 Summary 
Neutrophils have a pathological role in the progression of 
autoimmune diseases (11). It has been reported that neutrophils are an 
important contributing factor in disease pathology of SLE, including 
JSLE. JSLE is a subgroup of SLE, and patients usually have more severe 
clinical features and major organ involvements (e.g. kidneys and CNS) 
(55, 60, 61). Increased numbers of apoptotic neutrophils in patients with 
JSLE have been reported and this factor could can be a major cause of 
exposure of autoantigens leading to autoantibody production and 
subsequently induction of tissue and organ damage (49, 99, 100, 103). 
Moreover, an imbalance in the production of cytokines may be involved 
in the disease pathology, particularly TNF-!, type I IFNs, IL-6 and IL-17 
(83, 146, 216–219) these factors could also be responsible for increased 
neutrophil apoptosis in JSLE. In addition, neutrophil functional defects 
have been reported in patients with SLE, leading to susceptibility to 
infections. However, there are only a few reports describing defective 
neutrophil functions in JSLE patients (50–52, 95, 112). As the 
pathogenesis of the disease is still unclear, supportive treatments are only 
the option that prevent organ or system damage. Current treatments 
include corticosteroids, anti-malarial drugs (e.g. hydroxychloroquine), 
immunosuppressive drugs and new biologics. All medications have side 
effects, and so their clinical applications, particularly in juvenile patients, 
need to be carefully considered. 
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1.6 Research Aims 
The main objectives of my study were to: 
1. Determine if sera from patients with JSLE was defective in 
regulating neutrophil functions, such as cell survival, and 
opsonisation of bacteria for effective phagocytosis and activation 
of the respiratory burst. 
2. Investigate the effects of recombinant-cytokines, which have been 
reported as being imbalanced in patient serum, on neutrophil 
apoptosis and to measure cytokines in the sera of JSLE patients. 
3. Determine whether adding GM-CSF (a potent cytokine that 
delays neutrophil apoptosis) is capable of protecting neutrophils 
against apoptosis in JSLE patients. 
4. Determine the molecular events that regulate neutrophil responses 
to TNF-! signaling, as the role of TNF-! in disease pathology 
remains unclear. 
5. Investigate JSLE neutrophil functions in terms of cell survival, 
phagocytosis, ROS production and chemotaxis. 
6. Evaluate whether hydroxychloroquine, a commonly-used anti-
malarial agent for patients with JSLE, has any effects on 
neutrophil functions. 
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Chapter 2: Materials and Methods 
2.1 Materials 
Table 2.1 Materials for neutrophil isolation and culture 
Materials Supplier 
Lithium heparin vacutainers Grenier Bio-one 
(Gloucestershire, UK) 
PolymorphprepTM AxisShield (Cambs, UK) 
RPMI 1640                                               
(+25mM Hepes with L-glutamine)  
Gibco (Paisley, UK) 
Ammonium chloride lysis buffer 
 
Sigma (Poole, UK) 
   - Ammonium chloride (NH4Cl) 
   - Potassium hydrogen carbonate (KHCO3) 
   - Ethylenediaminetetracetic acid (EDTA) 
Isoton Beckman Coulter Inc. 
(Florida, USA) 
Rapid Romanowsky stain HD Supplies  
(Aylesbury, UK) 
Human pooled AB serum Sigma (Poole, UK) 
Fetal bovine serum Invitrogen (Paisley, UK) 
Phosphate buffered saline (PBS) tablets Oxid Ltd         
(Basingstoke, UK) 
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Table 2.2 Materials for preparation of protein lysates and Western 
blotting 
Materials Supplier 
Laemelli lysis buffer   
   - Glycerol 
   - Sodium dodecyl sulphate 
   - Tris 
Fisher Scientific 
(Loughborough, UK) 
   - Bromophenol blue Sigma (Poole, UK) 
Dithiothreitol (DTT)  
Glycine Sigma (Poole, UK) 
Sodium chloride (NaCl)  
Hydrochloric acid (HCl) VWR International 
(Leicestershire, UK) 
Ammonium persulphate (APS)  
Isopropanol  
Methanol Sigma (Poole, UK) 
Tetramethylethylenediamine (TEMED)  
Tween-20  
Polyacrylamide Severn Biotech 
(Kidderminster, UK) 
Biotinylated protein ladder detection pack Cell-Signalling 
Technology (USA) 
Polyvinylidene fluoride (PVDF) membrane Millipore (Hertfordshire, 
UK) 
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Whatman filter paper Sigma (Poole, UK) 
Marvel non-fat powered milk Home Bargain 
(Liverpool, UK) 
Bovine serum albumin (BSA) 
Sigma (Poole, UK) 
Ponceau S 
Immobilon Western Chemiluminescent          
HRP substrate 
Millipore             
(Billerica, UK) 
Enhanced chemiluminescence hyperfilm Amersham Life Science 
(Bucks, UK) 
Film developing (developer and fixer) Sigma (Poole, UK) 
 
Table 2.3 Cytokines and stimulants 
Materials Supplier 
Recombinant human GM-CSF  Roche Diagnostics Ltd. 
(East Sussex, UK) 
Recombinant human TNF-! 
Recombinant human IFN-# 
Calbiochem 
(Nottingham, UK) 
Recombinant human IL-1" 
Recombinant human IL-8 
Recombinant human IL-17 
Invitrogen (Paisley, UK) 
Recombinant human IL-6 
Sigma (Poole, UK) 
N-formylmethionyl-leucyl-phenylalanine 
(fMLP) 
Phorbol 12 myristate 13-acetate (PMA) 
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Table 2.4 Dyes and antibodies 
Materials: dyes and antibodies Supplier 
Hanks balanced salt solution (HBSS) Gibco (Paisley, UK) 
FITC-conjugated Annexin V Invitrogen (Paisley, UK) 
Propidium iodide (PI) Sigma (Poole, UK) 
Western blotting antibodies 
 
Cell-Signalling 
Technology (USA) 
   - anti-human  Mcl-1 
   - anti-human caspase 3 
   - anti-human caspase 7 
   - anti-human caspase 8 
   - anti-human caspase 9 
   - anti-human caspase 10 
   - anti-human FLIP 
   - anti-human TNFR1 
   - anti-human TNFR2 
   - anti-human FADD 
   - anti-human TRADD 
   - anti-human "-actin 
Bacterial lipopolysaccharide (LPS) 
Sigma (Poole, UK) 
Cycloheximide 
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   - anti-human GAPDH Cell-Signalling 
Technology (USA) 
 
Table 2.5 Materials for isolation neutrophil mRNA, cDNA synthesis 
and Quantitative PCR 
Materials Supplier 
Trizol® reagent Gibco (Paisley, UK) 
Chloroform 
Sigma (Poole, UK) Isopropanol 
Ethanol 
RNeasy kit 
Qiagen (Crawley, UK) 
DNA digestion solution 
Superscript III first strand cDNA synthesis 
kit Invitrogen (Paisley, UK) 
RNase OUT RNase inhibitors 
Random primers Promega (Southampton, 
UK) 
Quantitect SYBR green PCR kit Qiagen (Crawley, UK) 
Primers Eurofins (UK) 
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Table 2.6 Materials for measurement of neutrophil phagocytic assay 
and respiratory burst 
Materials Supplier 
Staphylococcus aureus (Oxford strain) 
Department of Medical 
Microbiology, University 
of Liverpool, UK 
LB agar and LB broth Merck (Feltham, UK) 
Propidium iodide, Gelatin Sigma (Poole,UK) 
Hanks balanced salt solution (HBSS) Gibco (Paisley, UK) 
Dihydrorhodamine 123 (DHR123) Invitrogen (Paisley, UK) 
 
Table 2.7 Materials for neutrophil chemotaxis assay and 
measurement of neutrophil ROS production 
Materials  Supplier 
Hanging cell culture inserts Millipore         
(Hertfordshire, UK) 
Luminol Sigma (Poole, UK) 
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Table 2.8 Other materials 
Other materials Supplier 
Serum vacutainers 
Grenier Bio-one          
(Gloucestershire, UK) 
Reacti-bind™ Protein L coated, clear 96-well 
plate (Blocking buffer) 
Thermo scientific 
(Illinois, USA) 
Hydroxychloroquine (HCQ) Sigma (Poole, UK) 
 
2.2 Methods 
2.2.1 Isolation of human neutrophils from whole blood 
For the UK cohort, the study of adult healthy controls was 
approved by the University of Liverpool Committee for Research Ethics 
(CORE), while the juvenile healthy controls and JSLE patient study was 
approved by the Liverpool Paediatric Research Ethic Committee. For the 
Thai cohort, the study of juvenile healthy controls and JSLE patients was 
approved by Chulalongkorn University Human Research Ethic 
Committee. The diagnosis of JSLE for both population is based on at 
least 4 out of the 11 criteria from the American College of Rheumatology 
(1997 revision) guidelines before the age of 17 years (59). The disease 
activity for the Thai cohort was classified into disease active and inactive 
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using clinical assessment and/or Systemic Lupus Eryhtematosus Disease 
Aactivity Index (SLEDAI) score (220). For example, JSLE patients with 
disease active usually present with skin manifestations (e.g. malar rash, 
oral ulcers, cutaneous vasculitis and diffuse hair loss) and renal 
involvement (e.g. lupus nephritis, proteinuria and hypertension), and 
increase in SLEDAI score of more than 3. Written informed consent 
and/or assent form were obtained from all participating subjects and/or 
their parents. Whole blood was collected into heparinized vacuette 
containers by venipuncture and was processed within 2 h of collection. 
Neutrophils were isolated by one-step centrifugation using 
Polymorphprep, according to the manufacturer’s instructions (221). The 
principle of neutrophil isolation by Polymorphprep is based on an 
isosmotic density barrier that separates the peripheral blood mononuclear 
cells and granulocytes (including neutrophils) into two layers after 
centrifugation, whereas erythrocytes sediment to the bottom of the 
solution (221). In brief, whole blood was layered in a 1:1 to 1.5:1 ratio 
onto Polymorphprep and centrifuged at 500 g for 30-35 min in room 
temperature. Plasma and peripheral blood mononuclear cell layers were 
discarded. The granulocyte later containing including neutrophils was 
harvested by a Pasteur pipette and resuspended in RPMI 1640 media plus 
25 mM Hepes with L-glutamine (2mM) then centrifuged at 500 g for 5 
min. The cells were resuspended in media and contaminating 
erythrocytes were removed by hypotonic lysis (ammonium chloride lysis 
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buffer: 13.4 mM KHCO3, 155 mM NH4Cl and 96.7 mM EDTA in 500 
mL distilled water) used in a ratio of 1:9 media:lysis buffer for 3 min 
before centrifugation at 500 g for 3 min. Ammonium chloride lysis buffer 
has little effect on neutrophil function (222). Neutrophils were 
resuspended in media and counted using a Multisizer 3 cell counter 
(Beckman Coulter), and the suspension volume was adjusted to give a 
final concentration of 5 x 106 cells/mL. The purity of samples (> 95% 
neutrophils) was assessed by examination of cytospins prepared using a 
Shandon 3 cytospin (20 µL cells in 180 µL PBS+EDTA). After 
centrifugation at 30 g for 5 min, neutrophils were stained with Rapid 
Romanowsky staining. Neutrophils were further resuspended in RPMI 
1640 media plus 25 mM Hepes supplemented with 10% (v/v) human AB 
serum or 10% (v/v) child healthy control serum or JSLE serum for 
specific experiments, as indicated in the text. Neutrophils were incubated 
in a 5% CO2 incubator at 37°C with gentle agitation. 
2.2.2 Serum collection 
Sera were collected from the peripheral blood samples of JSLE 
patients and healthy juvenile controls by centrifugation of clotted blood at 
500 g for 5 min. The sera were frozen in -80oC freezer for later use. 
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2.2.3 Flow cytometry for neutrophil apoptosis 
Neutrophil apoptosis and necrosis was measured using flow 
cytometry. Phosphatidylserine expressed on the membrane of apoptotic 
neutrophils was stained with annexin V-FITC and DNA of necrotic 
neutrophils in late apoptosis (with leaky plasma membrane) was stained 
with propidium iodide (PI). 1 x 105 cells of neutrophils in 100 µL HBSS 
were incubated with annexin V-FITC (10 µL/mL) for 15 min in the dark, 
at room temperature and PI (1 µg/mL) was added just prior to the flow 
analysis. 5,000 gated cells were analyzed using the Guava Easycyte flow 
cytometer. 
In all experiments measuring apoptosis by annexin V/PI staining 
and flow cytometry, absolute numbers of neutrophils were routinely 
counted after each experiment. Simply measuring the % of neutrophils 
that expressed markers of apoptosis (e.g. annexin V binding) could 
underestimate the level of cell death if some neutrophils had become 
necrotic and lysed. Therefore, in all experiments measuring neutrophil 
apoptosis, both the % number of apoptotic cells and the actual number of 
cells in the incubation were routinely measured. It was found that in all 
experiments, the numbers of neutrophils recovered after incubation was 
always > 95% of the initial incubation (1x106 cells/mL). Adjustment of 
this small loss of cells did not affect the values for % apoptosis and so in 
all experiments in this thesis, “% Apoptosis” values are presented.   
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2.2.4 Preparation of protein lysates 
Isolated neutrophils were centrifuged at 1,000 g for 3 min after 
incubation and/or treatment (as described in the text), the supernatant was 
discarded and the pellet was washed with PBS. The neutrophils were re-
centrifuged at 1,000 g for another 3 min. The supernatant was again 
discarded and the pellet was rapidly lysed in boiling Laemelli lysis 
buffer, consisting of 10% (v/v) glycerol, 1 M Tris-HCl (pH 6.8), 100 mM 
DTT, 3% (w/v) SDS and 0.001% (w/v) bromophenol blue, to a final 
concentration of 1x104 cells/µL. All samples were immediately boiled for 
5 min with occasional vortexing. Protein lysates were frozen at -20oC for 
later use. 
2.2.5 Western blotting 
Protein lysate samples were boiled, briefly centrifuged in a 
microfuge and 10-15 µL loaded onto 8-12% resolving polyacrylamide 
gels (dependent on the size of the protein of interest) with a 4.5% 
polyacrylamide stacking gel. The resolving gels were composed of 8-
12% (v/v) acrylamide, 1% (w/v) SDS, 370 mM Tris-HCl pH 8.8, 1% 
(w/v) APS and 0.1% (v/v) TEMED. The APS and TEMED were added 
last to aid polymerization. The stacking gels comprised 4.5% (v/v) 
acrylamide, 1% (w/v) SDS, 122 mM Tris-HCl pH 6.7, 1% (v/v) APS and 
0.1% (v/v) TEMED. A biotinylated protein molecular weight marker 
mixture was loaded alongside the samples. Gels were electrophoresed for 
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45-50 min at 200V in SDS running buffer (25 mM Tris, 0.1% (w/v) SDS 
and 192 mM glycine) using a Bio-rad Mini Protean II Electrophoresis kit. 
Proteins were transferred to polyvinylidenedifluoride membranes in 
transfer buffer (20% (v/v) methanol, 12.5 mM Tris and 95 mM glycine) 
by electrophoresis at 100V for 80 min using the same apparatus. 
Transferred proteins on the membranes were checked with Ponceau S 
staining (0.1% (w/v) Ponceau S and 5% (v/v) acetic acid). The stain was 
removed from the membranes by washing with wash buffer (150 mM 
NaCl, 0.1% (v/v) Tween-20 and 10 mM Tris-HCl pH 8) and the 
membranes were incubated with blocking buffer (5% (w/v) Marvel or 
non-fat skimmed milk in wash buffer) for at least 1 h on an orbital shaker 
at room temperature in order to prevent non-specific antibody binding. 
Membranes were then rinsed with wash buffer for 30 sec and incubated 
with the appropriate primary antibody in either blocking buffer or 5% 
(w/v) BSA in wash buffer at the appropriate concentration overnight at 
4°C on an orbital shaker. Following washing with wash buffer for 10 min 
three times, the membranes were incubated with the appropriate HRP-
conjugated secondary antibody in blocking buffer for at least 1 h at room 
temperature on an orbital shaker. Secondary antibody was removed by 
washing with wash buffer for 10 min (three times) and the membranes 
were stained with Enhanced Chemiluminescence (ECL) reagents 
(Millipore) and then were carefully exposed to Hyperfilm in the dark to 
detect bound antibodies, avoiding signal saturation. Densitometry 
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analysis of Western blots was performed using the AQM Advanced 6 
Kinetic Imaging System. Re-probing of membranes with other 
antibodies, such as "-actin or GAPDH, was carried out following 
stripping the membranes with stripping buffer (50 mM glycine, 0.1% 
(v/v) Tween-20, 150 mM NaCl and HCl to pH 2.5), followed by blocking 
with blocking buffer for 1 h. The band density of "-actin or GAPDH was 
measured and analyzed alongside with the band density of the protein of 
interest in order to confirm equivalent loading of proteins in each sample. 
Table 2.9 summarises antibodies used for Western blotting. 
Table 2.9 Western blot antibodies 
Protein of 
interest 
Primary antibody Secondary antibody 
Mcl-1 
Rabbit anti-human Mcl-1 
(1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
Caspase 3 
Rabbit anti-human 
Caspase 3 (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
Caspase 7 
Rabbit anti-human 
Caspase 7 (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
Caspase 8 
 Mouse anti-human 
Caspase 8 (1:1,000) 
HRP-conjugated sheep     
anti-mouse IgG (1:10,000) 
Caspase 9 
Rabbit anti-human 
Caspase 9 (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
! )$!
Caspase 10 
Rabbit anti-human 
Caspase 10 (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
FLIP 
Rabbit anti-human     
FLIP (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
TNFR1 
Rabbit anti-human     
TNFR1 (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
TNFR2 
Rabbit anti-human     
TNFR2 (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
FADD 
Rabbit anti-human     
FADD (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
TRADD 
Rabbit anti-human     
TRADD (1:1,000) 
HRP-conjugated donkey  
anti-rabbit IgG (1:10,000) 
"-actin 
Mouse anti-human       
actin (1:10,000) 
HRP-conjugated sheep     
anti-mouse IgG (1:10,000) 
GAPDH 
Mouse anti-human       
GAPDH (1:10,000) 
HRP-conjugated sheep     
anti-mouse IgG (1:10,000) 
 
2.2.6 Isolation of neutrophil mRNA 
1-2 x 107 isolated neutrophils were centrifuged at 1,000 g for 3 
min and the supernatant was discarded. The cell pellet was lysed using 1 
mL Trizol Reagent and the pellet was disrupted by repeatedly pipetting to 
obtain a homogeneous solution, which was then allowed to stand for at 
least 5 min at room temperature. 200 µL of chloroform was added and 
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mixed by vortexing the samples vigorously for 15 sec. The solution was 
allowed to stand for another 2-3 min at room temperature before 
centrifugation at 10,000 g for 15 min at 4°C. The aqueous layer 
containing RNA was removed and an approximately equal amount of 
isopropanol was added to precipitate the RNA at -20°C overnight. The 
RNA precipitate was centrifuged at 10,000 g for 30 min at 4°C to form a 
pellet and the supernatant was discarded. The pellet was washed using 
70% (v/v) ethanol/DEPC treated water and allowed to dry before 
resuspension in 100 µL RNase-free water. RNA was further cleaned to 
remove remaining contaminants using the Qiagen RNeasy kit, according 
to the manufacturers instructions. Genomic DNA contamination was 
eliminated by adding Qiagen DNase digestion solution in the column kit 
for 15 min at room temperature. RNA was finally eluted in 30 µL RNase-
free water. The quality and quantity of RNA was measured using a 
Nanodrop ND-100 spectrophotometer. The RNA samples were stored at -
80°C for later use. 
2.2.7 cDNA synthesis 
cDNA was synthesized from total RNA using the Superscript III 
First Strand cDNA synthesis kit (Qiagen) and RNase OUT (Qiagen), 
according to the manufacturer’s instructions. The total amount of each 
template RNA used in this study was usually 200-250 ng, and all RNA 
samples were adjusted to an equal amount within each experiment before 
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cDNA synthesis. Each RNA sample was added to 1 µL (250 ng or 20 
µM) random primer, 1 µL (10 mM) dNTPs and RNase free-water to a 
total volume of 13 µL before heating at 65°C for 5 min on heat block and 
then cooling on ice for at least 1 min. A mixture of 4 µL First-Strand 
buffer, 1 µL RNase OUT RNase inhibitor, 1 µL (0.1 M) DTT and 1 µL 
(200 units/µL) Superscript III reverse transcriptase was added into each 
sample on ice before incubation in a Thermo PX2 thermal cycler. cDNA 
synthesis was initiated at 25°C for 5 min, 50°C for 60 min and then 
heating to 70°C for 15 min. cDNA samples were stored at -20°C for 
further use. Table 2.10 summarises the cDNA synthesis procedure. 
2.2.8 Quantitative PCR (real-time PCR or qPCR) 
Quantitative PCR was carried out using the QuantiTect SYBR 
Green detection kit (Qiagen), according to the manufacturers instructions. 
1 µL cDNA was added to 10 µL QuantiTect, 0.8 µL (10 pM) of each 
forward and reverse primer and RNase-free water to a total reaction 
volume of 20 µL. Each sample was prepared in triplicate and Quantitative 
PCR was performed using the Roche LightCycler 480 qPCR machine. 
Levels of gene expression in samples were normalized to "-actin by 
comparing the Ct values, according to the Pfaffl method (223). Table 
2.11 and 2.12 summarise the Quantitative PCR cycle settings protocol 
and primer sequences. 
 
! )'!
Table 2.10 cDNA synthesis procedure 
Reagents 
Volume 
(µL) 
Concentration 
Temp 
(°C) 
Time 
(min) 
RNA+RNase free-water 
Random primers 
dNTPs 
11 
1 
1 
<10 ng/µL 
20 µM 
10 mM 
60 5 
On ice >1 
First-Strand buffer 
RNase OUT 
DTT 
Superscript III RT  
4 
1 
1 
1 
5X 
40 units/µL 
0.1 M 
200 units/µL 
25 5 
50 60 
70 15 
Total volume 20 
 
Table 2.11 Quantitative PCR cycle settings 
Step Procedure Temp (°C) Time  Cycles 
1. Taq activation 95 15 min 1 
2. Denaturation 95 1 min 45 
! )(!
Annealing 55 30 sec 
Elongation 72 30 sec 
3. Generating melt curves 
and checking product 
specificity 
 
60 
 
30 sec 
 
1 
 
 
Table 2.12 Primer sequences 
Gene 
symbol 
Product 
length (bp) 
Forward Sequence (5’-3’)                       
Reverse Sequence (5’-3’) 
Mcl-1L 170 TTATCTCTCGGTACCTTCGG 
TGCTTCGGAAACTGGACATC 
Mcl-1S 164 CCTTCCAAGGATGGGTTTG 
GGAGCTGGTTTGGCATATC 
TNF 219 CAGAGGGCCTGTACCTCATC 
GGAAGACCCCTCCCAGATAG 
BCL2A1 82 GAATAACACAGGAGAATGGATAAGG 
CCAGCCAGATTTAGGTTCAAAC 
CFLAR 93 ATAGATGTGGTTCCACCTAATGTC 
GTAGAGCAGTTCAGCCAAGTC 
TNFAIP3 113 AACATTTTGCTGCTGCCTCA 
TCCTTCAAACATGGTGCTTCC 
APAF1 94 CTTCCAGCCAACCTATTTTCCT 
CCTGATTAACCTTGGAGATAAAAGAA 
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BAX 101 ATGGAGCTGCAGAGGATGAT 
CAGTTGAAGTTGCCGTCAGA 
CASP10 124 GGAACGGACACACAACTCTC 
AGCCCACTCACTTACAGACTAA 
CASP8 95 AGTAAGCAACAAGGATGACAAGA 
ATCAATCAGAAGGGAAGACAAGTT 
FADD 176 CACAGACCACCTGCTTCTGA 
CTGGACACGGTTCCAACTTT 
FAS 104 TGTAGTATGAATGTAATCAGTGTATGT 
GATATTTCAGCAAAAGGTCATAGC 
TNFRSF1A 88 TGTGTCTCCTGTAGTAACTGTAAG 
AGTCCTCAGTGCCCTTAACA 
TNFRSF1B 145 GTCCACACGATCCCAACAC 
CACACCCACAATCAGTCCAA 
TRADD 88 GGTGCATCATTGGGGATTCT 
GGGAGAAGGTGAGGCTGAT 
GAPDH 106 CTCAACGACCACTTTGTCAAGCTCA 
GGTCTTACTCCTTGGAGGCCATGTG 
ACTB 211 CATCGAGCACGGCATCGTCA 
TAGCACAGCCTGGACAGCAAC 
B2M 114 ACTGAATTCACCCCCACTGA 
CCTCCATGATGCTGCTTACA 
PPIA 60 GCTTTGGGTCCAGGAATGG 
GTTGTCCACAGTCAGCCATGGT 
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2.2.9 RNA-sequencing and Bioinformatics 
RNA-sequencing and Bioinformatic analysis were performed as 
previously described by H. Wright and H. Thomas (224). In brief, 3 x 107 
isolated neutrophils were pelleted, and RNA from the pellet was 
extracted with Trizol reagent using an RNAeasy kit, which included a 
DNA digestion step (as described in section 2.2.6). Total RNA 
concentration and integrity were assessed using the Agilent 2100 
Bioanalyser RNA Nano chip. The total amount of RNA was >1 µg with 
an RNA integrity number (RIN) of 8 or more. Total RNA samples were 
enriched for mRNA using either poly-A selection or ribosomal depletion. 
Standard Illumina protocols were used to generate 50 bp single-end read 
libraries, which were then sequenced by the Illumina HiSeq 2000 
Analyser sequencing platform at the Beijing Genomics Institute (BGI). 
The human genome (hg19) was applied as a standard genome for read 
mapping using TopHat (225, 226) and Bowtie (227). Relative expression 
values (RPKM) were calculated using Cufflinks (228). Statistical analysis 
was performed using Cuffdiff to determine differential gene expression 
(228). Bioinformatics analysis was performed using Ingenuity Pathway 
Analysis (IPA) to identify how differentially expressed genes are mapped 
onto specific biochemical pathways. 
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2.2.10 Staphylococcus aureus (S. aureus) culture 
A glycerol stock of S. aureus (Oxford strain) in a cryovial tube 
stored at -80°C was streaked onto a sterile LB agar plate using aseptic 
technique. The plate was incubated at 37°C overnight to obtain single 
bacterial colonies and was then stored at 4°C for later use. A streak plate 
from the glycerol stock was discarded every 4 weeks, and a new fresh 
streak plate was prepared to ensure optimal bacterial growth. 
A single colony of S. aureus from the streak plate was inoculated 
into 10 mL of sterile LB broth and incubated at 37°C overnight on a 
gentle orbital shaker to mid-exponential growth phase of growth. An 
aliquot of culture was serially diluted with sterile LB broth and the 
absorbance of each dilution was recorded at 540 nm using a 
spectrophotometer. Known aliquots of each dilution were then plated and 
grown overnight. The number of colonies was counted and calibration 
curve of numbers of viable bacteria versus A540nm was prepared. The 
A540 of overnight cultures was then measured the concentration of viable 
bacteria determined (from the calibration curve) and the culture was 
centrifuged at 2,000 g for 10 min at room temperature. The supernatant 
was discarded and the bacterial cells were washed with PBS three times. 
The bacterial cells were then adjusted to a final concentration of 1 x 1010 
cells /mL and resuspended in PBS for immediate use. 
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2.2.11 Opsonisation of Staphylococcus aureus and PI labelling 
1 x 1010 bacterial cells/mL in PBS were heated-killed by 
incubation at 60oC for 30 min in a water bath. The bacteria were 
centrifuged at 2,000 g for 10 min and the supernatant was discarded. The 
bacteria were then washed with PBS three times and stained with 120 µM 
propidium iodide (PI) in PBS at 4oC for 2 h on an orbital shaker in the 
dark. S. aureus stained with PI were centrifuged at 2,000 g for 10 min 
and the supernatant was removed. The PI-stained bacteria were washed 3 
times with 0.1% gelatin in HBSS and then opsonised with 30% human 
AB serum or JSLE serum in PBS at 37oC for 1 h in a shaking incubator. 
The opsonised, PI-stained bacteria were washed with PBS three times 
and resuspended in PBS at a final concentration of 1 x 1010 bacteria/mL 
and were stored at 4°C. 
2.2.12 Measurement of neutrophil phagocytosis and respiratory burst 
1 x 106 neutrophils/mL were resuspended in RPMI 1640 media 
plus 25 mM Hepes (without human serum), and incubated with opsonised 
PI-stained S. aureus stained with PI at a 1:20 neutrophil:bacteria ratio, at 
37°C for 30 min with gentle agitation in a 5% CO2 incubator. Neutrophils 
were then washed with HBSS and centrifuged at 1,000 g for 3 min. The 
supernatant was discarded and the cells were resuspended in 2 mL HBSS. 
200 µL cells were added to well of a 96-well microtitre plate. For 
respiratory burst measurement, 1 x 106 neutrophils/mL were incubated 
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with opsonised PI-stained S. aureus for 15 min before 25 nM of 
Dihydrorhodamine 123 (DHR123) was added for a further 15 min. The 
percentage of neutrophils phagocytosing bacteria and showing respiratory 
burst activity was measured by flow cytometry.  
2.2.13 Neutrophil chemotaxis (transmigration assay) 
The chemotaxis assay was performed using Millipore Hanging 
Cell Culture plate inserts. 24-well tissue culture well plates were used and 
coated with poly (2-hydroxyethyl methacrylate) to prevent cell adhesion 
following transmigration, at a concentration of 12 mg/mL in ethanol. The 
plates were kept in a 37°C incubator overnight or until the ethanol 
evaporated. 800 µL RPMI 1640 plus 25 mM Hepes with or without 
chemoattractanct (IL-8) was added into each well. The hanging inserts 
with a 3 µm pore-size filter at their base, were suspended in the culture 
media and left to equilibrate for at least 10 min at room temperature. 1 x 
106 neutrophils in 200 µL culture media were added into the hanging 
inserts and incubated at 37°C in a 5% CO2 incubator for 90 min. The 
hanging inserts were then removed and migrated neutrophils in each well 
were counted using the Multisizer 3 cell counter (Beckman Coulter) after 
a dilution of 1:1,000 in Isoton II. The count number of migrated 
neutrophils was calculated as a percentage of the total number of cells 
originally added. 
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2.2.14 Measurement of neutrophil ROS production 
Luminol-dependent chemiluminescence was performed to 
measure total ROS production from neutrophils. The luminol can pass 
through cell membranes and so can be used to detect both intra- and 
extracellular oxidant production. The molecule is oxidized by free 
radicals and then releases energy in the form of light (229). 5 x 106 
cells/mL in RPMI 1640 plus 25 mM Hepes were incubated with or 
without different concentrations of hydroxychloroquine (2, 10, 20 and 40 
µM) for 1 h. The cells were washed and then primed with TNF-! (10 
ng/mL) for 30 min. The respiratory burst was induced in either a 
receptor-dependent manner by addition of fMLP, or a receptor-
independent manner using phorbol-ester PMA. 2 x 105 cells in 40 µL 
culture media were added to 50 µM luminol and stimulated the 
respiratory burst was stimulated by either 1 µM fMLP or 0.1 µg/mL 
phorbol-ester PMA, with HBSS in a total volume of 200 µL in a 96-well 
white microtitre plate. The produced oxidants were measured using the 
FLUOstar Omega plate reader from BMG Labtech. 
2.2.15 Cytokine assays 
Human Cytokine 10-Plex Panel from Invitrogen was used to 
measure the cytokine levels in healthy juvenile control serum and JSLE 
serum. The assay measured the levels of GM-CSF, IL-1", IL-2, IL-4, IL-
5, IL-6, IL-8, IL-10, IFN-# and TNF-! plus IL-17 and IFN-!. The 
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technology uses polystyrene beads stained with fluorophores of different 
intensities, each of which has a unique spectral property. Each bead is 
conjugated to a protein-specific capture antibody and added along with 
control or patient samples into the 96-well filter microplate where 
cytokines in each sample bind to the protein-specific capture antibody. 
Following this, protein-specific biotinylated detector antibodies are added 
and allowed to bind to the specific cytokines attached to the beads. 
Excess biotinylated detector antibodies are then removed, and 
streptavidin conjugated to the fluorescent protein (Streptavidin-R-
Phycoerythrin) is added and allowed to bind to biotinylated detector 
antibody-cytokine-bead complexes establishing a four-member solid 
phase sandwich. Each complex is quantified by a Bio-Plex Suspension 
Array System and analyzed using a flow cytometry, model Luminex 
(230) (Bio-Rad, Hemel Hempstead, UK).  
Each 50 µL from healthy juvenile control serum and JSLE serum 
was pre-incubated with 50 µL blocking buffer for 30 min at room 
temperature to prevent non-specific antibody binding to the beads using 
Reacti-bind™ Protein L coated into clear 96-well plate. All samples were 
transferred to a 96-well filter microplate and the Luminex assay was 
conducted using duplicate assays of protein standard. 50 µL blocked 
serum was incubated with 25 µL of the beads conjugated to a protein-
specific capture protein for 2 h on an orbital shaker. The samples were 
! *+&!
washed with wash buffer following incubation with 100 µL protein-
specific biotinylated detector antibodies for 1 h at room temperature. The 
samples were washed with wash buffer and 100 µL Streptavidin-R-
Phycoerythrin was added and incubated for further 30 min. The wells 
were washed with wash buffer and four-member solid phase sandwiches 
in each sample were resuspended in 125 µL wash buffer. The plate was 
analyzed using a Bio-Plex Suspension Array System and the levels of 
cytokine in each sample were measured and analyzed using reference 
solutions to generate a standard curve for each cytokine. 
2.2.16 Statistical analysis 
Statistical analysis was performed by using a combination of 
parametric and non-parametric statistical analyses. Normal distributed 
data were analyzed using the parametric Student’s t-test or One-way 
ANOVA followed by Bonferroni’s post hoc comparisons tests whilst 
non-normally distributed data were analyzed using the Mann-Whitney U 
test and Kruskal-Wallis test and post-hoc testing using Dunn’s Multiple 
Comparison test. Data were expressed as mean ± SEM or median with 
interquartile range, and differences were considered significant for values 
of p ' 0.05. 
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Chapter 3: Effects of JSLE Serum on Neutrophil Function 
3.1 Introduction 
Increased neutrophil apoptosis plays an important role in the 
pathogenesis of SLE, particularly JSLE patients (104). The expression of 
antigens on the surface of apoptotic cells has been suggested as a major 
source of autoantigens (50, 72, 103). These expressed autoantigens may 
then induce autoantibody production, leading to the abnormal immune 
responses that underpin the disease in these patients. However, the actual 
causes of increased neutrophil apoptosis in lupus patients are still unclear, 
but there are several possibilities: for example, an imbalance of cytokines 
in patient serum that normally regulate neutrophil apoptosis (e.g. GM-
CSF and TNF-!); an increased expression of death receptors and death 
receptor associated proteins on the cell membrane (e.g. Fas and FADD); 
the production of autoantibodies against neutrophil nuclear components 
(e.g. anti-dsDNA and anti-Ro antibodies) (100–102). These factors may 
trigger either the extrinsic and/or intrinsic apoptotic pathways, and 
subsequently induce neutrophil apoptosis.  
The extrinsic pathway is activated by factor(s) (e.g. FasL, TRAIL 
and high dose TNF-!) in serum, which bind to death receptors on the 
neutrophil cell surface, thereby regulating apoptotic proteins and the 
caspase cascade inside the cells (42). The caspase cascade is initiated by 
the activation of initiator caspase 8 into an active (cleaved) form. The 
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active form of caspase 8 then directly activates executioner caspases (e.g. 
caspase 3 and 7) into active forms, leading to neutrophil apoptosis, and/or 
indirectly activates the intrinsic pathway via Bid (Figure 1.4). Bcl-2 
family member proteins and the mitochondria mainly control the intrinsic 
pathway, which may involve activated Bid (truncated Bid; tBid) which 
induces the release of cytochrome c from mitochondria into the 
cytoplasm causing cell death via apoptosome formation (39, 42, 43). 
Cytochrome c induces Apaf-1 protein to recruit and cleave caspase 9 into 
an active form. The recruitment of Apaf-1 and the active form of caspase 
9 generates the formation of apoptosome which subsequently activates 
executioner caspases (3 and 7) (42). In human neutrophils, the release of 
cytochrome c from mitochondria via the intrinsic pathway can be 
prevented by an important anti-apoptotic protein, Mcl-1 (39). 
There are only a few studies that have investigated serum factors 
in JSLE that may regulate neutrophil apoptosis. Recently, it was 
demonstrated that addition of JSLE serum to healthy control neutrophils 
significantly increased neutrophil apoptosis (103, 105). The mRNA levels 
of caspases 7, 8 and 9 were significantly increased in JSLE neutrophils 
compared to healthy children controls, and the expression of cleaved 
caspase 3 was increased in JSLE neutrophils (103). Furthermore, caspase 
3 activation and Bid protein expression were further increased upon 
addition of JSLE sera. These findings suggest that extrinsic and/or 
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intrinsic apoptotic pathways are activated in neutrophils from patients 
with JSLE. 
Other impairments of neutrophil function have been reported in 
lupus patients, particularly in adult-onset SLE, leading to susceptibility to 
infections by different types of microbes, especially bacteria (e.g. S. 
aureus and E. coli) (95, 112). Neutrophil phagocytosis is an important 
process to eliminate bacteria, which requires effective opsonisation of 
bacteria (by serum proteins), phagocytosis (via binding to neutrophil 
opsonic receptors) and activation of killing mechanisms. Opsonin 
receptors on neutrophils include Fc# receptors and complement receptors 
(11) which bind to the opsonised pathogens and facilitate that process of 
phagocytosis. Previous studies have demonstrated decreased neutrophil 
phagocytosis in SLE patients, possibly because serum autoantibodies 
directed against CD11b/CD18 (Mac-1) interfered with opsonin receptors 
on the neutrophil cell surface, or decreased the expression of complement 
receptor (CR1) on neutrophils, leading to impaired bacterial recognition 
(113). Other reports have claimed that factor(s) in patient serum could 
promote neutrophil aggregation by activating neutrophils to overexpress 
adhesion molecules and subsequently hamper phagocytosis (114, 115). 
Bacterial opsonisation by serum is an essential step for efficient 
killing by neutrophils prior to phagocytosis (231). Pathogenic bacteria, 
particularly Gram-positive bacteria (e.g. S. aureus) are generally 
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opsonised by factor(s) in serum, such as complement fragments, 
immunoglobulins or acute-phase reactant proteins. Opsonised bacteria are 
eventually targeted and eliminated by neutrophils via the process opsono-
phagocytosis (4, 232). In lupus patients, dysregulation of serum factor(s) 
has been described (112). For example, levels of complement 
components are decreased in lupus patients because the circulating 
autoantigen-autoantibody complexes consume complement proteins and 
then activate an abnormal immune response. This condition generally 
occurs in patients when their disease is active (233). Transiently or 
permanently decreased levels of immunoglobulin have also been 
reported, although lupus patients usually present with hyperglobulinemia 
and increased levels of antibody due to autoantibody production (234). 
As a result, deficiencies in essential factor(s) in patient serum may 
contribute to decreased neutrophil phagocytosis. In addition, previous 
studies showed that JSLE serum significantly induced neutrophil 
apoptosis compared to healthy juvenile control serum (103), suggesting 
that enhanced neutrophil apoptosis could be another contributing factor 
involved in defective neutrophil phagocytosis. 
Apoptotic neutrophils have altered cell surface receptors and 
decreased functions compared to non-apoptotic neutrophils (26). For 
example, apoptotic neutrophils express lower levels of Fc#RIII compared 
to normal neutrophils (235). Moreover, disruption of cytoskeletal 
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integrity in apoptotic neutrophils can negatively affect functions such as 
cell adhesion, migration, and degranulation, as well as phagocytic ability 
(235). These findings suggest that serum defects and enhanced numbers 
of apoptotic neutrophils in SLE patients impair their functions and can 
result in enhanced susceptibility to infections. 
Dysregulation of ROS production in SLE has been described in 
several reports, but the results are still controversial and somewhat 
contradictory (130, 131). Some reports showed decreased superoxide 
production in patients compared to healthy controls, whilst other reports 
demonstrated increased levels of ROS production (124, 131). Therefore, 
ROS production in JSLE patients needs to be further investigated. In this 
Chapter, the effects of JSLE serum on neutrophil apoptosis, phagocytosis 
and ROS production were studied. 
3.2 Aims 
The aims of this Chapter were to determine if sera from a cohort 
of Thai patients with JSLE was defective, compared to healthy control 
sera, in regulating neutrophil functions, such as cell survival and 
opsonisation of bacteria for effective phagocytosis and activation of the 
respiratory burst. 
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Objectives 
• To compare rates of apoptosis of healthy control neutrophils after 
incubation with healthy juvenile control serum, or serum from 
Thai patients with active or inactive JSLE, as defined by clinical 
assessment (as described in Materials and Methods). 
• To measure the expression of activated caspases (initiator and 
executioner) and the anti-apoptotic protein, Mcl-1, after 
incubation of neutrophils with control or patient serum. 
• To determine the ability of JSLE serum to opsonise bacteria for 
subsequent phagocytosis and activation of the respiratory burst. 
3.3 Results 
3.3.1 JSLE serum induced neutrophil apoptosis 
 Sera from inactive JSLE (iJSLE) patients (n=12), active JSLE 
(aJSLE) patients (n=7) and healthy juvenile controls (HC) (n=9) were 
collected from patients attending clinics at Chulalongkorn University, 
Thailand. Isolated neutrophils from healthy adult controls were incubated 
with 10% iJSLE serum, 10% aJSLE serum or 10% HC serum for up to 6h 
and the percentage of neutrophil apoptosis (and the absolute numbers of 
apoptotic neutrophils) was measured by flow cytometry. Neutrophils 
incubated with iJSLE sera or aJSLE sera showed increased apoptosis at 
2h, but this did not reach statistical significance (iJSLE sera: median 
! **#!
8.7%, IQ range 6.3-10.1%; aJSLE sera: Median 10.0%, IQ range 5.7-
17.1%) compared to HC sera (Median 5.5%, IQ range 4.9-6.4%; p>0.05). 
After 6 h incubation, the levels of apoptosis from neutrophils incubated 
with iJSLE sera (21.6%, IQ range 19.2-24.7%) and aJSLE sera (22.3%, 
IQ range 18.6-28.6%) were significantly higher compared to HC sera 
(15.6%, IQ range 12.2%-18.9%, p<0.05). However, there was no 
significant difference in the mean values and the median levels of 
apoptosis between neutrophils incubated with iJSLE and aJSLE sera at 2 
h and 6 h (p>0.05) (Figure 3.1). 
3.3.2 Caspase activation in JSLE serum-induced neutrophil apoptosis 
To identify whether the intrinsic or extrinsic (or both) apoptotic 
pathways were activated by JSLE sera, healthy control neutrophils were 
incubated with inactive iJSLE, aJSLE and HC sera for 6 h, and the levels 
of expression of activated caspases were measured. Sera from iJSLE, 
aJSLE and HC that induced levels of apoptosis of 20.5%, 35.5% and 
7.1% apoptosis, respectively, were chosen for this study. Levels of 
activation of caspases -3, -7, -8 and -9 were measured by Western 
blotting. After incubation with the aJSLE serum, high levels of activated 
caspases -3 and -7 were detected, compared to levels after incubation 
with iJSLE serum or HC serum. Both iJSLE and aJSLE sera resulted in 
activation of caspase -8 compared to HC, but  
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Figure 3.1 JSLE serum-induced neutrophil apoptosis. (A) Representative 
flow cytometry results showing increased apoptosis (upper and lower 
right quadrant) after incubation of healthy control neutrophils with 
inactive JSLE sera (iJSLE), active JSLE sera (aJSLE) and healthy 
juvenile control sera (HC) for 6 h. (B-C) Show the percent of apoptosis 
from neutrophils incubated with inactive JSLE sera (n=12), active JSLE 
sera (n=7) and healthy juvenile control sera (n=9) at 2 h (B) and 6 h 
incubation (C). Data represent median values of three independent 
experiments using the same sera (* p<0.05, Non-parametric One-way 
ANOVA using Kruskal-Wallis test with Post-hoc using Dunn’s Multiple 
Comparison test). 
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smaller differences were detected in levels of activation of caspase -9 
(Figure 3.2). 
The effects of these three sera samples were repeated in three 
independent experiments on neutrophil preparations from different 
donors and the band densities of the western blots of each these activated 
caspases were measured using densitometry (Figure 3.3). The results 
showed that expression of the active form of caspase -3 in neutrophils 
incubated with aJSLE serum (0.7 ± 0.05) was significantly increased, 
compared to iJSLE serum (0.4 ± 0.03, p<0.005) and control serum (0.1 ± 
0.01, p<0.005), whilst there was no significant difference between iJSLE 
serum and HC serum (p>0.05). A similar result was obtained for caspase 
-7 expression, in that neutrophils incubated with aJSLE serum (0.02 ± 
0.005) had significantly increased levels of activated enzyme, compared 
to those after incubation with iJSLE serum (0.007 ± 0.005, p<0.05) or HC 
serum (0.004 ± 0.0006, p<0.01). There was no significant difference in 
activation levels following incubation with iJSLE serum or HC serum 
(p>0.05). Neutrophils incubated with active aJSLE serum had 
significantly elevated levels of caspase -8 (0.7 ± 0.05) compared to 
incubation with iJSLE serum (0.4 ± 0.03, p<0.005) or HC serum (0.12 ± 
0.01, p<0.005). The expression of the active form of caspase -9 
expression was elevated after incubation with aJSLE serum (1.45 ± 0.08) 
compared to iJSLE serum (1.1 ± 0.08, p<0.005), whilst there was no  
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Figure 3.2 Caspase activation in JSLE serum-induced neutrophil 
apoptosis at 6 h. Representative western blots of protein lysates from 
neutrophils probed for: A, pro-form of caspase -3 (35 kDa) and cleaved 
form (19/17 kDa); B, pro-form of caspase -7 (35 kDa) and cleaved form 
(20 kDa); C, pro-form of caspase -8 (57 kDa) and cleaved form (43/41 
kDa) and D, pro-form of caspase -9 (47 kDa) and cleaved form (37/35 
kDa). Lane 1, neutrophils were incubated with a HC serum (7.1% of 
neutrophil apoptosis); lane 2, neutrophils were incubated with iJSLE 
serum (20.5% of neutrophil apoptosis); lane 3, neutrophils were 
incubated with aJSLE serum (35.5% of neutrophil apoptosis). Also 
shown is the actin blot to confirm equal protein loading in each lane. 
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Figure 3.3 Relative expression of activated caspases (normalised to 
actin) from neutrophils incubated with HC serum, iJSLE serum and 
aJSLE serum. A, cleaved form of caspase -3; B, cleaved form of caspase 
-7; C, cleaved form of caspase -8 expression and D, cleaved form of 
caspase -9. Data represent mean ± SEM of three independent experiments 
(* p<0.05, ** p<0.01 and *** p<0.005, One-way ANOVA followed by 
Bonferroni’s post-hoc comparisons tests). 
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significant difference between HC serum (1.25 ± 0.06) and inactive or 
active JSLE serum (p>0.05) (Figure 3.3). 
3.3.3 Mcl-1 protein expression in JSLE serum-induced neutrophil 
apoptosis 
The anti-apoptotic protein Mcl-1 plays a key role in neutrophil 
survival, and its levels of expression regulate whether the neutrophil 
survives or undergoes apoptosis. Neutrophils were incubated with iJSLE 
and HC sera for up to 6 h and protein lysates were collected (insufficient 
aJSLE sera were available for these experiments). The expression levels 
of Mcl-1 were determined by western blotting (normalised to actin). Mcl-
1 expression in neutrophils incubated with iJSLE sera (n=8) was lower 
(at 0.43 ± 0.18) compared to the HC sera, but this was not statistically-
significant (n=4, 0.47 ± 0.13, p>0.05) (Figure 3.4). 
3.3.4 Effect of JSLE serum on bacterial opsonisation and phagocytic 
ability 
Isolated neutrophils from healthy donors, were incubated with or 
without opsonised PI-labelled S. aureus (SAPI), and were stained by 
Rapid Romanowsky staining (following cytospins) to visualise numbers 
of engulfed S. aureus (Figure 3.5). Quantification of phagocytosed SAPI 
was achieved using flow cytometry and showed that phagocytosis of 
SAPI opsonised with iJSLE (28.6 ± 8.3%) and aJSLE (21 ± 8.7%) was 
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Figure 3.4 Mcl-1 protein expression. (A) Representative western blot of 
neutrophil protein lysates after incubation of control neutrophils with HC 
sera (lane 1) and iJSLE sera (lanes 2-6) and probed for Mcl-1 (40 kDa). 
(B) Relative expression of Mcl-1 (normalised to actin) from neutrophils 
incubated with iJSLE sera (n=8) and HC sera (n=4) at 6h. (NS p>0.05, 
Mann-Whitney U test). 
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Figure 3.5 Cytospins of isolated neutrophils from healthy donors 
incubated without (A) or with (B) opsonised S. aureus-PI (SAPI). B 
shows S. aureus were engulfed by neutrophils (small black dots inside 
neutrophils).  
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decreased compared to HC serum (37.6 ± 18.6%), but these values did 
not reach statistical significance (p>0.05). Neutrophils only phagocytosed 
low levels on non-opsonised SAPI (Figure 3.6A). 
Figure 3.6B compares phagocytosis by freshly-isolated 
neutrophils and apoptotic (aged) neutrophils incubated with opsonised 
SAPI. Neutrophils incubated with 10% human AB serum overnight 
became apoptotic (70.1 ± 8.5%), and showed lower rates of phagocytosis 
of SAPI compared to freshly-isolated neutrophils, but these values did 
not reach statistical significance (p>0.05). However, apoptotic 
neutrophils showed decreased phagocytic ability when incubated with 
SAPI opsonised with aJSLE (5.0 ± 2.1%) and iJSLE (13.3 ± 1.3%) serum 
compared to HC serum (21.5 ± 3.3%, p<0.005 and p<0.05, respectively). 
Moreover, the phagocytic ability was significantly decreased when 
apoptotic neutrophils were incubated with SAPI opsonised with aJSLE 
serum compared with iJSLE serum (p<0.05). 
3.3.5 Effect of JSLE serum on ROS production 
Levels of ROS production by freshly-isolated neutrophils 
incubated with SAPI opsonised with iJSLE (37.1 ± 4.7%) and aJSLE 
(33.5 ± 1.4%) were decreased compared to HC serum (51.2 ± 8.9%), but 
this difference did not reach statistical significance (p>0.05) (Figure 3.7). 
The level of ROS production by freshly-isolated neutrophils incubated 
with SAPI without opsonisation was lower than for opsonised SAPI, but 
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Figure 3.6 (A) Phagocytic ability of freshly-isolated neutrophils incubated with 
S. aureus-PI (SAPI) with or without serum opsonisation. There was a decrease 
in the level of phagocytosis of SAPI opsonised with iJSLE or aJSLE serum 
compared to HC serum (HC). Phagocytosis, in the absence of serum 
opsonisation (NO) was further decreased compared to all other opsonisation 
conditions. (B) Phagocytic ability of freshly-isolated neutrophils or apoptotic 
(aged) neutrophils incubated with SAPI opsonised with different sera. The level 
of SAPI phagocytosis was decreased in apoptotic neutrophils compared to 
freshly-isolated cells. Opsonisation of SAPI with iJSLE serum resulted in 
significantly lower numbers of phagocytosed SAPI, compared to levels obtained 
with HC serum, and was further decreased in aJSLE serum (* p<0.05, *** 
p<0.005, One-way ANOVA followed by Bonferroni’s post-hoc comparisons 
tests). 
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Figure 3.7 (A) ROS production by freshly-isolated neutrophils incubated with 
S. aureus-PI (SAPI) with or without serum opsonisation. There was decreased 
ROS production with SAPI opsonised with iJSLE or aJSLE sera compared to 
HC serum. ROS production in the absence of serum opsonisation was further 
decreased. (B) ROS production of freshly-isolated neutrophils or apoptotic 
(aged) neutrophils incubated with SAPI opsonised with different sera. ROS 
production was significantly decreased in apoptotic neutrophils incubated with 
opsonised SAPI particularly with aJSLE and HC. Opsonisation of SAPI with 
aJSLE serum resulted in significantly decreased ROS production by apoptotic 
neutrophils, compared to iJSLE or HC serum opsonised SAPI. (* p<0.05, ** 
p<0.01, *** p<0.005, One-way ANOVA followed by Bonferroni’s post-hoc 
comparisons tests). 
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no statistical significance was demonstrated (p>0.05) (Figure 3.7A). 
Apoptotic (aged) neutrophils showed lower levels of ROS 
production compared to freshly-isolated neutrophils, particularly 
neutrophils incubated with opsonised SAPI with aJSLE and HC serum 
(p<0.05) (Figure 3.7B).  Apoptotic neutrophils incubated with SAPI 
opsonised with aJSLE serum had significantly decreased ROS production 
(7.0 ± 0.9%) compared to iJSLE (24.3 ± 3.3%) or HC sera (25.2 ± 0.8%, 
p<0.005). However, there were no statistically-significant differences in 
ROS production between apoptotic neutrophils incubated with SAPI 
opsonised in iJSLE serum and HC serum (p>0.05).  
3.4 Discussion 
In a recent study, it was shown that JSLE serum induced 
increased in apoptosis of healthy control neutrophils, suggesting that 
factor(s) in patient serum could induce neutrophil cell death (103, 105). 
Initial experiments in this Chapter confirmed and considerably extended 
these findings using serum from JSLE patient with a different genetic 
background i.e. a JSLE population from Thailand. Initial results were 
consistent with the previous study and showed that JSLE serum from a 
Thai population increased the level of apoptosis in healthy control 
neutrophils compared to healthy juvenile control serum. Results in this 
Chapter show that serum from patients with active JSLE induce 
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significantly greater levels of apoptosis, as assessed by caspase activation 
than serum from patients with inactive disease. 
A previous study in adult-onset SLE showed that increased levels 
of neutrophil apoptosis were correlated with disease activity (101). 
However, the correlation between the level of neutrophil apoptosis and 
disease activity in juvenile patients has not until now been investigated. 
In my study, sera from patients with active disease induced higher levels 
of neutrophil apoptosis compared with sera from inactive JSLE patients. 
Although the results of annexin V binding assays did not reach statistical 
significance, this probably reflects a relatively low sample size, and the 
difficulty in assessing JSLE disease as “active” or “inactive”. Ongoing 
studies in Thailand are recording SLEDAI scores of patients in 
preparation for an extension of this study. 
JSLE serum has been previously shown to activate both the 
extrinsic and intrinsic apoptotic pathways in neutrophils (103, 105) based 
on the types of caspases that were activated. These previous studies 
demonstrated that caspase activity was increased after adding JSLE 
serum, in particular caspases -8 and -9 and the levels of activation of 
these two caspases by JSLE serum closely correlated with the level of 
apoptosis (105). Furthermore, the induction of apoptosis observed 
following addition of JSLE serum, was significantly decreased by 
inhibitors of caspase -8 and -9 (105). These observations were matched 
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by the finding that levels of mRNA for caspase -7 and -9 (but not caspase 
-3) were elevated in JSLE neutrophils, compared to healthy controls. In 
contrast, mRNA levels for the inhibitors of apoptosis, IAP1, IAP2 and 
XIAP were all decreased in JSLE neutrophils (105).  
The results in this Chapter confirm that JSLE serum induces 
neutrophil apoptosis and activates caspases, but additionally that serum 
from patients with active disease induce higher levels of apoptosis and 
caspase activation, compared to healthy control and serum from JSLE 
patients with inactive disease. Caspases -3, -7 and -8 (but not -9) were 
activated by this serum. These findings suggest that JSLE serum induces 
neutrophil apoptosis largely via the extrinsic pathway (regulated by 
caspase -8) rather than the intrinsic pathway (largely regulated by caspase 
-9). To determine whether the intrinsic pathway was activated by JSLE 
serum, expression of the major anti-apoptotic protein, Mcl-1, was 
investigated. Unfortunately, serum samples from active JSLE patients 
were very limited. Only sera from inactive JSLE patients and healthy 
controls were compared and the results showed the protein expression of 
Mcl-1 in neutrophils incubated with inactive JSLE serum was lower, but 
the decrease in expression did not reach statistical significance, compared 
to expression induced by incubation with healthy juvenile control serum. 
This suggests that JSLE serum had a tendency to activate via intrinsic 
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pathway but the testing of serum samples from active JSLE patients 
would be required to confirm this finding. 
Apart from JSLE serum-induced neutrophil apoptosis, another 
function of neutrophils affected by JSLE serum, is their phagocytic 
ability. Previous studies have shown that factor(s) in serum from patients 
with lupus induced neutrophil aggregation leading to decreased 
neutrophil phagocytosis (114, 115). The reported deficiencies in 
complement components and immunoglobulins in patient serum, 
particularly during disease active (233, 234), may contribute to decreased 
efficiency of  bacterial opsonisation. In my study, bacterial opsonisation 
with JSLE serum and subsequent phagocytic ability by neutrophils were 
measured. Phagocytosis of S. aureus opsonised with JSLE serum and 
healthy juvenile control serum was compared, and the results showed that 
the level of phagocytosis of S. aureus opsonised with JSLE serum was 
decreased, and activity was further decreased when the bacteria were 
opsonised with active JSLE serum. Although the levels did not reach 
statistical significance, this suggests that JSLE serum (particularly in 
patients with disease active) is likely to decrease bacterial opsonisation 
leading to defective neutrophil phagocytosis and hence increased 
susceptibility to infections.  
 Defective neutrophil phagocytosis was also observed when 
freshly-isolated neutrophils were compared with apoptotic (aged) 
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neutrophils. S. aureus opsonised with inactive JSLE serum showed 
significantly decreased phagocytosis compared to bacteria opsonised with 
healthy control serum. Moreover, a further decrease of neutrophil 
phagocytosis was observed in S. aureus opsonised with active JSLE 
serum. Taken together, these findings suggest that defective neutrophil 
phagocytosis in JSLE patients is probably caused by factors in JSLE 
serum. These are likely to represent deficiencies in opsonising factors, 
but alternatively may be an increase in factors that inhibit opsonisation. 
This observation was supported by results that showed decreased 
neutrophil phagocytosis by apoptotic neutrophils incubated with bacteria 
that were opsonised with active JSLE serum. 
ROS production was evaluated alongside measurements of 
phagocytic ability and the results showed similar patterns. For example, 
the levels of ROS production by freshly-isolated neutrophils incubated 
with unopsonised SAPI were decreased compared to those observed in 
response to opsonised bacteria. Apoptotic neutrophils showed lower 
levels of ROS production compared to freshly-isolated neutrophils. ROS 
production was further decreased in apoptotic neutrophils incubated with 
SAPI opsonised with JSLE serum, particularly active JSLE serum. 
Significantly higher levels of ROS production by freshly-isolated 
neutrophils incubated with SAPI opsonised by healthy control serum 
were observed, compared to levels measured in apoptotic neutrophils 
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incubated with SAPI opsonised by inactive JSLE serum. This finding 
suggests that ROS production in JSLE patients is decreased probably 
because of JSLE serum induces neutrophil apoptosis and is less effective 
in bacterial opsonisation.  
Notably, JSLE patients with active disease usually present with 
decreased level of complement factors in serum (233). Thus, further 
studies are required to correlate levels of serum complement factors and 
the efficiency of serum to opsonise bacteria for subsequent neutrophil 
phagocytosis and ROS production. 
In conclusion, the composition and function of JSLE serum is 
likely to be a major factor involved in the pathogenesis of the disease. It 
has several effects on neutrophil function. Neutrophil apoptosis induced 
by JSLE serum, particularly from patients with active disease, is one 
important pathogenic feature. JSLE serum also a negative effect on 
neutrophil phagocytosis and ROS production. Therefore, it is important 
to further investigate the factor(s) in JSLE serum that induce neutrophil 
apoptosis. In the following Chapter, cytokines that are capable of 
regulating of neutrophil apoptosis will be studied in the serum of JSLE 
patients. 
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Chapter 4: JSLE serum analysis of cytokines and effect of 
recombinant-cytokines on neutrophils 
4.1 Introduction 
4.1.1 Role of cytokines in JSLE and effects on neutrophils     
Cytokines are major regulators of the immune system which 
activate cell proliferation, differentiation and maturation (83). An 
imbalance in the production of cytokines is associated with the immune-
pathogenesis of JSLE and adult-onset SLE (216–218). Cytokines are 
involved in almost every step of normal and abnormal immune responses. 
They act as mediators connecting one cell to other cells, and can 
ultimately lead to the tissue and organ damage that is observed in lupus. 
Increased production of cytokines, such as IL-1, IL-6, IL-17, type I IFNs, 
TNF-! and B lymphocyte stimulator (BLys) has been described in lupus 
and their levels usually correlate with the degree of disease activity (146, 
219), particularly IL-6, IL-17, type I IFNs and TNF-! (83).  
The precise role of cytokines in the pathogenesis of SLE is not 
fully defined, despite the fact that these molecules have been studied in 
this disease for many decades (146). IL-6 is one of the first cytokines that 
was described in SLE, as it is involved in the process of B cell 
maturation. An important role of IL-6 is to activate the differentiation of 
B cells into plasma cells producing autoantibodies. IL-6 also down-
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regulates levels of membrane CD5 expression in B cells, which allows 
for the expansion of autoreactive B cells (236). IL-17 is another cytokine 
that has been recently described in SLE pathogenesis and the role of IL-
17 is believed to be similar to IL-6, as it can also activate B cell 
proliferation and autoantibody production (76). Levels of Type I IFNs 
have been reported as abnormal in SLE, and are produced by 
plasmacytoid dendritic cells. The effects of type I IFNs (particularly IFN-
!) are to promote dendritic cell maturation and aid the process of antigen 
presentation by dendritic cells to T-cells. Moreover, they can activate B 
cell class-switching, B cell maturation and autoantibody production by 
plasma cells (237). While the role of IL-6, IL-17 and type I IFNs in the 
pathogenesis of SLE is fairly well defined, the role of TNF-! in the 
immune-pathogenesis of SLE is still controversial. It has been reported 
that the production of this cytokine is increased and that levels correlate 
with disease activity. In contrast, administration of anti-TNF-! therapy in 
some autoimmune patients, elevates the levels of autoantibody causing 
lupus-like symptoms (195). 
A recent study of JSLE patients has shown a contrasting finding 
to adult-onset of SLE, in terms of serum cytokine levels. It was reported 
that certain cytokines in serum, such as IL-6, TNF-! and GM-CSF, are 
significantly decreased compared to healthy juvenile controls (103). This 
study suggested that decreased levels of GM-CSF probably have a direct 
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effect on increased neutrophil apoptosis, leading to autoantigen 
production and an abnormal immune response in JSLE patients. 
However, the effects of decreased levels of IL-6 and TNF-! on delayed 
neutrophil apoptosis are still questionable. 
The effects of cytokines on neutrophil apoptosis have been widely 
studied (238). Evidence shows that IL-1", IL-2, IL-15, IL-8, IL-18, type 
II IFNs, G-CSF and GM-CSF can delay neutrophil apoptosis (239, 240). 
It has been reported that increased levels of these cytokines correlate with 
delayed neutrophil apoptosis in several diseases, such as rheumatoid 
arthritis, acute respiratory distress syndrome (ARDS), cystic fibrosis, 
septicemia and acute pneumonia (241–244). In contrast, the effects of IL-
6 on neutrophil apoptosis are more controversial. An in vitro study 
showed that increased rates of apoptosis were observed when neutrophils 
were incubated with IL-6, but another study showed a contrasting result 
as neutrophils treated with IL-6 had a lower rate of apoptosis (245, 246). 
However, it has been reported that IL-6 can prolong neutrophil survival 
after coronary bypass in patients with unstable angina and acute 
myocardial infarction (247). Similarly, the effects of TNF-! on neutrophil 
apoptosis is biphasic (248); high concentrations (>30 ng/mL) promote 
apoptosis whereas lower concentrations (~10 ng/mL) delay this 
phenomenon. Therefore, the effect of these cytokines on neutrophil 
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apoptosis in the pathogenesis of adult-onset SLE and JSLE needs further 
investigation. 
4.1.2 Effect of GM-CSF on JSLE serum-induced neutrophil apoptosis 
 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is 
a hematopoietic cytokine produced by activated T cells, macrophages, 
endothelium, fibroblasts and bone marrow stromal cells (249). It 
normally functions as an essential growth factor for leukocytes, 
particularly myeloid lineages. Hematopoietic myeloid progenitors (stem 
cells), stimulated by GM-CSF together with other cytokines, such as IL-
3, IL-4 and IL-5, develop into granulocytes (including neutrophils), 
monocytes/macrophages and dendritic cells (249).  
GM-CSF is a member of the short-chain 4-!-helical bundle family 
of cytokines that binds to a specific cytokine receptor on the cell 
membrane (250). The receptors are heterodimeric and composed of two 
subunits: a common " receptor ("c) subunit and a unique ! receptor (GM-
CSFR!). GM-CSF firstly binds to the GM-CSFR! on the cell surface and 
then recruits the "c subunit to initiate intracellular signaling pathways and 
physiological responses (249). There are at least three major intracellular 
pathways that have been described following GM-CSF activation: (1) the 
Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway; (2) the mitogen-activated protein kinase (MAPK) pathway and 
(3) the phosphatidylinositol 3-kinase (PI3-K) pathway (251). The three 
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pathways are mainly involved in the processes of cell 
proliferation/differentiation.  
Apart from GM-CSF activation of cell 
proliferation/differentiation, another of its important roles is to regulate 
the survival of immune cells, particularly mature neutrophils. It has been 
demonstrated that GM-CSF significantly delays neutrophil apoptosis by 
enhancing expression of the anti-apoptotic protein, Mcl-1 (41, 238, 252). 
The levels of Mcl-1 are increased because GM-CSF stabilizes the protein 
and also decreases its turnover rate via Erk/Mek and PI3-K/Akt 
pathways. However, the activation of Erk and Akt is only transient and 
other kinases (e.g. p38MAPK) may be responsible for regulation of Mcl-
1 turnover rate. Conversely, a decrease in expression and increased 
phosphorylation of the pro-apoptotic protein, Bax via PI3K/Act 
activation, has also been described in neutrophils treated with GM-CSF, 
which may also contribute to maintaining neutrophil survival (241). 
Furthermore, there are many other proteins involved in the control of 
apoptosis that are regulated by GM-CSF treatment (238). For example, 
increased phosphorylation of the pro-apoptotic protein, Bad which 
disrupts its binding to the anti-apoptotic protein Bcl-XL which then 
allows Bcl-XL to protect against the release of cytochrome c from 
mitochondria: this prevents caspase activation, and prevents neutrophil 
apoptosis (253). Taken together, these studies clearly show that GM-CSF 
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can regulate both anti- and pro- apoptotic proteins, including the anti-
apoptotic protein Mcl-1 of the intrinsic apoptotic pathway, and prevent 
neutrophil apoptosis. 
4.1.3 Effect of TNF-" on neutrophil apoptosis and JSLE serum-induced 
apoptosis 
It has been reported that serum levels of TNF-! are significantly 
increased in patients with SLE, particularly those with active disease 
(207–210). Increased levels of TNF-! have also been observed in 
glomerular tissue from lupus nephritic patients (209), suggesting that 
TNF-! plays an inflammatory role in patients with SLE. Moreover, levels 
of TNF-! are correlated with disease activity. However, one study has 
shown that SLE patients with inactive disease had higher serum levels of 
TNF-! compared to healthy controls and patients with active disease, 
suggesting a protective effect of TNF-! in these patients (207). 
Therefore, the precise role of TNF-! in the pathogenesis of SLE, is still 
unclear (195). In addition, anti-TNF-! therapy is largely ineffective in 
patients with SLE. Furthermore, several studies have shown that patients 
with other autoimmune diseases who received TNF-! blockers, have 
developed lupus-like symptoms and increase serum autoantibodies (215). 
Therefore, anti-TNF-! therapy for patients with SLE, particularly 
juvenile patients, needs to be carefully considered. 
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A previous study in JSLE patients showed that serum levels of 
TNF-! were lower compared to juvenile healthy control sera and low 
concentrations of TNF-! can delay neutrophil apoptosis (29). Therefore, 
TNF-! was added to JSLE serum to determine whether TNF-! could 
protect neutrophils from apoptosis, but no significant difference was 
observed (103).  
TNF-! has dual effects on neutrophil apoptosis: low 
concentrations (~10 ng/mL) protect against neutrophil apoptosis whilst 
higher concentrations (>30 ng/mL) promote apoptosis (248). 
Furthermore, the effects of TNF-! on target cells are varied, and 
regulated by the different types of surface receptors, TNFR1 (p55/p60) 
and TNFR2 (p75/p80). Ligation of these receptors can lead to activation 
of a range of cellular responses, including cell survival, apoptosis, 
differentiation and proliferation (254, 255). For example, TNF-! 
signaling can lead to the generation of an apoptotic signal via FADD-
mediated activation of caspase 8, whereas TRADD/TRAF-2 (TNF 
receptor associated factor-2) activation can lead to activation of NF-$B 
and triggering of downstream events that result in activated gene 
expression leading to an anti-apoptotic or a proliferative response (256–
260). In view of these varied neutrophil activities triggered by TNF-!, 
and its uncertain role in the pathology of SLE, it is important to 
determine its role on neutrophil function under conditions that mimic 
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pathological conditions. It is important to understand their responses to 
this molecule under conditions that mimic acute and chronic 
inflammation (e.g. in systemic lupus erythematosus). On the one hand, 
neutrophils can express TNF-! on their cell surface and release this 
molecule into the extra cellular environment, thereby triggering events in 
adjacent cells. On the other hand, they can themselves be stimulated by 
TNF-!, into either anti- or pro-apoptotic pathways, depending on the 
local concentration of this cytokine.  
4.2 Aims 
In the previous Chapter, it was found that JSLE serum 
significantly induced neutrophil apoptosis compared to healthy control 
serum. Imbalance in the levels of cytokines in serum from SLE patients, 
including JSLE, has been reported. It is important to determine the effects 
of these cytokines on neutrophil apoptosis and measure the levels of these 
cytokines in the serum. A previous study demonstrated decreased serum 
levels of GM-CSF in JSLE patients compared to healthy juvenile controls 
(103). Furthermore, JSLE serum decreased the levels of Mcl-1 expression 
(as shown in previous chapter). As GM-CSF stabilizes the anti-apoptotic 
protein, Mcl-1 leading to delayed neutrophil apoptosis (41, 238, 261), it 
is important to determine whether adding GM-CSF to neutrophils 
incubated with JSLE serum can increase the levels of Mcl-1 in 
neutrophils and protect them against apoptosis. In addition, the role of 
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TNF-! in the pathogenesis of SLE is still unclear (195). Therefore, it is 
necessary to more clearly understand the role of TNF-! in the 
pathogenesis of JSLE and other conditions in which this cytokine may 
play a role in pathology.  
Objectives 
• To determine the potential of recombinant-cytokines to affect 
neutrophil apoptosis and to measure the levels of cytokines in the 
serum of patients with active JSLE, inactive JSLE and healthy 
controls.  
• To establish whether adding GM-CSF to neutrophils incubated 
with JSLE serum can protect against apoptosis and “reverse” the 
pro-apoptotic effect of the serum.  
• To determine whether GM-CSF can reverse the decrease in Mcl-1 
in neutrophils incubated with JSLE serum. 
• To determine if GM-CSF could reverse the activation of caspases 
that is induced by JSLE serum. 
• To determine the molecular events that regulate neutrophil 
responses to TNF-! signaling.  
 
 
! *#)!
4.3 Results 
4.3.1 Effects of recombinant-cytokines on neutrophil apoptosis 
Neutrophils isolated from healthy adult controls were treated with 
the following cytokines; GM-CSF, IL-1", IL-6, IL-17, IFN! and TNF-! 
(low and high concentrations) for up to 22 h incubation. The absolute 
numbers of neutrophils and the percentage of neutrophil apoptosis were 
compared between untreated and treated cells using flow cytometry (as 
described in Materials and Methods section). Neutrophils were isolated 
from healthy adult controls (n=5) and incubated with 10% human AB 
serum with or without GM-CSF (5 ng/mL), IL-1" (10 ng/mL), IL-6 (10 
ng/mL), IL-17 (100 ng/mL), IFN-! (10 ng/mL) and TNF-! (10 or 100 
ng/mL) to determine whether any of these cytokines could either save or 
induce apoptosis. It was found that neutrophils were significantly 
protected against apoptosis after 22 h incubation with GM-CSF (31.5 ± 
4.4%), IL-1" (49.3 ± 3.1%) or low concentrations of TNF-! (55.4 ± 
2.5%), compared to untreated controls (70.1 ± 3.7%, p<0.05). 
Neutrophils incubated with IL-6 (69.4 ± 3.9%), IL-17 (72.1 ± 3.6%), 
IFN-! (75.4 ± 2.1%) and high concentrations of TNF-! (76.2 ± 0.8%) 
had no effect on apoptosis compared to the control (p>0.05) (Figure 4.1). 
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Figure 4.1 Effects of cytokines on neutrophil apoptosis. The graph shows 
the percent of neutrophil apoptosis after incubation with 10% human AB 
serum with or without cytokines at 22 h (5 replicates). TNF-! 10 = low 
concentrations of TNF-! (10 ng/mL) and TNF-! 100 = high 
concentrations of TNF-! (100 ng/mL) (* p<0.05, *** p<0.005, Student’s 
t-test). 
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4.3.2 Analysis of cytokines in JSLE serum 
 The levels of cytokines in JSLE serum were measured using a 
Human Cytokine 10-Plex panel and compared between inactive JSLE, 
active JSLE and healthy juvenile control sera. Table 4.1 summarises the 
levels of measurable cytokines in JSLE and control sera. The results 
show that the levels of IL-2, IL-4, IL-8 and IL-10 were detectable in both 
JSLE and control sera, but only IL-8 levels were significantly higher in 
active JSLE sera (Median 21.34, IQ range 11.30-58.35) compared to 
inactive JSLE sera (Median 0, IQ range 0-1.11, p<0.05) (Figure 4.2). The 
levels of GM-CSF, IL-1", IL-5, IL-6, IL-17, IFN-!, IFN-# and TNF-! 
were undetectable in all groups (i.e. GM-CSF < 26.34 pg/mL, IL-1" < 
11.25 pg/mL, IL-5 < 7.2 pg/mL, IL-6 < 7.06 pg/mL, IL-17 < 34.48 
pg/mL, IFN-! < 19.07 pg/mL, IFN-# < 21.96 pg/mL and TNF-! < 14.98 
pg/mL). 
4.3.3 Protective effect of GM-CSF on JSLE serum-induced neutrophil 
apoptosis 
Previous results in this thesis showed that inactive and active 
JSLE sera significantly induced apoptosis in healthy adult neutrophils at 
6h, and Figure 4.1 showed that, of the cytokines studied, GM-CSF was 
the most potent in delaying neutrophil apoptosis (p<0.005). As amounts 
of active JSLE sera were very limited, sera from inactive JSLE patients 
(n=3) were used for this study. Isolated neutrophils from a healthy adult  
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Table 4.1 Concentrations of measurable cytokines in serum (pg/mL) 
from healthy juvenile controls (n=5), inactive JSLE (n=5) and active 
JSLE (n=5), as measured by a Luminex assay. Data shown are median 
values plus interquartile range (IQ range). Statistical analysis carried out 
using a non-parametric one-way ANOVA, using Kruskal-Wallis with 
Post-hoc test using Dunn’s multiple comparison test (* p<0.05). 
Cytokines Control iJSLE aJSLE Kruskal-Wallis Post-hoc 
IL-2 0.71 
(0.68-1.73) 
0.66 
(0.58-0.71) 
0.71 
(0.68-0.73) 
NS - 
IL-4 4.68 
(4.34-5.02) 
4.01 
(4.01-4.34) 
4.01 
(3.84-4.34) 
NS - 
IL-8 0 
(0-1.10) 
0 
(0-1.11) 
21.34 
(11.30-58.35) * 
iJSLE 
VS 
aJSLE 
IL-10 0 
(0-2.22) 
0.13 
(0.05-0.79) 
0.07 
(0-1.69) 
NS - 
 
Note: The levels of GM-CSF, IL-1", IL-5, IL-6, IL-17, IFN-!, IFN-# and 
TNF-! were below the lower limit of detection amongst all groups (data 
not shown). 
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Figure 4.2 Cytokine concentrations in sera from healthy juvenile controls 
(HC, n=5), inactive JSLE (iJSLE, n=5) and active JSLE (aJSLE, n=5) 
measured by the Luminex assay; (A) IL-2, (B) IL-4, (C) IL-8 and (D) IL-
10. Data shown are the median concentrations of each cytokine in serum 
(represented by horizontal bar), (* p<0.05, Non-parametric one-way 
ANOVA carried out using Kruskal-Wallis with Post-hoc test using 
Dunn’s multiple comparison test). 
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control were incubated with 10% inactive JSLE serum with or without 
GM-CSF treatment (5 ng/mL) for up to 6 h. The result showed that 
adding GM-CSF to neutrophils incubated with inactive JSLE sera 
resulted in significantly decreased apoptosis at 6 h incubation (6.92 ± 
0.92%) compared to the neutrophils incubated in inactive JSLE sera 
without GM-CSF supplementation (21.79 ± 3.7%, p<0.05) (Figure 4.3). 
4.3.4 Effect of GM-CSF on JSLE serum-induced loss of Mcl-1 expression 
Neutrophils incubated with inactive JSLE serum exhibited 
significantly increased neutrophil apoptosis and decreased levels of Mcl-
1 protein expression (Figure 3.1 and Figure 3.4). GM-CSF stabilizes the 
levels of Mcl-1 protein expression in parallel with delaying neutrophil 
apoptosis (41, 238). Therefore, the effects of GM-CSF on Mcl-1 protein 
expression were determined in neutrophils that were incubated with JSLE 
serum. Isolated neutrophils from healthy adult controls were incubated 
with inactive JSLE serum (n=3) with or without GM-CSF treatment for 
up to 6 h. Protein lysates were prepared and the expression of Mcl-1 was 
quantified using Western blotting (normalised to actin) and densitometry. 
The results showed that the relative expression of Mcl-1 in neutrophils 
incubated with inactive JSLE sera and GM-CSF treatment were 
significantly higher (relative expression of 0.37± 0.05) compared to 
neutrophils incubated with inactive JSLE sera without GM-CSF (relative 
expression of 0.2 ± 0.01, p <0.05) (Figure 4.4). 
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Figure 4.3 Protective effect of GM-CSF on JSLE serum-induced 
neutrophil apoptosis. (A) Representative flow cytometry result showing 
decreased apoptosis (upper and lower right quadrant) after addition of 
inactive JSLE serum with GM-CSF to neutrophils at 6 h. (B) The graphs 
show the percent of apoptosis from neutrophils incubated with inactive 
JSLE sera (n=3) with or without GM-CSF treatment at 6 h incubation, 
data represent mean ± SEM of three independent experiments (* p<0.05, 
Student’s t-test). 
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Figure 4.4 Mcl-1 protein expression in neutrophils incubated with JSLE 
serum and GM-CSF. (A) Representative Western Blot of Mcl-1 levels 
after incubation of neutrophils with inactive JSLE sera, either with (lane 
2, 4 and 6) or without (lane 1, 3 and 5) GM-CSF. (B) Relative expression 
of Mcl-1 (normalised to actin) from neutrophils incubated with inactive 
JSLE sera (n=3) with or without GM-CSF treatment at 6 h. (* p<0.05, 
Student’s t-test) 
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4.3.5 Effect of GM-CSF on JSLE serum-induced caspase activation 
Previous work in this thesis has shown that JSLE serum induced 
apoptosis via the extrinsic and/or intrinsic apoptotic pathways by 
activating the caspase cascade, via activation of caspases -3, -7, -8 and -9. 
Therefore, it was important to determine whether GM-CSF could 
overcome the effect of JSLE serum-induced apoptosis and prevent 
caspase activation. Neutrophils were incubated with inactive JSLE serum 
in the presence or absence of GM-CSF for up to 6 h, and protein lysates 
were prepared. The expression of activated caspases -3, -7, -8 and -9 was 
measured using Western blotting (normalised to actin) and densitometry. 
The results showed that neutrophils incubated with inactive JSLE serum 
and GM-CSF treatment resulted in lower levels of activation of caspases 
-3, -7, -8 and -9, compared to neutrophils incubated without GM-CSF 
treatment (Figure 4.5A). The relative expression of the active form of 
caspase -3 in neutrophils incubated with inactive JSLE serum with GM-
CSF treatment was lower than that observed with inactive JSLE serum 
alone (relative expression 0.08 vs 0.23). This protection against activation 
was also observed for other caspases; caspase -7 (0.0007 vs 0.08), 
caspase -8 (0.42 vs 0.52) and caspase -9 (0.04 vs 0.17). Because the low 
availability of JSLE serum, only single experiments were performed. 
(Figure 4.5 B, C and D). 
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Figure 4.5 Caspase activation in neutrophils incubated with JSLE serum with or without 
GM-CSF treatment at 6 h. Representative western blots of protein lysates from 
neutrophils probed for: A, Caspase -3; B, Caspase -7; C, Caspase -8 and D, Caspase -9. 
Lane 1 is neutrophils incubated with inactive serum without GM-CSF, and lane 2 is 
neutrophils incubated with inactive JSLE serum with GM-CSF. Relative expression of 
caspases (normalised to actin) is represented in bar graphs. 
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4.3.6 Changes in expression of genes involved in death receptor signaling 
 The effects of TNF-! on neutrophil apoptosis have been 
demonstrated previously (e.g. Figure 4.1), showing that after 22 h 
incubation of untreated cells, levels of apoptosis were approximately 
70.1% (± 3.7 %) whereas in TNF-!-treated cells, the level of apoptosis 
was significantly lower (55.4 ± 2.5 %, n = 5, p < 0.05). It has been 
previously reported that this concentration of TNF-! also induces gene 
expression (248, 262) and so a PCR array was initially performed using a 
Human Apoptosis RT2 Profiler PCR Array (SA Biosciences) to detect 
neutrophil transcripts whose levels were regulated by TNF-! treatment 
(this assay was performed by Dr. Connie Lam and Dr. Kate Roberts). The 
relative expression of 84 key genes involved the regulation of apoptosis 
was measured, and 23 were selected for further analysis, based either on 
their relative transcript abundance in neutrophils (Ct values of 20 or less), 
or on the basis that their relative levels were affected, positively or 
negatively, by TNF-! treatment. Repeat experiments on neutrophils 
isolated from different donors were then performed for individual genes 
by quantitative PCR experiments (Figure 4.6). 
Following the addition of TNF-! (10 ng/mL) to neutrophils for 1 
h, one of the key genes whose expression was up-regulated was TNF-! 
itself, expression of which increased by over 20-fold (Figure 4.6). In 
addition, mRNA levels for TNFAIP3 (A20) increased by similar amounts  
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Figure 4.6 Low concentrations of TNF-! stimulate neutrophil gene 
expression. Neutrophils were incubated for 1 h in the absence (control) or 
presence of TNF-! (10 ng/mL). Fold changes in mRNA levels were 
quantified by real-time PCR (normalized to GAPDH) (black bar) and 
RNA-sequencing  (grey bar) (mean fold change ± SEM, n = 3 for each 
dataset). Abbreviations: BCL2A1 (BFL-1)= B-cell lymphoma 2-related 
protein A1 or; CFLAR (FLIP)=CASP8 and FAS-like apoptosis regulator 
of FLICE-like inhibitory protein; TNFAIP3=Tumor necrosis factor !-
induced protein 3; Apaf-1=Apoptotic protease activating factor 1; BAX= 
Bcl-2-associated X protein; CASP10= Caspase 10; CASP8= Caspase 8; 
FADD= Fas-Associated protein with Death Domain; TNFRSF1A&1B 
(TNFR1&2)=Tumor necrosis factor receptor superfamily member 
1A&1B or Tumor necrosis factor receptor 1&2; TRADD=Tumor 
necrosis factor receptor type 1-associated DEATH domain protein. 
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following TNF-! treatment. Transcripts for BCL2A1, CFLAR (FLIP), 
and FAS were also up-regulated. However, mRNA for some genes 
involved in apoptosis control was significantly down-regulated following 
TNF-! treatment. These down-regulated genes included APAF1, CASP8, 
CASP10, FADD, TNFRSF1A and TNFRSF1B.  
In a parallel study in the laboratory, RNA-sequencing was 
performed to measure the transcriptome of human neutrophils and 
identify changes induced by similar TNF-! treatment (conducted by Dr. 
Helen Wright). The real-time PCR results were therefore compared with 
results of these RNA-sequencing experiments, and both the qualitative 
and quantitative profiles of altered gene expression observed following 
TNF-! treatment using these two independent methods, were very similar 
(Figure 4.6).  
Bioinformatics analyses of the changes in gene expression 
following stimulation with TNF-! for 1 h are shown in Figure 4.7. This 
scheme was generated by Ingenuity Pathway Analysis software 
(Ingenuity® Systems, www.ingenuity.com) in which the fold change in 
gene expression values between the control samples and the TNF-! 
treated samples are projected onto the Death Receptor Signaling pathway. 
In this scheme, mRNA levels that decreased following TNF-! treatment 
are shown in green, while those that increased are shown in red. This 
scheme predicts that signaling of apoptosis via a range of death receptors  
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Figure 4.7 Bioinformatics analyses reveal changes in expression of genes 
associated with the Death Receptor Pathway. Data represent the mean 
fold change (n=3) in expression following stimulation with TNF-! for 1 h 
compared to untreated control measured using real-time PCR.  Up-
regulated genes are shown in red and down-regulated genes are shown in 
green, the analysis was generated using IPA (Ingenuity). Similar results 
were obtained when the RNA-sequencing data were analyzed in this way. 
This analysis was performed by Dr. Helen Wright and Huw Thomas. 
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would be down-regulated as a result of the re-programming of gene 
expression following TNF-! treatment of neutrophils. 
4.3.7 Time course and concentration dependence of TNF-" induced 
mRNA changes 
The above transcriptome analyses were performed after 1 h 
incubation in the presence and absence of TNF-! used at 10 ng/mL.  It 
was therefore necessary to determine (a) whether similar changes in gene 
expression were obtained at higher concentrations of TNF-! and (b) if 1 h 
was the optimal incubation time to observe these changes in neutrophil 
mRNA levels following stimulation. To address the first question, 
neutrophils were incubated for 1 h with 40 ng/mL of TNF-! and changes 
in gene expression were determined by real-time PCR and compared to 
the data observed following addition of this cytokine at 10 ng/mL.  
Figure 4.8 shows no significant differences in mRNA levels after 
incubation at either concentration of TNF-!. Next, the relative expression 
of a number of genes that were up- or down-regulated over a period of 6 
h following TNF-! exposure was measured. Maximal changes in gene 
expression were detected by 1 h incubation with 10 ng/mL TNF-!, and 
extension of the incubation time to either 3 h or 6 h did not result in any 
changes in expression of those genes of interest, above those observed 
after 1 h incubation (Figure 4.9). 
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Figure 4.8 Neutrophil gene expression is independent of the 
concentration of TNF-!. Neutrophils were incubated exactly as described 
in the legend to Figure 4.6, except that the concentration of TNF-! was 
40 ng/mL. After quantitation of transcript levels by real-time PCR, 
expression levels after incubation for 1 h with 40 ng/mL TNF-! (grey 
bars) were compared with those measured after incubation for 1 h with 10 
ng/mL (black bars) (mean fold change ± SEM, n=3 of each dataset). 
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Figure 4.9 Neutrophils were incubated for up to 6 h in the absence or 
presence of TNF-! (10 ng/mL). Gene expression was analyzed by real-
time PCR (normalized to GAPDH).  Samples were collected 1 h (black 
bar), 3 h (grey bar) and 6 h (open bar) after addition of TNF-!. Values 
shown are mean fold changes (± SEM) of three separate experiments. 
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4.3.8 Changes in protein levels following TNF-" treatment 
To determine if these TNF-!-induced changes in mRNA levels 
were accompanied by corresponding changes in protein levels, 
neutrophils were incubated for up to 6 h in the absence and presence of 
TNF-! (10 ng/mL) and protein lysates were prepared for measurement of 
protein levels by Western blotting. Very few changes in protein levels 
were detected following 2 h incubation, but for most proteins under 
investigation maximal changes in expression were detected by 4-6 h 
incubation. Figure 4.10 shows representative Western blot data and a 
summary of quantified data for FLIP, FADD and caspase 10 measured 4 
h after TNF-! treatment, while that for TNFR1, TNFR2, TRADD and 
caspase 8 are shown 6 h after TNF-! treatment. In line with the RNA-
sequencing data, expression of FLIP was significantly enhanced 
following TNF-! treatment (p<0.05), while the expression of all other 
proteins investigated significantly decreased following TNF-! treatment 
(p<0.05). Thus, levels of expression of TNFR1, TNFR2, TRADD and 
FADD were all significantly decreased after TNF-! treatment. 
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Figure 4.10 Changes in mRNA levels after TNF-! treatment result in parallel changes 
in expression of pro- and anti-apoptotic proteins. Neutrophils were incubated with TNF-
! (10 ng/mL) and at 2 h, 4 h and 6 h incubation, protein extracts were made and subject 
to Western blotting. In each panel, representative Western blots of the protein of interest 
are shown, together with the corresponding actin control blot to ensure equivalence of 
protein load. Underneath each blot in each panel is summary data of three separate 
experiments showing mean values (± SEM). For all data shown, there was a statistically 
significant difference between control (untreated) and TNF-!-treated neutrophils 
(p<0.05).  Panels A, D and G are analyses after 4 h incubation with TNF-!, while for the 
remaining panels, samples were analyzed after 6 h incubation. 
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4.4 Discussion 
An imbalance in the production of cytokines in the immune-
pathogenesis of JSLE and adult-onset SLE has been previously described 
(216–218) and such cytokines are major factors involved in the regulation 
of autoantibody production. The serum levels of cytokines such as IL-1, 
IL-6, IL-17, type I IFNs, TNF-! and B lymphocytes stimulators (BLys) 
have been reported to be increased and often show a strong correlation 
with disease activity (146, 219). For example, IL-6 and IL-17 play a role 
in B cell proliferation and autoantibody production, whilst type I IFNs 
support dendritic cell maturation and autoantigen presentation (76, 83, 
236, 263). However, the role of TNF-! is still questionable and one study 
on JSLE patients demonstrated that levels of IL-6, TNF-! were 
significantly decreased in patient sera (103). This study also showed 
decreased levels of GM-CSF in JSLE patient sera. 
This Chapter firstly set out to determine whether the reported 
imbalance in production of cytokines also had an effect on neutrophil 
apoptosis, as it has been proposed that neutrophil apoptosis is one of a 
major sources of autoantigen in JSLE patients (104). The effect of each 
of the dysregulated cytokines reported in adult-onset SLE and JSLE were 
studied. The results showed that GM-CSF, IL-1 and low concentrations 
of TNF-! significantly delayed neutrophil apoptosis, particularly GM-
CSF which showed the strongest protective effect on neutrophil apoptosis 
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(Figure 4.1). Next, levels of cytokines in JSLE serum were measured to 
determine whether the serum levels of these cytokine are dysregulated in 
JSLE patients, in line with some other previous studies. In my study, the 
levels of GM-CSF, IL-1", IL-6, IL-17, IFN-!, and TNF-! were below the 
lower limit of detection of the assay used (i.e. GM-CSF < 26.34 pg/mL). 
However, the levels of IL-2, IL-4, IL-8 and IL-10 were detectable, but 
only IL-8 was significantly increased in active JSLE serum, compared to 
inactive JSLE serum. It has been reported that increased serum IL-8 
levels in adult-onset SLE significantly correlated with disease activity, 
and the levels of IL-8 may serve as an indicator of disease activity in 
adult-onset SLE (264). Therefore, this finding suggests that the increased 
levels of IL-8 may be useful to predict disease flare in inactive JSLE 
patients. However, one previous study could not detect increased serum 
levels of IL-8 in patients with adult-onset SLE (265); thus, the correlation 
of serum IL-8 and SLE disease activity needs further studies, and analysis 
of more serum samples, particularly from patients with active disease is 
required. 
 As GM-CSF had the strongest protective effect on neutrophil 
apoptosis (showed in Figure 4.1), it was important to determine whether 
GM-CSF could protect neutrophils from the pro-apoptotic effects of 
JSLE serum. Unfortunately, serum samples from JSLE patients with 
active disease were very limited; therefore, sera from inactive JSLE 
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patients (which also induced neutrophil apoptosis), and from healthy 
juvenile controls were compared. The results showed that GM-CSF was 
able to prevent the effects of JSLE serum-induced neutrophil apoptosis as 
it significantly decreased the rate of apoptosis from neutrophils incubated 
with inactive JSLE serum. In addition, it significantly increased Mcl-1 
protein expression and decreased caspase activation; both initiator 
caspases (-8 and -9) and executioner caspases (-3 and -7). GM-CSF can 
delay neutrophil apoptosis by stabilizing Mcl-1 protein levels, and this 
finding showed that adding GM-CSF to neutrophils incubated with JSLE 
serum overcomes the pro-apoptotic effect of JSLE serum-induced 
neutrophil apoptosis that may be triggered via the extrinsic and/or 
intrinsic apoptotic pathways. This may be important for future studies 
that could consider the use of GM-CSF as an alternative treatment in 
JSLE patients. 
In spite of the fact that IL-1 and low concentrations of TNF-! also 
significantly delayed neutrophil apoptosis (as shown in Figure 4.1), the 
possibility of using IL-1 and TNF-! for the treatment in SLE patients is 
highly unlikely, as both cytokines seem to play an important role in the 
pathogenesis of inflammation in kidneys (202, 266). Therefore, 
therapeutic IL-1 and TNF-! for JSLE patients is inappropriate, 
particularly in view of their underlying kidney problems. As mentioned 
previously, the actual role of TNF-! in the pathogenesis of SLE is still 
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controversial. Many studies have shown that serum levels of TNF-! are 
significantly increased in patients with SLE and are correlated with 
disease activity (207–210). Nevertheless, another study has shown a 
contrasting finding of increased serum levels of TNF-! in SLE patients 
with inactive disease, suggesting a protective effect of TNF-! in disease 
pathology (207). Therefore, the role of TNF-! in the pathogenesis of 
SLE, including neutrophil apoptosis, needs to be further studied.  
Because of the dual effects of TNF-! on neutrophil apoptosis 
(248), previous reports have, until now, only provided part of the 
explanation as to how neutrophils respond to TNF-!. In the experiments 
described in this Chapter, the molecular events that regulate neutrophil 
responses to TNF-! signaling were investigated. Understanding the TNF-
! signaling pathway could lead to the development of new target 
therapies, in view of the success of TNF-! blockers in the pathology of 
many inflammatory conditions. The results showed a novel mechanism 
whereby human neutrophils undergo a re-programming of gene 
expression to protect themselves from TNF-!-induced cell death. They 
develop this protection from cell death by down-regulating the expression 
of key proteins involved in death receptor signaling (FADD, TRADD, 
TNFR1, TNFR2, caspase 8 and caspase 10) and in parallel, up-regulate 
expression of a number of anti-apoptotic genes (BCL2A1, CFLAR and 
TNFAIP3). These mechanisms would allow neutrophils to survive and 
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function in TNF-!-rich environments, and enable them to perform their 
role in inflammation.  As TNF-! itself is one of the genes that is 
markedly up-regulated when neutrophils are exposed to TNF-!, 
neutrophils can actively contribute to the TNF-! signaling network in 
inflammation (e.g. in renal tissue of lupus nephritis) without the 
possibility of autocrine-induced cell death. Taken together, these findings 
suggest that the role of TNF-! in JSLE may be highly tissue-specific. 
High concentrations of TNF-! (e.g. in serum) may induce neutrophil 
apoptosis whilst low concentrations (e.g. in renal tissue) may increase 
neutrophil survival leading to tissue inflammation and organ damage. 
Another important finding of my study was that TNF-! itself was 
one of the most abundant transcripts expressed by neutrophils exposed to 
this cytokine. This autocrine production of TNF-! would provide a 
positive feedback loop for neutrophils to actively contribute to TNF-! 
signaling in inflammatory conditions, such as SLE and more importantly 
provide an explanation for their resistance to TNF-!-induced death. 
Significant down-regulation of a number of genes that control 
responsiveness to death signals was shown in Figure 4.6. While changes 
in mRNA levels were maximal 1 h after stimulation with TNF-!, 
incubation periods in excess of 4 h were required before corresponding 
changes in protein levels were detected (Figure 4.10). This time course 
may help explain observations of TNF-!-mediated neutrophil death, 
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followed by survival. At early time points following TNF-! addition, 
neutrophils will not have had sufficient time to down-regulate their death-
receptor signaling pathways and so will be susceptible to apoptosis. 
Quantitative PCR and RNA-sequencing to measure transcript 
levels in neutrophils following TNF-! treatment were performed and 
showed a very close correlation between the sets of data generated by 
these two independent methods.  The former method is commonly-used 
to measure expression levels of specific transcripts in human neutrophils 
whilst the latter has not been used extensively to quantify the 
transcriptome of these cells. The benefits of RNA-sequencing over other 
transcriptome methods (qPCR arrays) are many-fold (226, 228), and 
together with the ever-decreasing costs of this technology, make this 
approach an effective and cost-effective way to study neutrophil function, 
both in vitro and ex vivo.  
In conclusion, the results presented in this Chapter have 
demonstrated the importance of an imbalance of cytokine production in 
JSLE serum and have determined the effects of each cytokine on 
neutrophil apoptosis. The results suggest that serum IL-8 could probably 
be useful as an indicator of disease activity in JSLE patients, while GM-
CSF could potentially be used as an alternative treatment in patients with 
JSLE. TNF-! has dual effects on neutrophil apoptosis and its effects are 
probably tissue-specific. The clinical application of TNF-!/ant-TNF-! 
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treatment in JSLE patients needs to be carefully considered. 
Understanding the molecular basis of TNF-! signaling will shed new 
light on the pathogenesis of SLE. 
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Chapter 5: JSLE neutrophil apoptosis and function 
5.1 Introduction 
 As autoantigens are a major cause of abnormal immune responses 
leading to tissue and organ damage in adult-onset SLE and JSLE, the 
source of autoantigens has been widely studied for many years. It has 
been found that autoantigens are produced and modified inside the 
apoptotic cells from lupus patients, following by the release of these 
modified autoantigens into the extracellular compartment (72). 
Autoantigens are subsequently processed by antigen presenting cells (e.g. 
dendritic cells) and then presented to CD4+ T cells and B cells resulting 
in autoantibody production. 
 Apoptosis or programmed cell death is a fundamental process as 
cells complete their lifespan, or when they are exposed/attacked by 
various types of pathogens and mechanical stresses from the 
environment. This controlled form of cell death allows apoptotic cells to 
limit the release of their intracellular components into surrounding tissues 
(25). The apoptotic cells are usually recognized and cleared by 
phagocytic cells (e.g. macrophages), otherwise the cells will undergo 
secondary necrosis and their intracellular components will be released to 
activate macrophages to produce pro-inflammatory cytokines (e.g. TNF-! 
and IL-8) leading to local tissue inflammation (267).  
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 Abnormal apoptotic cells and their defective clearance by 
phagocytic cells have been described in SLE (72, 268). These abnormal 
apoptotic cells can escape from phagocytic clearance and undergo 
secondary necrosis (267), in which their intracellular components 
including autoantigens (e.g. DNA, chromosome and histone) are released 
into extracellular compartment. The autoantigens are subsequently 
captured by immunoglobulins and complement factors forming immune 
complexes. These immune complexes activate antigen-presenting cells 
and B cells to produce further autoantibodies (72). On the other hand, the 
abnormal apoptotic cells may be engulfed by phagocytic cells (i.e. 
macrophages) and transferred to lysosomes for elimination. However, if 
there are defects in the degradation process or if it is overloaded, the 
degraded products may be able to activate innate immune cells, 
particularly plasmacytoid dendritic cells, leading to pro-inflammatory 
cytokine production (e.g. type I IFN and TNF-!) and abnormal immune 
responses (267).  
There are only a few reports describing the role of apoptotic cells 
particularly neutrophils (the most abundant white blood cells) in the 
pathogenesis of JSLE. However, one study has demonstrated that JSLE 
neutrophils are altered and have increased rates of constitutive apoptosis 
(103). Moreover, an imbalance of pro- and anti- apoptotic protein 
expression inside JSLE neutrophils has been described. The altered 
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apoptotic neutrophils from JSLE patients activate peripheral blood 
mononuclear cells to produce type I IFN, a key mediator in the 
pathogenesis of SLE, leading to abnormal inflammatory responses (50). 
One of the most important intracellular molecules regulating 
neutrophil apoptosis is the anti-apoptotic protein, Mcl-1. This anti-
apoptotic protein inhibits neutrophil apoptosis by blocking the release of 
cytochrome c from the mitochondria. The expression of this protein is 
controlled by numbers of cytokines and growth factors (39). In response 
to cell activation by these factors, the Mcl-1 gene will be transcribed into 
mRNA, and subsequently translated into anti-apoptotic protein Mcl-1. 
However, mRNA Mcl-1 can exist in two isoforms, which are Mcl-1 long 
form (Mcl-1L) and Mcl-1 short form (Mcl-1S). Mcl-1L is the product of 
normal transcription of the Mcl-1 gene and translation of the full length 
mRNA. It prevents apoptosis by binding to intracellular pro-apoptotic 
proteins (such as Bak and Bax). On the other hand, Mcl-1S is formed by 
alternative splicing and loss of exon 2 from the full length mRNA of the 
Mcl-1 gene (which contains 3 exons) (39). The loss of exon 2 generates a 
short protein Mcl-1S that can bind to and inhibit full length Mcl-1 and 
induce apoptosis (269). Mcl-1S has the properties of a BH3-only protein. 
Overexpression of Mcl-1L has been described in hematological 
malignancies (such as chronic myeloid leukemia), whilst up-regulation of 
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Mcl-1S has been reported during infections (270, 271). The expression of 
these two forms in JSLE neutrophils has never been reported. 
Apart from abnormal neutrophil apoptosis, impaired neutrophil 
functions have also been described in SLE patients. These defects 
include: decreased phagocytic ability (112); overexpression of 
inflammatory receptors on the cell surface, such as Fc#RI (CD64) and 
complement receptor CR3 (CD11b/ITGAM), leading to increased 
downstream inflammatory responses (115, 120, 121); abnormal 
neutrophil chemotaxis (97, 123, 124).  
In my previous Chapter, I showed that factor(s) in serum from 
patients with JSLE demonstrated several effects on healthy control 
neutrophils, such as cell survival, phagocytosis and ROS production. In 
this Chapter, the functions of JSLE neutrophils were characterized. 
5.2 Aims 
The aims of this Chapter were to determine if neutrophil functions 
from JSLE patients were defective, compared to healthy juvenile 
controls. 
Objectives 
• To compare rates of neutrophil apoptosis 
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• To measure the mRNA expression level of the anti-apoptotic 
gene, Mcl-1 long and short forms.  
• To quantify JSLE neutrophil phagocytosis and chemotaxis. 
5.3 Results 
5.3.1 JSLE neutrophil apoptosis 
 Neutrophils isolated from JSLE patients with inactive disease 
(iJSLE, n=5) and healthy juvenile controls (HC, n=5) were cultured with 
human AB serum for up to 2 h. The rate of neutrophil apoptosis was 
measured at time 0 and 2 h incubation using flow cytometry. The results 
showed increased rate of neutrophil apoptosis in iJSLE patients (3.4 ± 
0.7%) compared to HC (5.4 ± 0.7%) at time 0; however, this did not 
reach statistical significance (p>0.05). Following 2 h incubation, there 
was no significant difference in the rate of neutrophil apoptosis between 
iJSLE patients (8.1 ± 1.8%) and HC (9 ± 2.4%, p>0.05) (Figure 5.1). 
5.3.2 Mcl-1 mRNA expression in JSLE neutrophils 
 To determine if increased constitutive apoptosis if JSLE 
neutrophils was associated with increased expression of the pro-apoptotic 
Mcl-1S, mRNA was extracted from JSLE neutrophils (n=4) and healthy 
control neutrophils (n=4). Mcl-1L and Mcl-1S expression were 
determined by real-time PCR and normalised to actin mRNA. There was 
no difference in the relative expression levels of Mcl-1L between JSLE  
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Figure 5.1 JSLE neutrophil apoptosis. The graphs show the percentages 
of neutrophil apoptosis from inactive JSLE patients (iJSLE, n=5) and 
healthy juvenile controls (HC, n=5) at time 0  (A) and 2 h incubation (B). 
Data represent mean ± SEM (NS p>0.05, Student’s t-test). 
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neutrophils (1.33 ± 0.51) and healthy control neutrophils (1.31 ± 0.54, 
p>0.05). The relative expression of Mcl-1S in JSLE neutrophils was 0.99 
± 0.40, compared to the healthy control neutrophils (1.14 ± 0.67, p>0.05) 
(Figure 5.2). 
5.3.3 JSLE neutrophil phagocytosis 
Figure 5.3 compares phagocytosis by neutrophils from inactive 
JSLE patients (iJSLE) and healthy juvenile control neutrophils (HC) 
incubated with S. aureus that had been stained with PI and opsonised by 
human AB serum (opsonised SAPI) for 30 min. The percentage of 
neutrophils showing phagocytic activity was measured using flow 
cytometry. The results showed that iJSLE neutrophils incubated with 
opsonised SAPI had lower rates of phagocytosis of SAPI (69.3 ± 5%) 
compared to HC neutrophils (74.9 ± 1.5%), but these values did not reach 
statistical significance (p>0.05).  
5.3.4 JSLE neutrophil chemotaxis 
To determine whether JSLE neutrophils decrease chemotactic 
activity, chemotaxis assay was performed using Millipore Hanging Cell 
Culture plate inserts in 24-well tissue culture well plates pre-coated with 
poly (2-hydroxyethyl methacrylate). IL-8 (100 ng/mL) was added into 
each bottom well as a chemoattractant. Freshly-isolated neutrophils from 
inactive JSLE patients (iJSLE, n=5) and healthy juvenile controls (HC, 
n=5) were added into hanging inserts and they were incubated in an  
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Figure 5.2 Relative expression of Mcl-1L and Mcl-1S (normalised to 
actin). There was no significant difference in relative expression of Mcl-
1L and Mcl-1S between JSLE neutrophils (n=4) and healthy control 
neutrophils (n=4), Data represent mean ± SEM (NS p>0.05, Student’s t-
test). 
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Figure 5.3 JSLE neutrophil phagocytosis. Phagocytic ability of inactive 
JSLE neutrophils (iJSLE) incubated with opsonised S. aureus-PI (SAPI). 
There was no significant difference in the level of phagocytosis of 
opsonised SAPI by iJSLE neutrophils (n=3) compared to healthy juvenile 
control neutrophils (HC, n=3). Data represent mean ± SEM (NS p>0.05, 
Student’s t-test). 
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incubator at 37°C for 90 min. Migrated neutrophils in each well were 
counted and calculated as a percentage of the total number of cells 
originally added. Figure 5.4A demonstrates the chemotaxis assay used in 
this study. 
The result showed that neutrophils isolated from both iJSLE 
patients (25 ± 2.3%) and HC (21 ± 2.8%) showed chemotactic responses 
to IL-8 and the cells moved through the hanging inserts into the bottom 
wells, compared with cells without IL-8 treatment (p<0.05). However, 
the percentages of migrated neutrophils responding to IL-8 from iJSLE 
patients and healthy juvenile controls were not statistically-significant 
(p>0.05) (Figure 5.4B). 
5.4 Discussion 
 Dysregulated neutrophil apoptosis has been reported as a key 
event in the pathogenesis of JSLE (50, 103, 104). It has been proposed 
that increased neutrophil apoptosis is a major source of autoantigen 
exposure, inducing T and B cell activation, leading to abnormal immune 
responses in adult-onset SLE and JSLE patients (72, 268). In my previous 
Chapter, it was demonstrated that JSLE serum significantly induced 
neutrophil apoptosis, particularly JSLE serum from patients with active 
disease. However, the results in this Chapter showed that freshly-isolated 
JSLE neutrophils had slightly higher rates of apoptosis immediately after 
isolation compared to healthy juvenile control neutrophils, but this did  
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Figure 5.4 JSLE neutrophil chemotaxis. (A) Neutrophil chemotaxis assay 
was performed using Millipore Hanging Cell Culture plate inserts. IL-8 
(10 ng/mL) was added as a chemoattractant. Neutrophils were added into 
hanging insert and incubated for 90 min. (B) Migrated neutrophils from 
inactive JSLE patients (iJSLE, n=5) and healthy juvenile controls (HC, 
n=5) in the bottom wells with chemoattractant (IL-8) or without treatment 
(NO) were counted and calculated as a percentage of the total number of 
cell originally added. Data represent mean ± SEM (* p<0.05, Student’s t-
test). 
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not reach statistical significance. This finding suggests that JSLE serum 
is a major actor that induces neutrophil apoptosis in JSLE patients rather 
than JSLE neutrophils themselves. Nevertheless, Figure 5.1 shows higher 
rate of apoptosis in JSLE neutrophils at time 0, compared to healthy 
juvenile control neutrophils while the rate of apoptosis at 2 h incubation 
was similar between both groups. Although, this higher rate of JSLE 
neutrophil apoptosis at time 0 did not reach statistical significance, this 
may represent higher rates of apoptosis in vivo. After 2h incubation, 
JSLE neutrophils were incubated with human AB serum, that probably 
reversed the effect of JSLE serum in vivo, and subsequently protected 
JSLE neutrophils from apoptosis at 2 h. However, longer time points and 
experiments using healthy juvenile control serum are required to support 
the assumption that JSLE neutrophils could be saved by human AB 
serum and/or healthy juvenile control serum. It would also be interesting 
to have performed similar experiments with neutrophils isolated from 
JSLE with active disease, and this should be investigated in future 
studies. 
Mcl-1 is an important intrinsic anti-apoptotic protein regulated by 
expression of the Mcl-1 gene. Processing of the mRNA can generate 2 
isoforms via alternative splicing, Mcl-1L and Mcl-1S. Interestingly, both 
isoforms have different functions. Mcl-1L is derived from full length 
mRNA and the protein delays apoptosis, whilst Mcl-1S is a splicing 
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variant and it induces apoptosis (39, 269). Abnormal expression of Mcl-
1L and Mcl-1S has been reported in several conditions, but it has never 
been reported in JSLE patients (270, 271). Therefore, it was interesting to 
determine whether the expression of these two isoforms in neutrophils 
isolated from JSLE patients is dysregulated. However, the results showed 
that there was no significant difference in the expression of both isoforms 
in JSLE neutrophils compared to healthy juvenile control neutrophils. 
Decreased phagocytic ability by neutrophils has been reported in 
SLE patients (112). In the previous Chapter, it was demonstrated that 
defective neutrophil phagocytosis in JSLE patients is probably caused by 
factor(s) in JSLE serum, particularly when apoptotic neutrophils were 
incubated with opsonised bacteria with active JSLE serum. The aim of 
this Chapter focused on JSLE neutrophil function; however, the results 
showed that there were no significant differences in the percentages of 
phagocytic neutrophils between the two groups.  
Another crucial function of neutrophil is chemotaxis and it has 
been reported that neutrophil chemotaxis in patients with SLE is impaired 
(97, 123). Nevertheless, the results are still controversial and not 
confirmed in other reports. Neutrophil chemotactic activity has been 
reported as significantly decreased and correlated with a high incidence 
of infection in SLE patients, while hyperactivity of neutrophil chemotaxis 
was described in another study (124). In my results, the chemotactic 
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activity of JSLE neutrophils was not significantly different to healthy 
controls, suggesting that the susceptibility to infection in JSLE patients is 
not caused by defective JSLE neutrophil chemotaxis, but probably results 
from JSLE serum-induced neutrophil apoptosis and ineffective bacterial 
opsonisation by JSLE serum. 
However, the JSLE neutrophils in this Chapter were only isolated 
from patients with inactive disease, and further studies using neutrophils 
from patients with active disease should be performed. 
In conclusion, the results in this Chapter have demonstrated that 
JSLE neutrophils themselves have normal functions as the rates of 
neutrophil apoptosis, phagocytosis and chemotaxis were not significantly 
changed from healthy juvenile control neutrophils. These findings 
suggest that dysregulated neutrophil functions are mainly caused by the 
factor(s) in JSLE serum. 
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Chapter 6: Effects of anti-malarial agents on neutrophil 
function 
6.1 Introduction 
 Anti-malarial agents, alongside corticosteroids, are amongst the 
oldest drugs used for the initial treatment of JSLE and adult-onset SLE. 
They used to treat patients with malarial infection and for anti-malarial 
prophylaxis (272) but it was observed that soldiers in the Second World 
War who received anti-malarial prophylaxis, showed as improvement in 
their underlying rheumatic conditions, such as inflammatory arthritis and 
cutaneous lupus lesions. Consequently, these incidental findings leads to 
the beginning of systematic studies to investigate the beneficial effects of 
these agents for the treatment of rheumatic diseases, including SLE. 
The role and efficacy of anti-malarial agents for the treatment of 
SLE has been evaluated over many decades of their use (273–276). It has 
been shown that lupus patients treated with anti-malarial agents 
(particularly chloroquine and hydroxychloroquine) experienced 
decreased disease progression, improved clinical outcome and increased 
survival rate (90). However, the actual mechanisms responsible for the 
beneficial effects anti-malarial agents on this disease remain unclear. 
Anti-malarial agents also have an important role in the treatment of JSLE 
patients, and are very effective, particularly for patients presenting with 
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cutaneous lupus lesions and inflammatory joints (55, 60, 61). The 
majority of JSLE patients who receive hydroxychloroquine show 
decreased disease flares and slower progression of major organ damage 
(64). Although anti-malarial agents are commonly and successfully used 
in combination with corticosteroids for the initial treatment for JSLE 
patients, the most serious and irreversible side effect is ocular toxicity 
(i.e. retinopathy) (91). JSLE patients who receive anti-malarial agents 
require routine eye examination (every 6-12 months), and ocular toxicity 
needs to be closely monitored. 
 The major anti-malarial agents currently used in JSLE and adult-
onset SLE patients are chloroquine and hydroxychloroquine (55, 60, 61). 
Because of the higher (x3) toxicity of chloroquine, hydroxychloroquine is 
more commonly prescribed in JSLE patients (90). Both chloroquine and 
hydroxychloroquine are 4-amino-quinolines with lipophilic properties, 
and they can easily pass through cell membranes into intracellular 
compartments, including cell organelles (i.e. vesicles and granules) (272). 
Although the mechanisms of action of these agents are still unclear, both 
drugs show clearly-demonstrable anti-inflammatory effects, 
immunosuppression and photo-protection in patients with SLE (90). It 
has been reported that chloroquine and hydroxychloroquine suppress 
autoantigen presentation, and inhibit Toll-like receptor (TLR) signaling 
and leukocyte activation (277). The alteration of pH and stability of 
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lysosomes also seems to be an important mechanism of action of these 
agents in causing decreased binding of autoantigen to MHC class II 
molecules on the cell membranes, and interference of the TLR signaling 
pathway in antigen-presenting cells (278). Moreover, decreased 
production of pro-inflammatory cytokines, such as IL-1", IL-6, IL-18, 
IFN-# and TNF-! has been reported in patients who received anti-
malarial agents (279, 280).  
One interesting observation is that hydroxychloroquine induces 
apoptosis of peripheral blood lymphocytes of lupus patients (281). The 
increased apoptosis of lymphocytes, including T and B cells, can lead to 
decreased production of autoantibodies in SLE. Furthermore, the effect of 
hydroxychloroquine on increased synoviocyte apoptosis has been 
described in patients with rheumatoid arthritis (282). These pro-apoptotic 
effects on synoviocytes may decrease the production of pro-inflammatory 
cytokines and pannus formation in the joints of rheumatoid arthritis 
patients, may explain the anti-inflammatory effects of these agents. 
However, the effects of these drugs on neutrophil apoptosis have never 
been reported.  
There are only a few reported studies demonstrating the effects of 
anti-malarial agents on neutrophil function (283–285). It has been shown 
that neutrophil superoxide production is inhibited by chloroquine and 
hydroxychloroquine in vivo (284). Nevertheless, increased incidence of 
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bacterial infection has never been reported in patients treated with these 
agents.  
6.2 Aims 
 The aims of this Chapter were to determine whether 
hydroxychloroquine, a commonly-used anti-malarial agent for patients 
with JSLE, has any effects on neutrophil functions, in terms of cell 
survival, phagocytic ability, ROS production and chemotaxis. 
Objectives 
• To compare the rate of apoptosis of neutrophils incubated with or 
without hydroxychloroquine 
• To determine whether hydroxychloroquine decreases superoxide 
production (i.e. ROS production) and phagocytic ability by 
neutrophils 
• To measure chemotactic ability of neutrophils pre-treated with 
hydroxychloroquine, and to determine the effects of 
hydroxychloroquine on the efficacy of chemoattractant (IL-8) to 
attract neutrophils. 
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6.3 Results 
6.3.1 Effects of hydroxychloroquine on apoptosis of neutrophils and 
neutrophils treated with GM-CSF 
 Neutrophils were isolated from healthy adult controls (n=5) and 
incubated with 10% human AB serum with or without 
hydroxychloroquine (HCQ) to explore whether neutrophil apoptosis was 
either delayed or enhanced by this drug. The concentrations in serum 
from patients treated with HCQ are in reported to be within the range of 
0-23 µM (286). Therefore, neutrophils were incubated in vitro with 
concentrations of this drug up to 40 µM. The results showed no 
significant differences in the percentage apoptosis between neutrophils 
incubated with 2 µM (69.2 ± 5.4%), 10 µM (74.4 ± 4.4%), 20 µM (76.6 ± 
4.3%), 40 µM (77.7 ± 5%) of HCQ and neutrophils without treatment 
(67.3 ± 6.6%), after 22 h incubation (p>0.05) (Figure 6.1A). There was a 
trend for increased apoptosis as the concentration of HCQ was increased, 
but this did not reach statistical significance. 
HCQ is reported to induce apoptosis of peripheral blood 
lymphocytes and synoviocytes, but there are no report in its effects on 
neutrophil apoptosis (281, 282). As GM-CSF can significantly delay 
neutrophil apoptosis (Figure 4.1), it was therefore important to determine 
whether HCQ has an effect on apoptosis of neutrophils treated with GM-
CSF. Isolated neutrophils (n=5) were incubated with 10% human AB  
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Figure 6.1 Effects of hydroxychloroquine on neutrophil apoptosis. The graph 
shows the effects of hydroxychloroquine on neutrophil apoptosis after 
incubation with 10% human AB serum (A), or after incubation with 10% human 
AB serum with GM-CSF (B) after 22 h incubation (n=5). HCQ 2, 10, 20 and 40 
= hydroxychloroquine at 2 µM, 10 µM, 20 µM and 40 µM, respectively. GM= 
GM-CSF. Data represent mean ± SEM (NS p>0.05, Student’s t-test). 
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serum plus GM-CSF (5 ng/mL), in the absence or presence of HCQ. The 
results showed no significant difference in the percent of apoptosis 
between neutrophils treated with GM-CSF and 2 µM (40 ± 3%), 10 µM 
(43.6 ± 4.6%), 20 µM (45.4 ± 6.1%), 40 µM (54 ± 9.7%) of HCQ, and 
neutrophils without treatment (36.1 ± 4%) after 22 h incubation (p>0.05) 
(Figure 6.1B). Again, there was a trend for decreased protection of 
apoptosis by GM-CSF as the concentration of HCQ was increased, but 
this did not reach statistical significance. 
6.3.2 Effects of hydroxychloroquine on neutrophil phagocytosis and ROS 
production 
Figure 6.2A compares phagocytosis by neutrophils treated with 
hydroxychloroquine (HCQ) for 1 h with that of untreated neutrophils, 
following incubation with S. aureus that was previously stained with PI 
and opsonised by human AB serum (SAPI) for 30 min. The percentage 
neutrophils undergoing phagocytosis was measured using flow 
cytometry. The results showed that there were no significant differences 
in the percentage of phagocytosis between neutrophils treated with HCQ 
at 2 µM (93.4 ± 1.9%), 10 µM (90 ± 3.1%), 20 µM (88.7 ± 2%) and 40 
µM (89.6 ± 2.8%), and untreated neutrophils (91.6 ± 2.8%) (p>0.05) 
(Figure 6.2A).  
The percentage of neutrophils staining positively for ROS 
production in the presence and absence of HCQ was analysed using  
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Figure 6.2 (A) Phagocytic ability and (B) ROS production of neutrophils 
treated with increasing concentrations of hydroxychloroquine for 1 h, 
followed by incubation with PI-stained, opsonised S. aureus (n=5). HCQ 
2, 10, 20 and 40 = hydroxychloroquine at 2 µM, 10 µM, 20 µM and 40 
µM, respectively. Data represent mean ± SEM (NS p>0.05, Student’s t-
test). 
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DHR123 (as described in Materials and Methods). Levels of ROS 
production by neutrophils treated with HCQ, following incubation with 
SAPI for 30 min were as follows: 2 µM (60 ± 7.4%); 10 µM (60.8 ± 
5.6%); 20 µM (63.4 ± 8.2%) and 40 µM (61.4 ± 8.9%). These values 
were not significantly different from untreated neutrophils (58.1 ± 6.1%), 
(p>0.05) (Figure 6.2B). 
6.3.3 Effect of hydroxychloroquine on neutrophil chemotaxis 
A chemotaxis assay was performed using Millipore Hanging Cell 
Culture plate inserts (as previously described in Chapter 5). IL-8 was 
used as a chemoattractant (100 ng/mL), and hydroxychloroquine was 
added into each bottom well, together with IL-8 to investigate whether 
hydroxychloroquine could either increase or decrease the efficacy of IL-8 
to attract neutrophils. Freshly-isolated neutrophils (n=5) were added into 
hanging inserts and incubated in an incubator at 37°C for 90 min. 
Migrated neutrophils in each well were counted and calculated as a 
percentage of the total number of cells originally added. The results 
showed that the percentage of migrated neutrophils in IL-8 with HCQ 
were as follows: 2 µM (47.2 ± 1.1%); 10 µM (44.5 ± 2%); 20 µM (45.3 ± 
1.9%) and 40 µM (46.1 ± 3.2%). These values were not significantly 
different from migrated neutrophils in IL-8 alone (46.3 ± 3.1%) (p>0.05) 
(Figure 6.3A). 
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Figure 6.3 Effect of hydroxychloroquine on neutrophil chemotaxis. Neutrophil 
chemotaxis was performed using Millipore Hanging Cell Culture plate inserts. 
(A) IL-8 (100 ng/mL) and increasing concentrations of hydroxychloroquine 
(HCQ) were added into the bottom wells. Neutrophils were added into the 
hanging inserts for 90 min. Migrated neutrophils (n=5) were counted and 
calculated as a percentage of the total number of cells originally added. (B) 
Isolated neutrophils (n=5) were treated with HCQ for 1 h prior to the 
chemotaxis assay. IL-8 alone was added into the bottom wells. Migrated 
neutrophils (n=5) into the bottom well were counted. HCQ 2, 10, 20 and 40 = 
hydroxychloroquine at 2 µM, 10 µM, 20 µM and 40 µM, respectively. Data 
represent mean ± SEM (NS p>0.05, Student’s t-test). 
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To determine whether pre-incubation with HCQ had any effect on 
the chemotactic ability of neutrophils, neutrophils were treated with or 
without HCQ for 1 h prior to a chemotaxis assay. IL-8 alone was added 
into each bottom well as a chemoattractant. The results showed that the 
percentage of migrated neutrophils treated with HCQ at 2 µM (37.4 ± 
1.7%), 10 µM (40.3 ± 2%), 20 µM (38.7 ± 2.8%) and 40 µM (36.7 ± 
2.2%) were not significantly different from untreated neutrophils (37 ± 
1.2%) (p>0.05) (Figure 6.3B). 
6.4 Discussion 
 Hydroxychloroquine is an anti-malarial drug that is commonly-
used to treat patients with JSLE. The mechanisms of action of this agent 
is not clearly understood; however, it has been reported that anti-
inflammatory effects, immunosuppression and photoprotection are 
observed in JSLE patients treated with hydroxychloroquine (90). The 
possible mechanisms of hydroxychloroquine in the treatment of SLE and 
JSLE are (a) suppression of autoantigen presentation, (b) inhibition of 
Toll-like receptor signaling pathway and (c) prevention of leukocyte 
activation (277). However, it has been reported that hydroxychloroquine 
induces apoptosis of peripheral blood lymphocytes of lupus patients, 
leading to decreased production of autoantibodies in SLE (281). 
Furthermore, hydroxychloroquine induces synoviocyte apoptosis in 
patients with rheumatoid arthritis (282). As neutrophil apoptosis plays a 
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role in the pathogenesis of JSLE (103), it is important to determine the 
effects of this drug on neutrophil apoptosis. If hydroxychloroquine 
exerted a pro-apoptotic effect on neutrophils, this could lead to decreased 
inflammation, but if these apoptotic neutrophils were not efficiently 
cleared, then enhanced neutrophil apoptosis may increase autoantigen 
exposure and hence autoantibody production. This latter phenomenon 
could explain why some patients respond poorly to these agents and 
develop side effects (287). The results showed that hydroxychloroquine 
had no significant pro-apoptotic effects on neutrophils although the 
concentrations were increased up to 2 times the levels measured in 
patient serum (0-23 µM) (286). This finding suggests that 
hydroxychloroquine at normal or double concentrations in patient serum 
are harmless for neutrophils in terms of cell survival. 
One previous study reported that hydroxychloroquine could 
inhibit superoxide production by neutrophils in vivo (284). The study 
showed that the production of superoxide stimulated by fMLP was 
decreased in neutrophils incubated with hydroxychloroquine in a dose 
dependent manner. A 50% decrease in superoxide release was observed 
in neutrophils treated with hydroxychloroquine at the concentration of 
100 µM. In my study, phagocytosis and ROS production by neutrophils 
treated with hydroxychloroquine were investigated, when intracellular 
ROS were measured following phagocytosis. The results showed that 
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hydroxychloroquine at normal (2-20 µM) or double (40 µM) 
concentrations had no significant effect on phagocytosis and ROS 
production by neutrophils incubated with SAPI, suggesting that 
neutrophils exposed to serum concentrations of hydroxychloroquine still 
function normally. Similarly, the chemotactic ability by neutrophils was 
also unaffected by this drug. The results showed that hydroxychloroquine 
did not either interfere the efficacy of the chemoattractive agent (i.e. IL-
8) in terms of attracting neutrophils or affect the chemotactic ability of 
neutrophils pre-treated with hydroxychloroquine. These findings confirm 
that at the concentrations of hydroxychloroquine attained in patient 
serum, neutrophils normally respond to IL-8 and their chemotactic ability 
is still effective. 
In conclusion, the results presented in this Chapter have 
demonstrated that hydroxychloroquine, a commonly-used anti-malarial 
agent in the treatment of JSLE patients, has no effect on neutrophils in 
terms of cell survival, phagocytosis, ROS production and chemotaxis at 
the normal concentrations attained in patient serum. It is therefore very 
unlikely that the use of hydroxychloroquine in JSLE patients induces any 
neutrophil dysfunction that can result in a higher incidence of bacterial 
infections. 
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Chapter 7: General discussion and conclusions 
Neutrophils are the most abundant white blood cells (leukocytes) 
in the circulation of human blood and play an important role during acute 
inflammation. Neutrophils are the first leukocytes that rapidly migrate to 
the inflammatory site, recognize and subsequently remove pathogens (2). 
There are several steps in the process of pathogen elimination, such as 
neutrophil priming, neutrophil rolling and adhesion, neutrophil 
transmigration/chemotaxis, neutrophil opsono-phagocytosis and ROS 
production, and neutrophil apoptosis and clearance (4). Therefore, 
effective control of neutrophil function is vital at the site of 
infection/inflammation. 
In contrast, neutrophils also play damaging roles in the 
pathophysiology of many diseases, including autoimmune diseases (11). 
Neutrophils have been reported as one of the most important contributing 
factors in disease pathology of systemic lupus erythematosus (SLE), 
particularly in terms of neutrophil survival and apoptosis (49). It has been 
found that there are increased numbers of apoptotic leukocytes (e.g. 
neutrophils) in patients with SLE (100). It has also been found that 
autoantigens may be clustered in blebs on the surface of apoptotic cells 
and trigger abnormal immune responses and autoantibody production 
which is hypothesised as a major cause of the disease pathology (99). 
Moreover, neutrophil functional defects have been reported in patients 
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with SLE. For example, ineffective phagocytosis, decreased cytokine 
production and dysregulated chemokine response by neutrophils have all 
been described and can contribute to increased susceptibility of patients 
to infections, particularly by bacteria and fungi (95, 112).  
Juvenile SLE (JSLE) is a subgroup of SLE, and patients usually 
have more severe clinical features than those with adult-onset SLE (55, 
60, 61). JSLE patients usually present with major organ involvement (e.g. 
lupus nephritis, blood dyscrasia and neuropsychiatric lupus) at the time of 
diagnosis, which is indicative of a worst prognosis. Although there are 
only a few reports on disease pathology of JSLE, including a correlation 
with neutrophil defects, such studies have clearly demonstrated an 
abnormal neutrophil function that is involved in the immune-
pathogenesis of JSLE (50–52). Therefore, the main objective of my study 
was to characterize abnormal neutrophil function, in terms of cell 
survival, phagocytosis, ROS production and chemotaxis in JSLE patients. 
Furthermore, factor(s) that could affect normal neutrophil function (e.g. 
recombinant human cytokines, commonly-used medications.) were also 
investigated. 
The main findings of my study were as follows: 
• Factor(s) in JSLE serum (particularly in active JSLE serum) 
significantly induced healthy neutrophils become apoptotic via 
the extrinsic and/or intrinsic apoptotic pathways 
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• JSLE serum resulted in decreased bacterial opsonisation, leading 
to defective neutrophil phagocytosis and ROS production; these 
defects were, again more marked in serum from patients with 
active JSLE serum. 
• An imbalance of cytokines that are reported in JSLE serum had 
either protective (e.g. GM-CSF, IL-1 and low concentrations of 
TNF-!) or neutral effects on neutrophil apoptosis (e.g. IL-6, IL-17 
and IFN-!). 
• IL-8 levels in JSLE serum could potentially be useful as a 
biomarker of disease activity in JSLE patients, as the levels of this 
chemokine were significantly higher in serum from JSLE patients 
with active disease compared with serum from JSLE patients with 
inactive disease. 
• GM-CSF, a potent cytokine for delaying neutrophil apoptosis, 
overcame the pro-apoptotic effect of JSLE serum-induced 
neutrophil apoptosis and it could possibly be used as an 
alternative treatment in patients with JSLE. 
• Although low concentrations of TNF-! significantly saved 
neutrophil apoptosis, the clinical application of TNF-!/ant-TNF-! 
treatment in JSLE patients needs to be thoroughly considered 
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because of the dual effects of this cytokine on neutrophil 
apoptosis and its tissue-specificity. 
• Neutrophils isolated from JSLE patients (with inactive disease) 
are likely to have normal functions, because the rates of apoptosis, 
phagocytic ability and chemotaxis were not significantly different 
from healthy, juvenile control neutrophils. 
• Hydroxychloroquine; a commonly-used anti-malarial agent for 
the treatment of JSLE patients, at concentrations achieved in 
serum following treatment, had no significant effect on neutrophil 
functions, in terms of cell survival, phagocytosis, ROS production 
and chemotaxis. 
 
Results from my study strongly indicate that JSLE serum is 
possible to be a crucial factor responsible for the dysregulated neutrophil 
functions. Factor(s) in JSLE serum could activate the caspase cascade (-3, 
-7 and -8) of either the extrinsic and/or intrinsic pathways, and decreased 
the levels of major anti-apoptotic protein; Mcl-1, leading to increased 
neutrophil apoptosis (as described in Chapter 3). These findings were 
consistent with previous reports that showed that JSLE serum increased 
the level of apoptosis in healthy control neutrophils compared to healthy 
juvenile control serum (103, 105). In addition, my study has 
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demonstrated that serum from JSLE patients with active disease induce 
higher levels of apoptosis compared to serum from patients with inactive 
disease, although the results did not reach statistical significance because 
of the relatively small sample size. This finding provides new 
information on the immune-pathogenesis of the disease, suggesting that 
disease activity in JSLE patient correlates with the degree of neutrophil 
apoptosis. However, further studies are needed to confirm this finding, 
and a greater number of serum samples from patients with both active 
and inactive disease need to be collected to increase the sample size. The 
difficulty in assessing patients with JSLE disease as “active” or 
“inactive” is sometime problematic but can be largely overcome by using 
disease activity scores (i.e SLEDAI scores). Recording SLEDAI scores 
of JSLE patients in Thailand for an extension of my study is now ongoing 
and has been initiated by my studies. An extension of my work, therefore, 
will be to determine if there is a correlation between SLEDAI scores and 
the rate of neutrophil apoptosis induced by serum from JSLE patients. 
Factor(s) in JSLE serum also affected other functions of 
neutrophils, such as phagocytic ability and ROS production. In my study, 
both phagocytic ability and ROS production were decreased when 
neutrophils were incubated with S. aureus opsonised with JSLE serum, 
and further decreased when the bacteria were opsonised with active JSLE 
serum. Although the decreases did not reach statistical significance, these 
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results suggest that serum from JSLE patients is more likely to decrease 
bacterial opsonisation leading to impaired phagocytic ability and 
decreased ROS production. These findings were also observed when 
apoptotic neutrophils were used instead of freshly-isolated neutrophils. 
Apoptotic neutrophils were incubated with the bacteria opsonised with 
JSLE serum and both phagocytic ability and ROS production were 
significantly decreased, compared with freshly-isolated neutrophils 
incubated with the bacteria opsonised with healthy control serum. Taken 
together, these findings suggest that both phagocytic ability and ROS 
production by neutrophils in JSLE patients is decreased, probably 
because JSLE serum induces neutrophil apoptosis and is less effective in 
opsonisation. Clinically, this could lead to increased susceptibility to 
infections in JSLE patients. These findings indicate that neutrophil 
apoptosis is an important factor involved in both the pathogenesis of 
JSLE (i.e. a major source of autoantigens), and is related with the disease 
etiology of susceptibility to infections (i.e. less effective in bacterial 
opsonisation) in JSLE patients. The next experiments, therefore, focused 
on characterising JSLE serum, as it is likely to be a major factor that 
induces neutrophil apoptosis in JSLE patients.  
It has been reported that the levels and types of cytokines in 
serum regulate neutrophil survival in vitro (238). In previous studies, an 
imbalance of cytokine levels has been reported in the serum of patients 
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with JSLE (e.g. GM-CSF, IL-1, IL-6, IL-17, type I IFNs and TNF-!) (83, 
146, 219). Therefore, it is important to investigate the effect of these 
cytokines on neutrophil apoptosis and to determine their levels in serum 
from patients with JSLE. The results showed that only three of the 
cytokines tested (GM-CSF, IL-1 and low concentrations of TNF-!) 
significantly saved neutrophil apoptosis, whereas the others tested 
showed no significant effects. Unfortunately, the Luminex assay did not 
show decreased levels of GM-CSF, IL-1 and TNF-! in serum, which 
could have offered an explanation for the increased neutrophil apoptosis 
observed in JSLE patients. Moreover, most cytokines in JSLE serum that 
have been previously reported as increased, particularly IL-6, IL-17, type 
I IFNs and TNF-!, and that their levels correlated with the degree of 
disease activity (83, 146, 219), were undetectable in the assay used in my 
studies. However, these cytokines were also undetectable in serum from 
healthy juvenile controls. These findings probably either reflect that (a) 
the levels of these cytokines in serum are essentially very low in both 
JSLE patients and healthy juvenile controls, (b) the detection limitations 
of the assay used in this study are too low (i.e GM-CSF < 26.34 pg/mL, 
IL-1" < 11.25 pg/mL and IL-6 < 7.06 pg/mL) or (c) serum protein can 
somehow interfere with the detection assay. 
There were four cytokines in serum from both JSLE patients and 
healthy juvenile controls detectable in my study, one of which was IL-8 
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and it was significantly higher in JSLE patients with active disease, 
compared to levels in serum from JSLE patients with inactive disease. IL-
8, a potent neutrophil chemoattractant, has been reported as a cytokine 
that can save/delay neutrophil apoptosis (288, 289). For this reason, IL-8 
is unlikely to be a factor that induces neutrophil apoptosis in JSLE 
patients. Moreover, the median levels of IL-8 detected in this study was 
21.34 pg/mL (IQ range 11.30-58.35), which are low and unable to affect 
on neutrophil apoptosis (288) (also shown in Appendix; Figure 8.2). 
Nevertheless, there are other factor(s) in serum that induce neutrophil 
apoptosis (e.g. Fas, TRAIL) and these many be elevated in serum from 
patients with JSLE. The future plan, therefore, is to measure these 
factor(s) in patient serum. The relatively small sample size of my study is 
another issue that needs to be considered in future studies. For this, serum 
samples from both JSLE patients and healthy juvenile controls are 
necessary to be recruited, and the disease status more rigorously defined 
(see above). Even though the levels of IL-8 detected in active JSLE 
serum are unlikely to be a factor that can regulate neutrophil apoptosis, 
their levels could be useful as a biomarker of disease activity in JSLE 
patients. The levels of this chemokine could predict disease flare in 
inactive JSLE patients, as has been proposed in adult-onset SLE with 
disease flare (264). 
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There are at least three cytokines (e.g. GM-CSF, IL-1 and TNF-!) 
that significantly delayed neutrophil apoptosis in my study, one of which 
was GM-CSF. The results demonstrated that GM-CSF was the most 
potent cytokine that could save/delay neutrophil apoptosis. As JSLE 
serum induced neutrophil apoptosis, this study therefore focused upon the 
effect of GM-CSF on neutrophil apoptosis and the next aim was to 
determine whether GM-CSF could overcome the pro-apoptotic effect of 
JSLE serum and protect neutrophils against apoptosis. The results 
showed that GM-CSF not only overcame the pro-apoptotic effect of JSLE 
serum and saved neutrophil apoptosis, but also prevented caspase 
activation (-3, -7, -8 and -9) and increased/maintained the levels of the 
anti-apoptotic protein Mcl-1 in neutrophils incubated with JSLE serum. 
This finding suggests that GM-CSF could be considered as an alternative 
treatment in patients with JSLE, in order to decrease number of apoptotic 
neutrophils, leading to decreased autoantigen production, and subsequent 
decreased T- and B- cell activation. 
GM-CSF is a common therapeutic agent used for treatment of 
several diseases, particularly hematological malignancy (e.g. leukemia 
and lymphoma) (290, 291). GM-CSF is usually administered in patients 
with leukemia following a complete course of chemotherapy. The 
purpose of GM-CSF administration is to increase number of normal 
granulocytes and monocytes, in order to protect the patients from 
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opportunistic infections, as chemotherapeutic agents have a common side 
effect on bone marrow suppression (290). As the adverse effects of GM-
CSF are minimal (292, 293), the concept of GM-CSF administration in 
patients with JSLE, as an alternative treatment in order to decrease 
neutrophil apoptosis, and thereby decrease autoantigen production, is 
feasible. Future plans should identify the autoantigens on the apoptotic 
neutrophil surface induced by JSLE serum, and determine whether the 
expression of autoantigens on the cell surface of apoptotic neutrophils is 
decreased following GM-CSF treatment. 
Although IL-1 and low concentrations of TNF-! also showed an 
anti-apoptotic effect on neutrophils in this study, the application of both 
cytokines for treatment in patients with JSLE would be problematic. It 
has been reported that both IL-1 and TNF-! are involved in the 
pathogenesis of lupus nephritis, and renal histopathology from these 
patients reveals high levels of these cytokines surrounding the inflamed 
tissue, suggesting that both cytokines play an inflammatory role in 
patients with JSLE. Furthermore, the effect of TNF-! on neutrophil 
survival/apoptosis is biphasic. Low concentrations (~10 ng/mL) protect 
against neutrophil apoptosis whereas higher concentrations (>30 ng/mL) 
promote apoptosis (248). Consequently, the application of TNF-! as a 
therapeutic treatment is seemingly inappropriate, and obtaining the 
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appropriate dosage of TNF-! will be extremely challenging in JSLE 
patients. 
The precise role of TNF-! in the pathogenesis of SLE is still 
controversial. Although TNF-! appears to be an important pro-
inflammatory cytokine involved in the pathogenesis of JSLE and adult-
onset SLE (195), anti-TNF-! therapy in treatment of patients with SLE is 
unsuccessful. Therefore, understanding the role of TNF-! in the 
pathogenesis of JSLE (and other inflammatory conditions) in which this 
cytokine may play a role in pathology is crucial, particularly in terms of 
neutrophil responses to TNF-! under conditions that mimic acute and 
chronic inflammation (e.g. in JSLE). Here, my results showed that 
neutrophils down-regulated the expression of proteins involved in death 
receptor signaling (i.e. FADD, TRADD, TNFR1, TNFR2, caspase 8 and 
caspase 10) following TNF-! exposure, in order to protect themselves 
against apoptosis, and in parallel, up-regulated the expression of anti-
apoptotic genes (BCL2A1, CFLAR and TNFAIP3). This phenomenon 
allows neutrophils to survive and function in TNF-!-rich environments, 
and enables them to perform their role in inflammation. These findings 
suggest a tissue-specific role of TNF-! in JSLE, as high concentrations 
(e.g. in serum) probably induce apoptosis resulting in autoantigen 
exposure, whereas low concentrations (e.g. in kidneys) delay apoptosis 
leading to tissue inflammation and organ damage. An interesting 
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observation in this study is elevated transcripts for TNF-! in neutrophils 
following TNF-! exposure. This autocrine production probably provides 
a positive feedback loop for neutrophils and subsequently explains their 
resistance to TNF-! induced cell death.  
Apart from the effects of JSLE serum and recombinant-cytokines 
on neutrophil function, this study also investigated the function of 
neutrophils isolated from JSLE patients. First, the apoptotic rate of JSLE 
neutrophils was measured. The results showed that the levels of 
neutrophil apoptosis in JSLE neutrophils at time 0 were slightly higher 
than that of healthy juvenile control neutrophils, whereas comparable 
levels were observed in both groups after 2 h incubation in human AB 
serum. Although this higher rate of JSLE neutrophil apoptosis at time 0 
did not reach statistical significance, it suggests that JSLE neutrophils 
might have been activated by JSLE serum in vivo and the pro-apoptotic 
effects of JSLE serum were reversed after neutrophils were incubated 
with human AB serum in vitro.  
Previous studies have shown that the transcript for the anti-
apoptotic protein, Mcl-1 can exist in two forms, a normal transcript (Mcl-
1L) and its splicing variance (Mcl-1S). These proteins, encoded by these 
two splice variants, have opposing effects on apoptosis. I therefore 
determined if there were variations in the levels of these two transcripts 
in neutrophils from JSLE patients and healthy juvenile controls. 
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However, no differences in the levels of these two transcripts were 
detected. Taken together, JSLE serum might affect JSLE neutrophils at 
the levels of Mcl-1 protein but not the level of Mcl-1 splicing. 
Nevertheless, longer incubation times and incubations with healthy 
juvenile control serum are required to confirm these findings.  
Next, my study measured the phagocytic ability and chemotaxis 
activity of JSLE neutrophils, as these properties have been reported to be 
impaired in adult-onset SLE patients, leading to opportunistic infections 
(97, 112, 123). The results showed that both phagocytic ability and 
chemotaxis are not significantly altered in JSLE patients, reflecting that 
the susceptibility to infections in JSLE patients is probably caused by 
defects in JSLE serum that can induce neutrophil apoptosis and decrease 
the efficiency of bacterial opsonisation. 
This study finally investigated the effects of a common anti-
malarial drug (hydroxychloroquine) used in patients with JSLE, on 
neutrophil functions. Corticosteroids and anti-malarial drugs are usually 
an initial treatment for patients with JSLE. It has been reported that 
corticosteroids have several inhibitory effects on neutrophil functions 
such as phagocytosis, ROS production, chemotaxis and cell apoptosis 
(294–297). However, the effects of anti-malarial drugs, particularly 
hydroxychloroquine have never been reported. Here, my study 
demonstrated that hydroxychloroquine at concentrations found in patient 
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serum (0-23 µM) have no effect on neutrophil functions, in terms of cell 
survival, phagocytosis, ROS production and chemotaxis. The 
administration of hydroxychloroquine in JSLE patients at normal doses is 
therefore unlikely to lead to neutrophil dysfunction and increase the risk 
of bacterial infection. However, had time permitted, it would have been 
useful to have repeated these studies on the effects of 
hydroxychloroquine in the presence of corticosteroids, as these two drugs 
are usually used in combination. 
In conclusion, my study showed several abnormalities of 
neutrophil function in JSLE patients. The main findings are that JSLE 
serum induced neutrophil apoptosis and resulted in decreased bacterial 
opsonisation, leading to defective neutrophil phagocytosis and ROS 
production. Factor(s) in JSLE serum (i.e. cytokines) regulated neutrophil 
survival/death, but only IL-8 levels were detectable and significantly 
increased in JSLE serum. Although IL-8 did not induce neutrophil 
apoptosis, it could probably be used as an indicator of disease activity in 
JSLE patients. GM-CSF was the most protective cytokine and overcame 
the pro-apoptotic effect of JSLE serum. GM-CSF could potentially be 
used as an alternative treatment in JSLE patients. The effects of TNF-! 
are probably tissue-specific and concentration-dependent and so the 
clinical application of TNF-!/ant-TNF-! treatment in JSLE patients is 
unlikely to be of benefit. The functions of neutrophils from JSLE and 
! "+&!
neutrophils treated with hydroxychloroquine (a common anti-malarial 
drug used for treatment of JSLE) still function normally. Taken together, 
this study demonstrated that factor(s) in JSLE serum play important roles 
in JSLE neutrophils. 
Future directions 
 Further studies should recruit both JSLE patients and healthy 
juvenile controls in order to increase the sample size to confirm the 
validity of some of the key experiments presented in this thesis. Particular 
areas of focus would be serum analysis particularly to confirm whether 
IL-8 and other pro-apoptotic proteins (e.g. FAS and TRAIL) are 
markedly increased in JSLE patients. This could explain the mechanism 
by which JSLE neutrophils become apoptotic in vivo. In addition, disease 
activity scores (i.e. SLEDAI scores) should be recorded and then used to 
search for a correlation between disease activity and the levels of 
neutrophil apoptosis induced by JSLE serum, and to determine whether 
the serum levels of IL-8 are significantly increased in patients with active 
disease. As GM-CSF is a potent cytokine for delaying neutrophil 
apoptosis, it is important to determine whether the production of 
autoantigen from apoptotic neutrophils induced by JSLE serum would be 
decreased after GM-CSF treatment. This finding would support the idea 
that GM-CSF could probably used as an alternative treatment in patients 
with JSLE. Neutrophils isolated from JSLE patients, particularly those 
! "+'!
with active disease, would be used to investigate their functions in terms 
of apoptosis, phagocytosis, ROS production and chemotaxis and confirm 
that JSLE neutrophils still function normally in host defense and that 
serum from JSLE patients is a major factor involved in dysregulation of 
neutrophil function. 
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Chapter 8: Appendix 
Table 8.1 Demographic data of healthy juvenile controls (n=9) and the 
patients diagnosed with JSLE and fulfilled ( 4 of the ACR criteria for 
SLE; inactive JSLE patients (n=12) and active JSLE patients (n=7).
 
Demographic data 
Healthy 
juvenile 
controls 
Inactive 
JSLE 
Active 
JSLE 
Number of patients 9 12 7 
Age 13.4 (± 1.3) 15.3 (± 1.9) 14 (± 1.4) 
Gender: female, male 5,4 8,4 4,3 
ANA positive N/A 12 7 
Medications 
• Corticosteroids 
• Hydroxychloroquine 
• Immunosuppressive drugs 
(e.g. cyclophosphamide, 
methotrexate, AZA, 
MMF) 
 
0 
0 
0 
 
12 
8 
1 
 
5 
3 
7 
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Table 8.2 Neutrophil gene expression is independent of the concentration 
of TNF-!. Neutrophils were incubated exactly as described in the legend 
to Figure 4.6. After quantitation of transcript levels by real-time PCR, 
expression levels after incubation for 1 h with 40 ng/mL TNF-! (high 
concentrations) or 10 ng/mL TNF-! (low concentrations). Data represent 
mean fold changes (± SEM) of three separate experiments. 
 
Genes Low dose TNF-! (10 ng/mL) High dose TNF-! (40 ng/mL) 
APAF1 -2.06 (± 0.53) -0.38 (± 1.24) 
BAX 1.4 (± 0.1) -0.22 (± 1.61) 
BCL2A1 4.31 (± 0.41) 4.95 (± 0.91) 
BCL3 3.36 (± 0.32) 4.72 (± 1.82) 
CASP10 -2.22 (± 0.45) -2.31 (± 0.53) 
CASP8 -3.54 (± 0.81) -3.78 (± 1.3) 
CD40 2.75 (± 0.44) 27.23 (± 19.6) 
CFLAR 1.9 (± 0.07) 2.96 (± 0.53) 
FADD -5.69 (± 1.97) -6.51 (± 0.91) 
FAS 2.58 (± 0.35) 3.59 (± 0.24) 
ICAM1 13.65 (± 1.3) 16.63 (± 5.5) 
IKBKE 3.08 (± 0.24) 3.51 (± 0.99) 
NFKB1 2.44 (± 0.65) 4.26 (± 0.76) 
NFKB1A 16.46 (± 3.23) 16.82 (± 4.39) 
NFKB2 5.38 (± 1.15) 8.07 (± 0.87) 
REL 3.54 (± 0.43) 4.8 (± 0.8) 
REL A 2.35 (± 0.04) 4.15 (± 0.2) 
REL B 2.39 (± 0.13) 2.28 (± 0.25) 
TNF 23.38 (± 5.01) 80.85 (± 42.28) 
TNFAIP3 19.95 (± 1.93) 24.59 (± 8.75) 
TNFRSF1A -2.23 (± 0.43) -2.44 (± 0.82) 
TNFRSF1B -1.46 (± 0.3) -1.55 (± 1.6) 
TRADD 1.32 (± 0.22) -1.68 (± 0.34) 
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Table 8.3 Neutrophils were incubated for up to 6 h in the absence or 
presence of TNF-! (10 ng/mL) (as described in Figure 4.9). Gene 
expression was analyzed by real-time PCR (normalised to GAPDH).  
Samples were collected 1 h, 3 h and 6 h after addition of TNF-!. Data 
shown are mean fold changes (± SEM) of three separate experiments. 
 
Genes 1h 3h 6h 
TNF 13.37 (± 4.77) 4.82 (± 2.64) 7.32 (± 8.46) 
FADD -3.34 (± 1.14) -3.13 (± 2.14) -1.54 (± 0.61) 
CASP8 -1.71 (± 0.36) -2.25 (± 1.03) -1.72 (± 1.38) 
CASP10 -1.41 (± 0.16) -1.44 (± 1.01) -1.01 (± 0.63) 
TNFRSF1A -1.7 (± 0.28) -1.28 (± 0.65) -0.86 (± 0.54) 
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Figure 8.2 Effects of IL-8 on neutrophil apoptosis. The graph shows the 
percent of neutrophil apoptosis after incubation with 10% human AB 
serum with or without IL-8 at 22 h (3 replicates). The different 
concentrations of IL-8 (pg/mL or ng/mL) were shown. Data represent 
mean ± SEM (*** p<0.005, Student’s t-test). 
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